Control of macrophage homeostasis by Davies, Luke C.
March, 2014 
Control of Macrophage 
Homeostasis 
A thesis presented for the degree of Doctor of Philosophy 
 
Luke Cynlais Davies 
 
 
 
  
2 
 
 
  
 
3 
 
DECLARATION 
This work has not been submitted in substance for any other degree or award at this 
or any other university or place of learning, nor is being submitted concurrently in 
candidature for any degree or other award. 
Signed ………………………………… (candidate)       Date: 24/03/2014 
 
STATEMENT 1 
This thesis is being submitted in partial fulfilment of the requirements for the degree 
of PhD. 
Signed ………………………………… (candidate)       Date: 24/03/2014 
 
STATEMENT 2 
This thesis is the result of my own independent work/investigation, except where 
otherwise stated. Other sources are acknowledged by explicit references. The views 
expressed are my own. 
Signed ………………………………… (candidate)       Date: 24/03/2014 
 
STATEMENT 3 
I hereby give consent for my thesis, if accepted, to be available for photocopying and 
for inter-library loan, and for the title and summary to be made available to outside 
organisations. 
Signed ………………………………… (candidate)       Date: 24/03/2014 
 
STATEMENT 4: PREVIOUSLY APPROVED BAR ON ACCESS 
I hereby give consent for my thesis, if accepted, to be available for photocopying and 
for inter-library loans after expiry of a bar on access previously approved by the 
Academic Standards & Quality Committee.  
Signed ………………………………… (candidate)       Date: 24/03/2014 
4 
 
Acknowledgements 
First and foremost, I would like to thank Phil Taylor for his fantastic supervision, 
excellent support, ongoing contribution to and original conception of this thesis. I 
would also like to express my gratitude to Marcela Rosas whose initial work helped 
construct this project; and for her additional supporting work, which is critical for the 
overall message of this thesis. I would also like to acknowledge the rest of the Taylor 
group, particularly Nicola Dierkes and Dina Fathalla for their technical support, and 
Bashar Kharfan (Masters student) for his aid in production of lentiviral vectors. 
Of course, I would not have achieved anything in this thesis without the constant 
support of my friends, family and Xbox; which played no small part in the maintenance 
of my sanity. Six Nations weekends (especially Super Saturday) and excellently hosted 
events by Christopher Rice and Helen Brook helped make the time during my PhD 
enjoyable. The quantity and quality of drinking games constructed during my PhD far 
outstripped any experiences in undergrad. And, in particular, I enjoyed the weeks 
‘wasted’ on the design of an intriguingly complex game of thrones board game, that 
nearly resulted in murders and/ or suicides. 
Additionally, I would like to thank beer in all its splendour. Principally, I would like to 
express my appreciation to the Banterstreet brewery, for the expertly crafted real ales, 
which were full of exceptional character. The long hours brewing and designing new 
beer labels were one of the escapes from a macrophage driven world, and I thank 
Christopher Rice and Matthew White for all those steamy evenings... basking in the 
glory of the boiling wort in the Banterstreet kitchens. 
I would like to express my appreciation to the Cardiff Blues rugby team for having a 
few terrible seasons in a row, which really allowed me to concentrate on my work. I 
would also like to thank Tristan Ardley and Matthew White for keeping me humble, by 
repeatedly destroying my soul in countless squash matches. The numerous curses used 
in squash, were critical for relieving the constant pressures of postgraduate research.  
Schließlich, möchte ich mich herzlich bedanken bei meine Freundin Anja Bloom, vor 
allem für ihre tagtägliche Unterstützung und ihrem Beistand. Sie hat mich zu einem 
besseren Mensch und Wissenschaftler gemacht. Danke schön mein Liebling.  
5 
 
Contents 
 
Summary ......................................................................................................................... 12 
Abbreviations ................................................................................................................. 13 
Chapter 1 – General Introduction .................................................................................. 17 
1.1 – Macrophages: discovery, origins and heterogeneity ............................................. 18 
1.1.1 – Discovery of macrophages .............................................................................. 18 
1.1.2 – Tissue resident MØ heterogeneity .................................................................. 18 
1.1.3 – Origins of ResMØs ........................................................................................... 21 
1.2 – MØs in inflammation .............................................................................................. 24 
1.2.1 – The peritoneal acute immune response ......................................................... 24 
1.2.2 – Role of MØs in acute inflammation................................................................. 28 
1.3 – Work leading up to this thesis ................................................................................ 31 
1.3.1 – Microarray analysis of MØ populations .......................................................... 31 
1.3.2 – The GATA family of transcription factors ........................................................ 34 
1.4 – General hypothesis................................................................................................. 35 
1.5 – Aims ........................................................................................................................ 35 
Chapter 2 – Methods ...................................................................................................... 36 
2.1 – Notes ...................................................................................................................... 37 
2.2 – Health and safety ................................................................................................... 37 
2.3 – Antibodies and dyes ............................................................................................... 38 
2.4 – Cell counting ........................................................................................................... 40 
2.4.1 – Haemocytometer ............................................................................................. 40 
2.4.2 – Millipore Muse ................................................................................................ 40 
2.4.3 – Haemacolor staining ........................................................................................ 41 
2.5 – Cell Culture ............................................................................................................. 42 
2.5.1 – General cell culture ......................................................................................... 42 
6 
 
2.5.2 – Culture of primary peritoneal cells .................................................................. 43 
2.5.3 – Culture of bone marrow (BM) MØs ................................................................ 43 
2.5.4 – Culture of 293-T cells ....................................................................................... 44 
2.5.5 – Culture of MØ precursor cells ......................................................................... 44 
2.5.6 – Culture of Jurkat-Eb.1 cells .............................................................................. 45 
2.6 – Animal work ........................................................................................................... 46 
2.6.1 – Animals used in this study ............................................................................... 46 
2.6.2 – Intra-peritoneal (i.p.) injection ........................................................................ 46 
2.6.3 – Sub-cutaneous (s.c.) injection ......................................................................... 47 
2.6.4 – Genotyping ...................................................................................................... 47 
2.6.5 – Peritoneal lavage ............................................................................................. 48 
2.6.6 – Pleural lavage .................................................................................................. 49 
2.6.7 – Adoptive transfer ............................................................................................. 50 
2.6.8 – Femur extraction ............................................................................................. 50 
2.7 – Flow Cytometry ...................................................................................................... 52 
2.7.1 – Total cell staining ............................................................................................. 52 
2.7.2 – Use of nuclear isolation media (NIM)-DAPI for flow cytometry ..................... 53 
2.7.3 – Flow cytometric cell sorting ............................................................................ 53 
2.8 – Lentiviral vector cloning ......................................................................................... 55 
2.8.1 – Primer design ................................................................................................... 55 
2.8.2 – Restriction endonuclease digestions ............................................................... 57 
2.8.3 – Agarose gel electrophoresis (AGE) .................................................................. 57 
2.8.4 – Gel extraction and DNA purification ............................................................... 58 
2.8.5 – Polymerase chain reaction (PCR) .................................................................... 58 
2.8.6 – In-fusion cloning .............................................................................................. 59 
2.8.7 – E. coli transformation via heat shock .............................................................. 60 
2.8.8 – E. coli culture ................................................................................................... 61 
7 
 
2.8.9 – Plasmid DNA extraction ................................................................................... 61 
2.8.10 – DNA sequencing and validation .................................................................... 62 
2.9 – Viral particle production ........................................................................................ 63 
2.9.1 – Transfection ..................................................................................................... 63 
2.9.2 – Viral particle concentration ............................................................................. 63 
2.9.3 – Multiplicity of infection (MOI) calculations ..................................................... 64 
2.9.4 – Use of lentiviral particles in culture ................................................................. 65 
2.10 – Real-time PCR ....................................................................................................... 66 
2.10.1 – RNA extraction ............................................................................................... 66 
2.10.2 – Reverse transcription .................................................................................... 66 
2.10.3 – Primer design ................................................................................................. 66 
2.10.4 – Real-time PCR ................................................................................................ 67 
2.11 – Immunocytochemistry ......................................................................................... 71 
2.11.1 – Cytospins, fixation and permeablisation ....................................................... 71 
2.11.2 – Staining .......................................................................................................... 71 
2.11.3 – Slide mounting ............................................................................................... 72 
2.11.4 – Fluorescence microscopy .............................................................................. 72 
2.11.5 – Image processing ........................................................................................... 72 
2.12 – Statistics ............................................................................................................... 72 
Chapter 3 - ResMØs self-renew by in situ proliferation. .............................................. 73 
3.1 – Introduction............................................................................................................ 74 
3.1.1 – Zymosan peritonitis ......................................................................................... 74 
3.1.2 –Proliferation ...................................................................................................... 75 
3.1.3 – Hypothesis ....................................................................................................... 76 
3.1.4 – Aims ................................................................................................................. 76 
3.2 – Results .................................................................................................................... 77 
3.2.1 – Doublet discrimination in complex polychromatic flow cytometry ................ 77 
8 
 
3.2.2 – Definition of ResMØs in complex inflammatory environments ...................... 78 
3.2.3 – Identification of non cell cycle-associated DNA content and ResMØs in cell 
cycle ............................................................................................................................. 80 
3.2.4 – ResMØs expand by proliferation during the neonatal period ........................ 83 
3.2.5 – ResMØs recover from acute inflammation by proliferation ........................... 86 
3.2.6 – ResMØs in the naïve tissue survive inflammation and proliferate ................. 92 
3.2.7 – A significant proportion of ResMØs are generated by proliferation during 
inflammation ............................................................................................................... 96 
3.3 – Discussion ............................................................................................................... 99 
3.3.1 – Flow cytometric analysis of MØ populations .................................................. 99 
3.3.2 – Nuclear profile of ResMØs ............................................................................ 100 
3.3.3 – ResMØs proliferate in homeostasis and neonatal growth ........................... 101 
3.3.4 – ResMØs proliferate during acute inflammation to restore depleted numbers
 ................................................................................................................................... 102 
3.3.5 – ResMØs renew in situ, without the need for blood monocyte precursors .. 102 
3.3.6 – Conclusion ..................................................................................................... 103 
Chapter 4 – InfMØs proliferate in situ during inflammation. ..................................... 104 
4.1 – Introduction.......................................................................................................... 105 
4.1.1 – Ly-6B+ InMØ persistence ............................................................................... 105 
4.1.2 – Prospect of Ly-6B+ InfMØ proliferation ......................................................... 107 
4.1.3 – Hypothesis ..................................................................................................... 109 
4.1.4 – Aims ............................................................................................................... 109 
4.2 – Results .................................................................................................................. 110 
4.2.1 – Definition of Ly-6B+ InfMØs in complex inflammatory environments .......... 110 
4.2.2 – Ly-6B+ InfMØs proliferate during the resolution of zymosan induced 
peritonitis .................................................................................................................. 111 
4.2.3 – Proliferation of Ly-6B+ InfMØs is not restricted to zymosan peritonitis ....... 114 
9 
 
4.2.4 – Both Ly-6B+ and Ly-6B– InfMØs are derived from the bone marrow. ........... 117 
4.2.5 – M-CSF is required but not sufficient for substantial ResMØ proliferation ... 120 
4.2.6 – IL-4 is not essential for MØ proliferation during acute inflammation .......... 127 
4.3 – Discussion ............................................................................................................. 131 
4.3.1 – Ly-6B+ InfMØs ................................................................................................ 131 
4.3.2 – Ly-6B+ InfMØs proliferate during inflammation ............................................ 132 
4.3.3 – Ly-6B+ InfMØ and ResMØ proliferation is a general phenomenon in 
inflammation ............................................................................................................. 132 
4.3.4 – Ly-6B+ InfMØs are bone marrow-derived ..................................................... 133 
4.3.5 – M-CSF dependency of MØs ........................................................................... 133 
4.3.6 – MØ proliferation is not dependent upon IL-4 ............................................... 136 
4.3.7 – Conclusion ..................................................................................................... 137 
Chapter 5 – Lentiviral modification of MØ gene expression ...................................... 138 
5.1 – Introduction.......................................................................................................... 139 
5.1.1 – Lentiviral vectors ........................................................................................... 139 
5.1.2 – RNA interference ........................................................................................... 140 
5.1.3 – Markers used to identify infected cells ......................................................... 140 
5.1.4 – Hypothesis ..................................................................................................... 141 
5.1.5 – Aims ............................................................................................................... 141 
5.2 – Results .................................................................................................................. 142 
5.2.1 – Lentiviral titre calculations in vitro ................................................................ 142 
5.2.2 – Lentiviral infection of BMMØs and ResMØs in vitro ..................................... 143 
5.2.3 – Specific lentiviral infection of ResMØs in vivo .............................................. 145 
5.2.4 – Lentiviral knockdown of target gene expression in ResMØs in vivo ............. 146 
5.2.5 – Validation of a lentiviral expression vector ................................................... 147 
5.2.6 – Lentiviral vectors constructed for this thesis ................................................ 148 
5.2.7 – Preferential inflammatory loss of infected ResMØs in vivo .......................... 149 
10 
 
5.3 – Discussion ............................................................................................................. 153 
5.3.1 – Viral titre ........................................................................................................ 153 
5.3.2 – Selective infection of ResMØs ....................................................................... 154 
5.3.3 – Immune rejection of infected ResMØs ......................................................... 154 
5.3.4 – Conclusion ..................................................................................................... 155 
Chapter 6 – Gata6 controls ResMØ renewal ............................................................... 156 
6.1 – Introduction.......................................................................................................... 157 
6.1.1 – Pleural ResMØs .............................................................................................. 157 
6.1.2 – Hypothesis ..................................................................................................... 158 
6.1.3 – Aims ............................................................................................................... 158 
6.2 – Results .................................................................................................................. 159 
6.2.1 – Gata6 is expressed selectively by peritoneal ResMØ .................................... 159 
6.2.2 – Knockdown of Gata6 expression results in a reduction in F4/80 protein ..... 161 
6.2.3 – Knockout of the Gata6 gene causes a marked reduction in the F4/80 
phenotype of adult ResMØ ....................................................................................... 162 
6.2.4 – Gata6 knockout in the myeloid lineage gives viable ResMØs with an altered 
F4/80 phenotype ....................................................................................................... 164 
6.2.5 – Knockout of Gata6 has a cell-intrinsic effect on peritoneal ResMØ 
proliferation and polyploidy ...................................................................................... 168 
6.2.6 – Knockout of Gata6 has a cell-intrinsic effect on pleural ResMØ proliferation, 
polyploidy and phenotype ......................................................................................... 171 
6.2.7 – Absence of Gata6 results in a reduced ability of ResMØs to recover after 
inflammation by proliferation ................................................................................... 174 
6.2.8 – Myeloid Gata6 deficiency is associated with delayed clearance of neutrophils 
from the peritoneal cavity during inflammation ....................................................... 182 
6.2.9 – Enforced expression of Gata6 in adoptively transferred BMMØs alters their 
phenotype and peritoneal retention ........................................................................ 183 
6.3 – Discussion ............................................................................................................. 185 
11 
 
6.3.1 –Selective expression of Gata6 in peritoneal and pleural ResMØ ................... 185 
6.3.2 –Phenotypic changes in ResMØ after Gata6-depletion ................................... 185 
6.3.3 – Identification of ‘WT’ F4/80high ResMØs in Gata6-KOmye mice ...................... 187 
6.3.4 – Gata6 effects cell proliferation and euploidy in a cell-intrinsic manner ....... 187 
6.3.5 – Conditional myeloid knockout of Gata6 results in altered homeostatic cell 
numbers ..................................................................................................................... 188 
6.3.6 – Absence of Gata6 results in a reduced ability of ResMØs to recover after 
inflammation by proliferation ................................................................................... 188 
6.3.7 – Potential mechanism for altered ResMØ proliferation ................................. 190 
6.3.8 – The absence of Gata6 is associated with alterations in inflammatory 
resolution .................................................................................................................. 190 
6.3.9 – Gata6 imparts a peritoneal-like phenotype and increases the tissue retention 
of BMMØs .................................................................................................................. 191 
6.3.10 –Microarray analysis of Gata6-deficient ResMØs .......................................... 191 
6.3.11 –Conclusion .................................................................................................... 192 
Chapter 7 – General Discussion ................................................................................... 193 
7.1 – MØ origins and self-renewal ................................................................................ 194 
7.1.1 – Past reflection ................................................................................................ 194 
7.1.2 – Current paradigms ......................................................................................... 195 
7.2 – MØ tissue specific phenotype and function ........................................................ 199 
7.2.1 – Gata6 as a transcriptional regulator of ResMØ phenotype and renewal ..... 199 
7.2.2 – Other examples of MØ transcriptional regulation ........................................ 200 
7.3 – Conclusion ............................................................................................................ 202 
7.3.1 – Conclusions .................................................................................................... 202 
7.3.2 – Future perspectives ....................................................................................... 202 
Supplemental appendix figures ................................................................................... 204 
Bibliography .................................................................................................................. 204 
12 
 
Summary 
Tissue resident macrophages are extremely heterogeneous, which reflects their unique 
microenvironments and tissue specific functions. They are a constituent of all tissues, 
and are involved in homeostatic processes and inflammatory disease. Recent studies 
have shown that select tissue resident macrophage populations, such as Langerhans 
cells of the skin and microglia of the brain, are able to self-renew independently from 
the bone marrow. This is contrary to the prevailing model macrophage origins, the 
‘mononuclear phagocyte system’, which dictates that all macrophages are derived 
from bone marrow monocytes. The work carried out in this thesis investigated the self-
renewing potential of peritoneal tissue resident macrophages, and its control. Several 
novel discoveries were made: i) peritoneal resident macrophages proliferate at low 
levels to maintain their numbers during homeostasis, at higher levels during neonatal 
growth, and undergo a burst in proliferation during acute inflammation to restore their 
depleted population; ii) renewal of peritoneal resident macrophages during an acute 
inflammatory episode was found to be independent from the bone marrow, and 
dependent upon macrophage colony stimulating factor, but importantly, not 
interleukin-4; iii) Monocyte-derived macrophages could also proliferate within an 
inflammatory lesion. Collectively, these observations challenge the dogma of the 
mononuclear phagocyte system: they demonstrate that in vascular tissues, tissue 
resident macrophages could self-renewal independently of monocytes, and that 
monocyte-derived cells are not terminally-differentiated. Additional work leading up to 
these studies implicated Gata6 as a peritoneal macrophage-specific transcription 
factor. In this thesis, Gata6 was found to be necessary for peritoneal macrophage 
phenotype, normal proliferation, euploidy, and normal responses to inflammation. In 
summary, these studies demonstrate not only are macrophages capable of self-
renewal, but this is dependent upon discrete transcriptional control. Understanding 
the molecular controls of tissue macrophage heterogeneity and renewal could provide 
novel avenues for the therapeutic manipulation of their activities.  
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1.1 – Macrophages: discovery, origins and heterogeneity  
1.1.1 – Discovery of macrophages 
The word macrophage (MØ) is derived from the Greek words for large/ big (macro) 
and devourer/ eater (phage). MØs are phagocytic (Greek: devouring cell) cells which 
engulf apoptotic cells, debris or pathogens to help maintain the function of body 
tissues. The Russian/ Ukrainian zoologist Ilya Ilyich Mechnikov (Elie Metchnikoff) was 
one of the first to describe phagocytosis as an active, purposeful event by a 
‘professional’ cell (Metchnikoff, 1880, Metchnikoff, 1883). Metchnikoff described 
phagocytic cell activity during inflammation (Metchnikoff, 1892), and formulated the 
beginnings of the MØ system of innate immunity. However, phagocytosis itself was 
reported to have been discovered a few years before Metchnikoff’s publications 
(Ambrose, 2006, Osler, 1875). These studies were unrefined at the time, and therefore 
Metchnikoff was accredited the discovery of phagocytosis due to his extensive body of 
research (Gordon, 2007). Metchnikoff is considered to be the father of natural 
immunity (Gordon, 2008), and was awarded the Nobel Prize in Medicine along with 
Paul Ehrlich (adaptive immunity) in 1908. MØ biology has been continually refined 
since these discoveries (Gordon, 2007), and remains an active area of research to date. 
 
1.1.2 – Tissue resident MØ heterogeneity 
Before blood monocytes were identified as a source of phagocytic cells (Sabin, 1925), 
tissue histocytes formed part of the reticuloendothelial system (Aschoff, 1924). These 
histocytes were phagocytic cells which existed within the tissues (endothelia) 
themselves and were known to play a major role in tissue regulation. These cells are 
now known as tissue resident (Res) MØs; the origin of which still remains a current and 
controversial issue (discussed below 1.1.3). MØs are often classified functionally into 
one of two main categories: the ‘M1/M2’ MØ activation nomenclature (Mantovani et 
al., 2004). This was based on the initial observations of ‘classical’ (M1) MØ activation 
by interferon (IFN) γ (Nathan et al., 1983), and ‘alternative activation’ by interleukin 
(IL) 4 (Stein et al., 1992) and IL-13 (de Waal Malefyt et al., 1993). This paradigm has 
been extended to include M1 activation states induced by granulocyte/MØ colony 
stimulating factor (GM-CSF); and M2 activation states induced by MØ colony 
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stimulating factor (M-CSF)/ IL-10/ transforming growth factor β (TGFβ) and steroids 
(Gordon, 2003). M1 ‘classically’ activated MØs are associated with inflammation, while 
M2 ‘alternatively activated’ MØs are linked with tissue repair (anti-inflammatory) 
(Gordon, 2003). ResMØs are sometimes termed M2-like cells (Satoh et al., 2013). 
However, the M1/M2 paradigm was intended as a ‘simplified conceptual framework’ 
(Mantovani et al., 2005) and is an oversimplification, given the complexity of ResMØ 
heterogeneity and activation. Therefore, cells originating in the tissue will be referred 
to as ResMØs in this thesis, even during inflammation where these cells are likely 
activated (or ‘polarised’). Monocyte-derived MØs which are recruited to the tissue 
during inflammation are discussed below (1.2), but the same principle is followed, in 
that these cells will be termed ‘inflammation-associated’ (Inf) MØs. 
Different tissues have diverse physiological environments and micro-environments, 
which require distinct homeostatic functions. As an integral part of the tissue, ResMØs 
are appropriately placed to both shape and be shaped by the tissue physiology. MØs 
are most commonly known for their principal ability to phagocytose pathogens during 
infection (Metchnikoff, 1892). However, the roles of ResMØs include: the phagocytosis 
of apoptotic cells, presentation of antigens to lymphocytes, regulation of immune 
responses, maintenance of stem cell populations, and control of physiological 
metabolism (Davies et al., 2013a). These processes are not a feature of all ResMØ, and 
some are restricted to specific tissue niches. However, the role of phagocytosis, 
specifically with the removal of apoptotic cells, is considered to be common to all MØs 
whether tissue resident or monocyte derived (Gordon, 2007).  
ResMØs in different tissues are often given unique nomenclature, and have differential 
expression of clusters of differentiation (CD) antigens and additional surface receptors, 
which are often used as markers to define cellular subsets. A few examples of such 
specialised ResMØs subsets are osteoclasts, Langerhans cells and microglia (Gordon 
and Taylor, 2005). Osteoclasts are multinucleated MØs (formed from cell fusion) which 
reside in and resorb bone matrices during homeostasis (Pollard, 2009). These cells are 
usually separated from other MØs by their multinuclear phenotype and expression of 
the calcitonin receptor (Quinn et al., 1999). Langerhans cells were discovered by Paul 
Langerhans in 1868, and were originally described as neurones due to their dendritic 
appearance (Langerhans, 1868). These cells reside in the epidermal layer of the skin 
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and are usually differentiated from dendritic cells (DCs) by their expression of Langerin 
(CD207), and high expression of F4/80 (Chorro et al., 2009). Langerhans cells are well 
known for their roles in immunosurveillance and have the ability to present antigens to 
T-lymphocytes of the adaptive immune system (Merad et al., 2008). For this role, 
Langerhans cells have been traditionally viewed as DCs. However their resemblance to 
ResMØ populations, such as microglia, and their dependence on M-CSF means they 
can be considered as ResMØs (Satpathy et al., 2012). Microglia are ResMØs which 
reside in brain tissues and play a major role in promoting neuronal survival and 
synaptic remodelling (Paolicelli et al., 2011, London et al., 2013). These cells are usually 
described as being CD45low, CD11b+ and F4/80+ in the brain (Prinz et al., 2011), 
however these antigens are common to most MØ populations (Davies et al., 2013a).  
F4/80 is a common antigen found on numerous MØ populations, it was first discovered 
by the creation of a monoclonal antibody (the 80th hybridoma in the 4th attempted 
fusion) which bound to an antigen expressed by MØs (Austyn and Gordon, 1981). This 
antigen was found to be a G-protein coupled receptor and a member of the epidermal 
growth factor receptor 7 pass trans-membrane (EGF-TM7) family (McKnight et al., 
1996). F4/80 shares structural identity with growth factors, suggesting it is involved in 
cell adherence and signalling. There has been some evidence to suggest that F4/80 
plays a role in the generation of immune tolerance (van den Berg and Kraal, 2005). 
However, the specific function of the F4/80 protein has been poorly categorised. 
CD11b is the αM subunit of the integrin αMβ2 complex, also known as Mac-1 and 
complement receptor 3. It was originally identified as a surface receptor on 
neutrophils (Hickstein et al., 1987), but is now used as a common pan-myeloid cell 
marker for the identification of neutrophils, eosinophils and MØs. However, it is also 
expressed on B1 cells (Morabito et al., 1987).  
The specific expression patterns of both F4/80 and CD11b can help distinguish MØs 
from eosinophils and neutrophils, particularly when using physical parameters such as 
light scatter in flow cytometry. MØs of the peritoneal cavity can be used as an 
example, as they consist of two major populations that are commonly separated by 
CD11b and F4/80 expression: F4/80high CD11bhigh ResMØs and F4/80low CD11b+ 
MHCIIhigh ResDCs/MØs (Dioszeghy et al., 2008), the latter is most likely a mix of cells. 
Eosinophils and neutrophils can also be distinguished using these markers; which is 
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explained in more detail in chapter 3 of this thesis. However, additional markers can be 
used to subdivide the major ResMØs populations.  
The peritoneal ResMØ population can be further divided into multiple sub-populations 
using a few additional markers, such as: Tim4 (Miyanishi et al., 2007), CD73 (Petrovic-
Djergovic et al., 2012), SignR1 (Taylor et al., 2004), and CRIg (Gorgani et al., 2008). 
Tim4 is a phosphatidylserine receptor which is selectively expressed on the vast 
majority (95 %) of peritoneal ResMØ, but is also seen in CD11b+ cell populations in 
other tissues (Miyanishi et al., 2007). CD73 (ecto-5'-nucleotidase) is involved (along 
with CD39) in the direct extracellular production of adenosine from exported cyclic 
AMP or ATP. Adenosine, ATP and cyclic AMP are important modulators of 
inflammation, and adenosine can additionally modulate neurotransmission (Cohen et 
al., 2013, Latini and Pedata, 2001, Petrovic-Djergovic et al., 2012). SignR1 (Sign related 
1) is a mannose receptor found on MØ, and is involved in the recognition of fungal 
carbohydrates (Taylor et al., 2004). CRIg (complement receptor of the immunoglobulin 
superfamily) is a complement receptor which binds to C3b on opsonised apoptotic 
cells and microbes (Kim et al., 2008), but inhibits activation of the alternative 
complement pathway, preventing autoimmunity (He et al., 2008). These surface 
receptors can be used purely as markers; however, as shown above, they have defined 
functions which will provide this heterogeneous ResMØ population with a broad 
spectrum of functional characteristics. This likely equips the population with a diversity 
of responses, which are needed to efficiently survey the tissue for potential pathogenic 
threats and maintain tissue homeostasis. 
 
1.1.3 – Origins of ResMØs 
The MØ system was first introduced by Elie Metchnikoff in the late 19th century, and 
described phagocytic activity during inflammation (Metchnikoff, 1892). This system 
was refined in 1924 by Aschoff and formed part of the reticuloendothelial system 
(Aschoff, 1924); a tissue system comprised of reticuloendothelia (histocytes/ ResMØs) 
and endothelial cells. These cells were proposed to have a common tissue origin and 
regulated their numbers through the local expansion of cells. However, this system 
was flawed due to the false assumption that phagocytosis was the only mechanism 
which lithium carmine (the tracer used in these studies) could be absorbed into cells. 
22 
 
The discovery of pinocytosis (cell drinking) (Lewis, 1931) cast doubts over the 
phagocytic ability of reticuloendothelia. At the same time as the reticuloendothelial 
system was formulated, blood monocytes were identified as a source of phagocytic 
cells (Sabin, 1925), with the others considered to be of tissue origin. These two 
populations (tissue and monocyte exudate) were investigated during later years, and 
with the aid of technological advances, more increasing differences were observed, 
such as the differential peroxidase activity of these cells (Daems, 1971).  
In 1968 van Furth and Cohn showed that major populations of MØs were derived from 
blood monocytes (van Furth and Cohn, 1968) and this concept was extended to the 
broader range of phagocytes including ResMØs, establishing the mononuclear 
phagocyte system (MPS) (van Furth et al., 1972). These results were disputed at the 
time due to evidence of proliferation (Parwaresch and Wacker, 1984, Sawyer et al., 
1982, Czernielewski and Demarchez, 1987), the apparent longevity of ResMØs 
(Melnicoff et al., 1988), and the fact that MØ populations were present in the yolk sac 
before primitive haematopoiesis (Naito et al., 1996). However, due to the limited 
technology of the time these observations could not be validated as representing a 
divergence from the MPS. One example is an experiment using aliphatic dye labelling 
of peritoneal ResMØs (Melnicoff et al., 1989). Naϊve ResMØs were labelled with a dye 
in vivo, and then inflammation was initiated with thioglycollate broth. The number of 
dyed MØs was found to be nearly double the number seen in naϊve mice. The authors 
attributed this to either ResMØs or their precursors expanding by in situ proliferation 
during the recovery from inflammation. This experimental approach was later applied 
to homeostatic renewal over a period of 49 days, and found that dyed cells persisted in 
the peritoneal cavity (Melnicoff et al., 1988). However, these dyes can be transferred 
by membrane transfer (Harvey et al., 2008) or via phagocytosis of apoptotic cells 
(Soehnlein and Lindbom, 2010), and are not readily degraded. This cast doubts over 
the conclusions made in these reports. Another example is the incorporation of 
tritiated thymidine into ResMØs (Parwaresch and Wacker, 1984). The authors 
explained that this was evidence of ResMØ proliferation. However this was also 
disputed, because this proliferation could have occurred either in monocytes or other 
MØ precursors. 
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Work on MØ heterogeneity carried on through to the end of the twentieth century 
and more deficiencies were detected in the absolutes of the MPS (Takahashi, 2000, 
Naito et al., 1996). In 2000, Ovchinnikov and colleagues concluded that embryonic 
phagocytes were of a separate lineage and this raised the possibility of their 
persistence into adulthood (Ovchinnikov, 2008, Lichanska and Hume, 2000). This 
theory was cemented with the breakthrough work on Langerhans cells and microglia. 
Langerhans cells were originally thought of as bone-marrow derived DCs, but their 
proliferative capacity has been known in humans for some time (Czernielewski and 
Demarchez, 1987). More recent data revealed that human Langerhans cells were still 
donor derived 4.5 years after a double hand allograft (Kanitakis et al., 2004). The self-
renewing capacity was confirmed in mice (Merad et al., 2002) and similar observations 
were made in the brain, with microglia also renewing their population via local 
proliferation (Ajami et al., 2007). Both microglia and Langerhans cells could be derived 
from blood monocytes, but only under certain conditions (Mildner et al., 2007, Merad 
et al., 2002). MØ proliferation has also been observed in many other tissues (Gordon 
and Taylor, 2005). So it was becoming clear that the MPS was too limited to answer 
the questions of MØ origins, fate, function and control of heterogeneity. In response 
to this, Chorro et al. investigated the origins of Langerhans cells and showed that the 
adult population was created by the local expansion of Langerhans cells in the neonate 
(Chorro et al., 2009). This contradicts the basic principles of the MPS, but may as the 
authors suggested, be a special case and restricted to tissues with limited vasculature. 
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1.2 – MØs in inflammation 
1.2.1 – The peritoneal acute immune response 
A major tool used in this thesis is a murine model of acute peritonitis (peritoneal 
inflammation). This involves the intra-peritoneal transfer of an inflammation-inducing 
agent (e.g. live pathogens, pathogen derived materials or irritants) into the peritoneal 
cavity which triggers an acute, innate immune response. During this response the 
cellular kinetics are altered in order to eliminate potential pathogens and restrict 
tissue damage. An example of a typical cellular change during an acute inflammatory 
episode is depicted in figure 1.1; this figure depicts that these cellular changes are 
occurring simultaneously, and conveys that this is a fluid system. The acute 
inflammatory response is initiated by interaction of an inflammatory agent (e.g. a 
pathogen) with various recognition systems, such as complement components, 
immunoglobulins (Ig) and receptors on tissue resident cells, such as mast cells and 
MØs.  
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Figure 1.1. The acute peritoneal immune response 
Schematic showing changes in the number of different cell populations after an acute 
inflammatory stimulus. Note the ‘disappearance’ of ResMØs early in the inflammatory 
response, when neutrophil numbers are at their peak; followed by the return of 
ResMØs with declining neutrophil numbers. 
Complement activation can occur via the classical, alternative or mannose-binding-
lectin (MBL) or lectin pathway (Muller-Eberhard, 1988, Matsushita, 1996). The classical 
pathway involves binding of C1 (via C1q) either to pre-bound Ig or directly to antigens. 
IgG molecules are produced by plasma B lymphocytes to recognise foreign antigens; 
however this usually requires adaptive immunity. Alternatively, ‘natural’ IgM can bind 
to specific antigens, such as carbohydrate without requirement for pre-immunisation 
(Bos et al., 1989). The binding of the C1 complex leads to the first stage of the 
complement cascade and the sequential cleavage of C4, C2, and C3 (the latter into C3a 
and C3b). In the alternative complement pathway: C3a and C3b are generated directly 
from C3 via activated factors B and D. Alternatively, in the lectin pathway: MBL forms a 
complex with MBL associated serine proteases (MASPs), which leads to cleavages 
similar to the classical pathway. All pathways converse on the cleavage of C3 and the 
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generation of the opsonin C3b. The cleavage of C3 leads to the assembly of a C5 
convertase and the generation of the potent anaphylotoxin C5a, and the first part of 
the membrane attack complex: C5b, which initiates the ‘terminal’ complement 
pathway. The peritoneal cavity contains basal levels of complement that are able to 
effectively opsonise microbial material (Tsoni et al., 2009). However, it is likely that all 
pathways will be activated during inflammation, such as that seen with pathogenic 
fungal infections (Ip and Lau, 2004, Kozel, 1996, Speth et al., 2004). Complement 
activation liberates the C3a and C5a anaphylatoxins, which bind to their respective 
receptors on immune cells to activate their chemotaxis and/ or expression of pro-
inflammatory mediators (Sacks, 2010).  
In addition to complement receptors, resident peritoneal cells including mast cells, 
ResMØs, DCs and mesothelial cells, have a broad range of pattern recognition and Fc 
receptors. In the peritoneal cavity these receptors include: toll-like receptors, such as 
TLR4 (Kato et al., 2004, Iwasaki and Medzhitov, 2004); scavenger receptors, such as 
MØ receptor with a collagenous structure (MARCO) (Peiser et al., 2002); and 
carbohydrate receptors, such as SignR1 and mannose receptor (Taylor et al., 2004). 
These receptors are heterogeneously expressed in different tissues and discrete tissue 
niches (Taylor et al., 2005a).  
These pattern recognition receptors bind specific motifs, referred to as pathogen 
associated molecular patterns (PAMPs). The binding of certain receptors during 
infection/ inflammation triggers downstream signalling cascades, such as the myeloid 
differentiation primary response gene 88 (MyD88) – nuclear factor-κ light chain 
enhancer of activated B cells (NFκB) pathway; which leads to cellular activation and 
production of inflammatory mediators. In addition, mast cells secrete pro-
inflammatory granules upon their activation. These granules contain histamine, 
platelet activating factor, and inflammatory cytokines such as IL-6 and tumour necrosis 
factor α (TNFα) (St John and Abraham, 2013). These inflammatory regulators trigger 
the release of further inflammatory mediators via positive feedback loops, but will also 
produce specific neutrophil chemo-attractants such as CXCL1 and CXCL2 (Soehnlein 
and Lindbom, 2010).  
An increase in these chemo-attractants leads to neutrophil infiltration from the blood, 
which is aided by an increase in vascular permeability (Davis et al., 2004). Neutrophils 
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phagocytose and destroy invading pathogens using oxidative burst (Nathan, 2006), 
secretion of biocidal granules (Borregaard et al., 2007) and neutrophil extracellular 
traps (NETs) (Brinkmann et al., 2004). However the cytotoxic effects of neutrophils can 
cause collateral damage to the tissue (Weiss, 1989). At the same time as neutrophil 
recruitment, MØs, mast cells, mesothelial cells and neutrophils produce chemo-
attractants such as CCL2-4; which leads to an influx of monocytes into the peritoneal 
cavity. These monocytes quickly differentiate into phagocytic MØs, and will aid in the 
clearance of pathogens (Soehnlein and Lindbom, 2010). Eosinophils are also recruited 
to the inflammatory lesion via chemo-attractants such as CCL11 (Ganzalo et al., 1996), 
which also restricts neutrophil recruitment (Cheng et al., 2002).  
The neutrophils recruited during inflammation eventually become apoptotic, and are 
subsequently cleared from the peritoneal cavity by MØs. This decline in neutrophil 
numbers is associated with the resolution of inflammation. During this resolution 
phase, the total number of inflammation-associated cells decline and tissue 
homeostasis is restored. Neutrophil-mediated damage is repaired, and this is usually 
attributed to a shift in the cytokine balance in the tissue from pro-inflammatory to 
anti-inflammatory, with the associated repair mechanisms.  
This process known as wound healing can be categorised into three stages: 
inflammation, tissue formation and remodelling (Gurtner et al., 2008). Tissue 
formation overlaps with the resolution of inflammation. Damaged tissue must first be 
cleared, and then new cells migrate and proliferate to form new granulation tissue and 
blood vessels; this is usually followed by collagen deposition by fibroblasts. This 
deposition can lead to fibrosis, which is a rapid process to aid the restoration of tissue 
homeostasis, but can lead to later complications and impairment of proper tissue 
function. This type of repair is usually restricted to chronic inflammation, and in the 
peritoneal cavity this is known to be driven by cytokines such as IL-6 (Fielding et al., 
2014). However, in many tissues, this is considered to be associated with a Th2-
mediated environment and the growth factor TGFβ (Leask and Abraham, 2004). Tissue 
remodelling by fibroblasts, MØs and endothelial cells works to remove the collagen 
core from the fibrotic lesion restoring normal tissue structure; however this can take 
years (Gurtner et al., 2008). 
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1.2.2 – Role of MØs in acute inflammation 
MØs have an integral role in the initiation, modulation and resolution of inflammation. 
ResMØs initially play a role in the recruitment of neutrophils to the peritoneal cavity 
following the initial inflammatory insult. Depletion of peritoneal MØs before 
inflammatory stimulus can result in the loss of CXCL1 and CXCL2 neutrophil chemo-
attractants, and a substantial reduction in neutrophil numbers (Cailhier et al., 2005). In 
the case of zymosan induced peritonitis (as seen in Cailhier et al. and described in 
3.1.1), this could be attributed to lack of MØ specific recognition of zymosan particles 
with molecules such as dectin-1 (Brown and Gordon, 2001); as mesothelial cells alone 
are known to respond to endotoxin and secrete CXCL2 (Kato et al., 2004). Consistent 
with this, Dectin-1 KO mice exhibit significantly reduced neutrophil recruitment in 
response to a fungal pathogen (Taylor et al., 2007). 
After the initial inflammatory stimulus, the number of recoverable ResMØs decreases, 
at the same time as neutrophil influx. This fall in ResMØ numbers is termed ‘the 
disappearance reaction’ (see figure 1.1). In the peritoneal cavity this is defined as an 
experiential failure to recover the cells by lavage. This could be due to increased 
adherence to the mesothelial tissues, cell migration to draining lymph nodes, or cell 
death (Barth et al., 1995). Tissue adherence is a likely contributor, as adhesion 
molecules such as intercellular adhesion molecule (ICAM) 1 are known to be regulated 
upon MØ activation (Hubbard and Giardina, 2000); and additionally,  ResMØ adhesion 
has been observed in the peritoneal cavity during inflammation (Bellingan et al., 2002). 
As the inflammation progresses, ResMØs along with recruited neutrophils and 
mesothelial cells produce monocytic chemo-attractants, such as CCL2-4. This results in 
the invasion of the tissue by peripherally recruited monocytes (Soehnlein and 
Lindbom, 2010). Two subsets of monocyte are recruited to the inflammatory lesion, 
and are separated by expression of Ly-6C (Geissmann et al., 2003): Ly-6Clow and Ly-
6Chigh. These monocytes differentiate into InfMØs, and are initially distinguishable 
from ResMØs by their expression of F4/80 and CD11b. InfMØs are also frequently 
termed ‘M1 polarised’ MØs in the early stage of acute inflammation (Mantovani et al., 
2004). The immediate role of InfMØs in acute models is to aid neutrophils in the 
phagocytic clearance of pathogens and secrete pro-inflammatory cytokines (Soehnlein 
and Lindbom, 2010). However, these InfMØs also play a key role in the resolution of 
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inflammation. For example, Ly-6Clow InfMØs limit leukocyte recruitment and aid in 
tissue recovery (Gautier et al., 2012a). However, the number of InfMØs slowly 
decreases after inflammation, while ResMØs return to their normal numbers (Rosas et 
al., 2010).  
Some of these InfMØs are lost during these late stages of inflammatory resolution 
possibly through emigration to draining lymph nodes (Bellingan et al., 1996). This is a 
process which is dependent upon regulation of the very late antigens (VLA) 4 and 5 
(Bellingan et al., 2002). Therefore, these InfMØs (which could include ‘TNF and iNOS 
producing (Tip) DCs’) could present pathogenic antigens to the T-cells within the 
lymphatics. However, it has recently been reported that the majority of InfMØs are 
cleared from the lesion via apoptosis and subsequent phagocytosis by ResMØs 
(Gautier et al., 2013, Janssen et al., 2011). 
During the resolution of inflammation, apoptotic neutrophils are preferentially cleared 
by ResMØs, but InfMØs which are usually in the majority, can also phagocytose them. 
ResMØs have been suggested to actively inhibit the ability of InfMØs to phagocytose 
apoptotic neutrophils; potentially preventing autoimmunity (Uderhardt et al., 2012). In 
addition to this, extracellular adenosine (a product of ResMØ CD73 and CD39) can 
inhibit the respiratory burst of neutrophils, therefore preventing excess tissue damage 
(de la Harpe and Nathan, 1989). Hence, not only are specific subsets of MØs present 
during inflammation, but they also have distinct functions.  
MØs are also essential for tissue remodelling and repair after injury, by producing 
factors such as TGFβ and wingless-type MMTV integration site family members (Wnts). 
Vascular endothelial growth factor (VEGF) and angiopoietin are up-regulated by MØ 
produced Wnts and promote vascular regeneration at the site of injury (Rao et al., 
2007). The TGFβ pathway has been studied extensively during wound healing, TGFβ1 
and TGFβ2 contribute to scarring whist TGFβ3 can promote scar free healing (Beanes 
et al., 2003). During wound healing it is generally considered that most MØs are 
derived from circulating monocytes (Brancato and Albina, 2011). These monocytes are 
recruited to wounds where they appear to play differential roles producing pro-
inflammatory mediators such as TNF in the early phase, and anti-inflammatory repair 
roles in the later phases (Nahrendorf et al., 2007). A specific role of ResMØs in wound 
healing has been largely neglected. However, time-dependent conditional depletion of 
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MØs in mice revealed differential MØ functions throughout the wound healing process 
(Lucas et al., 2010). Depletion in the inflammatory phase demonstrated roles for MØs 
in the formation of vascularised granulation tissue, impaired epithelialisation, and 
minimised scar formation. Depletion during the tissue formation stage led to 
haemorrhage and a failure of wound closure and transition to the remodelling stage. 
MØ depletion during the remodelling stage had less impact on the natural healing 
progress.  
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1.3 – Work leading up to this thesis 
In 2005, Siamon Gordon and Phil Taylor reviewed monocyte and MØ heterogeneity 
(Gordon and Taylor, 2005). This review emphasised the vast heterogeneity seen in 
MØs within and between tissues in both the human and mouse. Additionally,the 
authors highlighted evidence of ResMØ proliferation, such as that seen in Langerhans 
cells (Merad et al., 2002), microglia (Lawson et al., 1992) and alveolar ResMØs (Tarling 
et al., 1987). The lessons learnt from this review were combined with studies carried 
out in Prof. Phil Taylor’s laboratory on MØ heterogeneity during inflammation, to 
formulate the working hypothesis of this thesis (see 1.4). Marcela Rosas identified that 
the unknown antigen 7/4 was synonymous with Ly-6B (Rosas et al., 2010), and showed 
heterogeneous expression of Ly-6B, F4/80 and CD11b on MØs during inflammation. 
Her observations provided a basis on which cell populations could be separated for 
further analysis, enabling detection of differential functions and genetic 
programmeming. These subsequent experiments were to form the foundations of this 
thesis, and some of which are described below. 
 
1.3.1 – Microarray analysis of MØ populations 
In 2007, Dr. Marcela Rosas carried out microarray analysis of monocyte and MØ 
populations during peritoneal inflammation, based upon cell populations identified in 
her previous work (Rosas et al., 2010). The results of this microarray are currently 
within a manuscript that is in submission (Rosas et al., 2014). The primary objective of 
this microarray study was to investigate the differences in the transcriptional profiles 
of ResMØs and InfMØs. Peritonitis was induced with 2×106 particles of zymosan, and 
target cell populations were purified by flow cytometric cell sorting using select 
markers, including Ly-6B, F4/80 and CD11b (table 1.1). Monocytes from the bone 
marrow were additionally purified as a reference population. The populations used in 
this microarray were selected as they represent a typical model of ResMØs and 
monocytes/ InfMØs with distinct lineage origins (Rosas et al., 2010). The RNA was 
extracted from the cells, then amplified, labelled and hybridised to Affymetrix MOE430 
2.0 GeneChips. Expression data was calculated and probe-sets were annotated using 
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the database for annotation, visualization and integrated discovery (DAVID) (Dennis et 
al., 2003).  
Cell type Zymosan  Purification Criteria Simplification (Population Number) 
Bone marrow 
monocytes 
0 hours Ly-6Bhigh, Ly-6G– Naϊve bone marrow monocytes (1) 
Inflammatory 
monocytes  
4 hours Ly-6Bhigh, Ly-6G– Early recruited monocytes (2) 
Inflammatory 
monocytes/MØ 
18 hours Ly-6B+, Ly-6G– 
Late recruited monocytes/ InfMØs 
(3) 
MØ 3 days F4/80+/high, CD11b+/hi Mixed ResMØs/ InfMØs (4) 
Ly-6B+ MØ 7 days F4/80high, Ly-6B+ Ly-6B+ InfMØs (5) 
Ly-6B– MØ 7 days F4/80high, Ly-6B– Predominantly ResMØs (6) 
ResMØ 0 hours F4/80high, CD11bhigh Naϊve ResMØs (7) 
Table 1.1. Purification criteria for monocyte and MØ populations 
Table showing the different cell populations, which were purified by flow cytometric 
cell sorting and used for microarray analysis. Inflammation was induced with 2×106 
particles of zymosan and cell populations extracted at the indicated time after 
zymosan. Purification criteria shows the antibody targets used to label the cells for 
sorting. These cells are heterogeneous phenotypes that are reminiscent of ResMØs 
and InfMØs/ monocytes. The simplification column separates the cells into these 
categories, but this was not known until after microarray analysis and subsequent 
hierarchical clustering. The bold lettering in the simplified column shows a broad 
separation into monocyte and ResMØ groupings. 
Differentially-expressed probe-sets were identified using a one-way ANOVA with the P-
values corrected for false discovery and multiple testing with the false discovery rate 
(FDR) methodology. Hierarchical clustering of these differentially-regulated probe-sets 
separated the 7 subsets broadly into a ‘monocytic-like’ and ‘ResMØ-like’ groupings 
(figure 1.2a) and emphasized the relationship between the three ResMØ enriched 
populations (table 1.1). ResMØ-like groupings were labelled as such because the 
majority of cells shared the same CD11bhigh F4/80high phenotype as naϊve ResMØ. 
Probe-sets with ANOVA P-values of <0.001 were subject to K means clustering using 
Genesis (Sturn et al., 2002), generating 15 distinct gene expression clusters. ‘Cluster 
15’ consisted of ≈800 genes and was highly expressed only in the ResMØ enriched 
preparations. Within this cluster, 215 individual probe-sets exhibited 10-fold higher 
expression than the mean expression in the ‘monocytic’ hierarchical cluster. ‘Cluster 
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15’ was validated by transcripts that are suggested to be restricted to ResMØs in 
C57BL/6 mice: SignR1, CRIg and Tim4 (figure 1.2b). The cluster was further 
authenticated by assessment of the surface expression of these proteins (figure 1.2c).  
The 215 individual probe-sets in ‘cluster 15’ defined a ResMØ-restricted gene profile, 
which allowed identification of novel ResMØ-restricted probe-sets. Among these was 
the zinc finger transcription factor Gata6 (figure 1.2b).  
 
 
Figure 1.2. Clustering of monocyte and MØ populations by microarray analysis 
A) Heat map depicting the hierarchical clustering into ‘monocytic-like’ and ‘ResMØ-
like’ groupings. Population numbers 1-7 (A-B) are shown in table 1.1. B) Heat map 
showing the enriched expression of SignR1, CD73, CRIg, Tim4 and Gata6 in the MØ-like 
cluster. Gata6 expression was validated by semi-quantitative (sq) PCR using the 
endogenous control B2m (β2 microglobulin). C. Representative density plots showing 
the expression of SignR1, CD73, CRIg and Tim4 restricted to the F4/80high ResMØs from 
the peritoneal cavity of naϊve C57BL/6 mice. Plots were pre-gated to remove doublets 
and eosinophils, and gated on F4/80+ CD11b+ MØ. 
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1.3.2 – The GATA family of transcription factors 
The Gata family of class IV zinc finger transcription factors is separated into two main 
groups: Gata1-3 function in haematopoietic cells, while Gata4-6 are considered 
restricted to mesoderm/ endoderm derived tissues (Maeda et al., 2005). The latter 
group has been implicated in the control of tissue specific genes in these mesoderm/ 
endoderm-derived tissues, such as the heart and gastrointestinal tract (Molkentin, 
2000). The Gata6 gene encodes a single transcript which contains two potential 
translational initiation sites. Translation at the first site encodes a long Gata6 isoform, 
while the second gives rise to a shorter isoform. The skipping of the first site has been 
attributed to ‘leaky scanning’ by ribosomes, and occurs in all tissues containing Gata6. 
The short length Gata6 is similar to the other Gata factors 4 and 5, while the long 
version contains an extra 146 amino acids at the N-terminus (Takeda et al., 2004). The 
short version of Gata6 is reported to have lower activity than the long version of Gata6 
(Takeda et al., 2004). This has been attributed to the lack of a PEST sequence 
(Obayashi et al., 2012), that is usually associated with protein degradation (Rogers et 
al., 1986). Therefore, although short Gata6 has lower activity, it is likely to be more 
stable, due to the lack of this PEST sequence. However, additional protein interactions 
with the PEST sequence itself, or the other missing amino acids could have an impact 
on additional DNA binding activity. 
Gata6 itself binds to the (A/T/C)GAT(A/T)(A) consensus sequence in regulatory 
elements of target genes, with the AGAT(A/T)A sequence giving the strongest binding. 
It is normally associated with the embryonic mesoderm/ endoderm (Morrisey et al., 
1996); or organs derived from these, such as the heart and gastrointestinal tract 
(Maeda et al., 1996). Gata6 is vital for the development of these organs (Morrisey et 
al., 1996), but has also been shown to regulate proliferation and differentiation in cells 
of the small intestine of adult mice (Beuling et al., 2011).  
Gata6 is one target among many which were linked to proliferation and enriched in 
ResMØs. Additional genes associated with proliferation were identified and enriched in 
ResMØs and interestingly, in Ly-6B+ InfMØs. The sum of data revealed by this 
microarray lead to the formation of the hypothesis tested in this thesis (below). 
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1.4 – General hypothesis 
The hypothesis tested in this thesis is that MØs have the capacity to proliferate in 
homeostasis and inflammation. This proliferation is under the control of specific 
mediators, which includes the ResMØ enriched zinc finger transcription factor Gata6. 
 
1.5 – Aims 
 To determine whether ResMØs have the capacity to self-renew by proliferation 
 To examine whether InfMØs can proliferate during inflammation  
 To determine the role of Gata6 in ResMØs 
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Chapter 2 – Methods
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2.1 – Notes 
All concentrations given are final reaction concentrations (working concentrations) 
unless specifically stated. 
Autoclaving was carried out at 120°C and 100 kPa for 15 minutes to sterilise 
equipment. 
All lab equipment, e.g. centrifuge tubes, conical flasks and tissue culture plates was 
from Thermo-Fisher Scientific, unless otherwise stated. All reagents were from Sigma 
Aldrich unless otherwise stated. 
 
2.2 – Health and safety 
The appropriate risk assessments were adhered to when using all reagents and 
equipment. 
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2.3 – Antibodies and dyes 
Antibody/Dye Clone Company Final Conc. 
Flow cytometry 
CD45.1 FITC A20 Biolegend 10 µg/ ml 
GFP AlexaFluor647 FM264G Biolegend 4 µg/ ml 
B220 PerCP-Cy5.5 RA3-6B2 Becton Dickinson 2 µg/ ml 
B220 eFluor450 RA3-6B2 eBioscience 2 µg/ ml 
CD43 FITC S7 Becton Dickinson 5 µg/ ml 
ICAM-1 PE 3E2 Becton Dickinson 2 µg/ ml 
ICAM-1 Biotin YN1/1.7.4 Caltag Laboratories 1 in 50 
CD3 PerCP-Cy5.5 17A2 Biolegend 2 µg/ ml 
CD19 APC 1D3 eBioscience 2 µg/ ml 
CD23 PE B3B4 Becton Dickinson 2µg/ ml 
CCR2 PE 475301 Research&Development 0.625 µg/ ml 
CD226 APC 10E5 eBioscience 2 µg/ ml 
IgM PE-Cy5 II/41 eBioscience 2 µg/ ml 
CD5 PE-Cy7 53-7.3 eBioscience 2 µg/ ml 
Siglec F PE E50-2440 Becton Dickinson 1 µg/ ml 
Myc-tag AlexaFluor647 9B11 New England Biolabs 1.5 µg/ ml 
SignR1 AlexaFluor647 22D1 eBioscience 2 µg/ ml 
CRIg FITC MBI4 
In House (Gift from Dr. 
Claire Harris) 
9.2 µg/ ml 
rCD2 AlexaFluor647 OX-34 ABD Serotec 1 in 100 
rCD2 AlexaFluor488 OX-34 ABD Serotec 1 in 100 
CRIg Biotin MBI4 
In House (Gift from Dr. 
Clair Harris) 
6.2 µg/ ml 
CD45.2 APC-Cy7 104 Biolegend 2 µg/ ml 
CD45.1 APC A20 eBioscience 2 µg/ ml 
Tim 4 PE RMT4-54 Biolegend 0.4 µg/ ml 
Tim 4 AlexaFluor647 RMT4-54 Biolegend 0.25 µg/ ml 
CD45.2 PerCP-Cy5.5 104 Becton Dickinson 4 µg/ ml 
Rabbit IgG1 DA1E New England Biolabs 0.25 µg/ ml 
pHH3 AlexaFluor488 D2C8 New England Biolabs 0.25 µg/ ml 
Ki67 PE Kit B56 Becton Dickinson 1 in 5 
Ki67 FITC Kit B56 Becton Dickinson 1 in 5 
Ly6G Pe-Cy7 1A8 Becton Dickinson 2 µg/ ml 
Ly-6B.2 PerCP 7/4 In House 12 µg/ ml 
F4/80 APC CI:A3-1 ABD Serotec 1 in 100 
F4/80 Pacific Blue CI:A3-1 ABD Serotec 1in 10 - 1 in 100 
F4/80 Pacific Blue BM8 Biolegend 5 µg/ ml 
F4/80 V405 CI:A3-1 ABD Serotec 1 in 100 
F4/80 PE-Cy7 BM8 Biolegend 4 µg/ ml 
F480 PerCP CI:A3-1 In House 10.8 µg/ ml 
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F4/80 PE CI:A3-1 ABD Serotec 1 in 100 
F4/80 PE-AlexaFluor750 CI:A3-1 ABD Serotec 1 in 100 
F4/80 PE-Texas Red BM8 Life Technologies 1 in 50 
F4/80 Biotin CI:A3-1 In House 20 µg/ ml 
CDllb FITC 5C6 In House 8 µg/ ml 
MHCII PerCP-Cy5.5 M5/114.15.2 Biolegend 1 µg/ ml 
CDllb PerCP-Cy5.5 M1/70 Becton Dickinson 2 µg/ ml 
CDllb APC-Cy7 M1/70 Becton Dickinson 0.2 µg/ ml 
FcγRII/III 2.4G2 In House 4 µg/ ml 
CD11c PeCy7 HL3 Becton Dickinson 4 µg/ ml 
CD73 Biotin TY/11.8 Biolegend 5 µg/ ml 
CD73 PE-eFluor710 TY/11.8 eBiosciences 4 µg/ ml 
Dyes 
DAPI N/A Life Technologies 25 ng/ ml 
Draq5 N/A Biostatus 25 µg/ ml 
Propidium Iodide N/A Life Technologies 125 ng/ ml 
LDS 751 N/A Life Technologies 100 ng/ ml 
Streptavidin linked fluorochromes 
-PE-Texas Red N/A Becton Dickinson 2 µg/ ml 
-Pacific Blue N/A Becton Dickinson 2 µg/ ml 
-APC N/A Becton Dickinson 2 µg/ ml 
-PE N/A Becton Dickinson 2 µg/ ml 
-AlexaFluor488 N/A Becton Dickinson 2 µg/ ml 
-Dylight594 N/A Biolegend 2 µg/ ml 
Immunocytochemistry 
Gata6 Biotin Polyclonal R&D Systems 40 µg/ ml 
Table 2.1. Antibodies and dyes 
Table showing the antibodies, dyes and streptavidin linked fluorochromes used in this 
thesis. Antibody concentrations are a rough guide for flow cytometry. New antibody 
lots were tested/ titrated before use due to variability in production; some companies 
do not disclose the antibody concentration. Abbreviations: FITC= fluorescein 
isothiocyanate, PE= phycoerythrin, Cy= cyanine, PerCP= peridinin chlorophyll, APC= 
Allophycocyanin, DAPI= 4’,6-diamino-2-phenylindole. 
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2.4 – Cell counting 
Most of the cell counting carried out in this thesis was performed using a 
haemocytometer. However, the Muse cell counter was used in chapter 6 of this thesis, 
and gave more accurate, objective results than the haemocytometer. The cell counter 
showed lower coefficients of variation than the haemocytometer, which is mainly 
attributed to the higher number of events counted (nominally 1000 in the Muse, 
compared with ≈200 on the haemocytometer). 
 
2.4.1 – Haemocytometer 
Cells were counted with a Neubauer bright line haemocytometer (depth: 0.1mm, small 
square area: 0.0025mm2). The cells in four large squares (20×20 small squares) were 
counted and the number divided by 4 to gain an average number of cells in 0.0001cm3 
(20×20×0.0025mm2×0.1mm). This cell number was multiplied by 10,000 to give the 
number of cells per ml (1cm3). 
 
2.4.2 – Millipore Muse 
The Millipore Muse cell counter contains a 532 nm green laser which stimulates the 
fluorescence of two deoxyribonucleic acid (DNA) dyes. One is LDS 751, and the other is 
propidium iodide (both from Life Technologies). LDS 751 is cell permeant, binds to the 
DNA of live cells and becomes fluorescent (peak emission = 543nm). Propidium iodide 
(peak emission = 617 nm) is cell impermeant, so only binds exposed DNA; for example: 
dead/ dying cells, whose plasma membranes are permeant. Thus, when cells were 
labelled with these dyes, all cells were LDS 751+, but only dead cells were propidium 
iodide+. Debris and non-nucleated cells (e.g. erythrocytes) were negative for both dyes. 
This, along with the cell counting ability (events/ µl) allowed for accurate counts of 
both live and dead cells (to additionally gain viability %). 
The short staining protocol was as follows:  
A cell aliquot (20 µl) was added to 80 µl of Muse staining solution (625 ng/ml 
Propidium iodide, 500 ng/ml LDS 751 in phosphate buffered saline (PBS)) within a 
screw-cap 1.5 ml microcentrifuge tube (VWR International), and incubated at room 
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temperature (RT) for 10 minutes. During this incubation the Muse cell counter was 
turned on and cleaned as per instrument instruction. The dyed cells were counted 
according to instrument instruction. The total number of cells was calculated using the 
dilution factor (this was 5 for 20:80 µl), total volume, and number of LDS 751+ events/ 
µl. Viability counted was the percentage of propidium iodide+ events within the LDS 
751+ population. If the cells were too concentrated (this was advised by the 
instrument), then a set volume of dyed cells was further diluted with PBS as required. 
If the cells were too dilute, a 50 µl aliquot of fresh cells were added to 50 µl staining 
solution, and recounted. Note: this was the limit of cell to staining solution mix (1:1 
ratio) for this stock concentration (625 ng/ml Propidium iodide, 500 ng/ml LDS 751 in 
PBS). However, a more concentrated stock could be formulated for very dilute cells. 
After counting the instrument was cleaned as per instrument instruction and switched 
off. 
 
2.4.3 – Haemacolor staining 
Cells (0.4-1.2×105) in 100 µl PBS were centrifuged onto polylysine-coated glass slides 
(Fisher Scientific) using a cytospin 3 (Thermo Scientific). The cells were air-dried for a 
maximum of 5 minutes, and the cells stained using the Haemacolor staining kit 
(Millipore). This involved fixing the cells with methanol, and subsequent staining with 
eosin and haematoxylin (by immersion, 30-60 seconds per step). After staining, cells 
were covered with 10 mm thin glass cover slips (Fisher Scientific) using 5 µl of DPX 
mountant (Sigma). Cells were viewed under a light microscope, and photographs were 
taken using the Leica DFC 490 camera. 
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2.5 – Cell Culture 
2.5.1 – General cell culture 
Canonical volumes of complete media (see individual cell sections below) used in 
Nunclon delta-treated tissue culture flasks (abbreviated as T) (Thermo-Fisher Scientific) 
are as follows: T25 (surface area – 25 cm2)= 5 ml; T75 (75 cm2)= 20 ml; T175 (175 cm2)= 
40 ml.  
Subculture: As an example, a 1 in 5 subculture translates as transferring 1/5 the cells 
from an old flask to a new flask, and restoring the volume to canonical levels (as 
mentioned above) with fresh complete media. All cells were incubated/ cultured at 37 
°C in a humidified incubator with 5 % CO2. For subculture of adherent cells: excess 
media was removed from the cells via aspiration. The cells were lifted from the flask 
surface by a 3 minute incubation at 37 °C with 2-10 ml (depending on flask size, see 
below) 0.05 % trypsin – EDTA (Life Technologies). The trypsin was inactivated by 
adding an equal volume of complete media to the flask, and a suitable volume of cells 
removed to a new flask containing 5-40 ml (depending on flask size, see above) of 
fresh complete media. Trypsin volumes used for various flask sizes were as follows: 
T25 = 2 ml; T75 = 5 ml; T175 = 10 ml. 
Freezing of cell lines: Viable cells were centrifuged at 350 × g for 5 minutes, the 
supernatant removed by aspiration and the pellet resuspended in foetal calf serum 
(FCS) supplemented with 10 % (v/v) dimethylsulfoxide (DMSO). The cells were 
aliquoted into 1 ml cryogenic vials (VWR), placed into a ‘Mr. Frosty’ freezing container 
(Thermo Scientific) filled with isopropanol (Sigma), and stored at -80 °C for 2 hours 
(assuming a -1 °C/ minute freezing time). The cells could then be removed from the 
‘Mr. Frosty’ container and stored long-term in liquid nitrogen storage (< -196 °C) or at -
80 °C for up to 1 year (lower levels of viability with time). 
Revival of frozen cell lines: A 1 ml aliquot of frozen cells was thawed quickly in a 37 °C 
water bath until only a small frozen fragment remained. These cells were then 
aliquoted into a 50 ml centrifuge tube containing 10 ml complete media and 
centrifuged at 350 × g for 5 minutes. The supernatant containing DMSO was removed 
and the pellet resuspended gently in 1 ml complete media. The cells were transferred 
to a tissue culture flask containing 10-40 ml (depending on flask size, see above) pre-
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warmed complete media, the flask was rocked gently to mix, and then placed 
horizontally in a humid 37 °C incubator (5 % CO2). 
 
2.5.2 – Culture of primary peritoneal cells 
Lavaged murine peritoneal cells (lavaged with Aim-V instead of standard lavage 
solution, see 2.6.5) were centrifuged at 350 × g for 5 minutes, and the supernatant 
aspirated with an aspirator pump. The cells were resuspended in 1ml of Aim-V and 
counted. The cell solution was made up to 1 × 106 cells per ml of Aim-V, and 0.5ml (0.5 
× 106 cells) was aliquoted into each well of a 48 well Nunc UpCell plate (Thermo-
Fisher). Cells were washed and resuspended in Aim-V media on day 1 and were 
cultured as required before further analysis. 
 
2.5.3 – Culture of bone marrow (BM) MØs  
Complete media: Roswell Park Memorial Institute medium (RPMI) (Life Technologies) 
supplemented with 10 % FCS, 0.2U/µl Penicillin and 100 µg/µl Streptomycin. 
An extracted femur (2.6.8) was placed in a bacterial Petri dish, submerged with 70 % 
ethanol and left to sterilise/wash for 1 minute. The ethanol was aspirated and the 
femur re-submerged in PBS, to remove excess ethanol. One end of the femur was 
removed carefully (to avoid shattering the bone) using forceps and a pair of scissors. A 
20 ml syringe (attached to a 23 G needle) filled with complete media was used to 
carefully flush out the bone marrow. The bone was held with a pair of forceps 
(exposed lumen up) over a 50 ml centrifuge tube and the needle tip was placed gently 
into the exposed bone lumen, whilst slowly pushing fluid through the needle. The 
needle was slowly pushed all the way into the bone lumen (still slowly ejecting fluid) 
and moved up and down through the lumen to remove all bone marrow. The 
previously dark red core of the bone looked white and semi-translucent after this 
procedure. If there was a substantial volume of bone marrow remaining near the 
closed end of the bone: this end was carefully removed and the procedure repeated to 
remove all the bone marrow. The 50ml centrifuge tube containing bone marrow was 
poured into a nylon membrane filter attached to a 50ml centrifuge tube. The new tube 
containing filtered bone marrow cells was centrifuged at 350 × g for 5 minutes. The 
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pellet was resuspended gently in 1 ml ACK red blood cell lysis buffer (Life Technologies) 
and 9 ml PBS was added. FCS (1 ml) was drawn into a 1 ml plastic Pasteur pipette, 
placed into the bottom of the tube containing the PBS/lysis solution and slowly ejected 
to create a layer of FCS at the bottom of the tube. This layer helped separation of 
debris from cells. The tube was centrifuged at 350 × g for 5 minutes and the pellet 
washed twice with complete media: the supernatant was removed and the pellet was 
resuspended in 1 ml of complete media and made up to 10 ml. The tube was 
centrifuged at 350 × g for 5 minutes. After the last wash, the cell pellet was 
resuspended in 1 ml complete media supplemented with 20 ng/ µl M-CSF, and made 
up to 10 ml. The cells were counted and 1 × 107 cells were plated onto a 145 mm Petri 
dish (4 × 105 cells per ml in 25 ml total volume) using complete media supplemented 
with 20 ng/ µl M-CSF. Additional complete media supplemented with 20 ng/ µl M-CSF 
(10 ml) was added every three days for up to 10 days, until the cells were confluent 
enough to re-seed for experimentation (as in 2.9.4). 
 
2.5.4 – Culture of 293-T cells 
Complete media: Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10 
% FCS, 0.2U/µl penicillin and 100 µg/µl streptomycin. 
These adherent cells were sub-cultured 1 in 10 roughly every 2 days to maintain cell 
health. The cells were sub-cultured 1 in 20 if left for more than 2 days. These cells were 
never allowed to reach 100 % confluency, due to the tendency of the cells to clump/ 
fuse.  
 
2.5.5 – Culture of MØ precursor cells 
Complete media: RPMI supplemented with 10 % FCS, 400µM L-glutamine, 0.2U/µl 
penicillin, 1 µM Oestrogen (β-estradiol), 10 ng/ml GM-CSF and 100 µg/µl streptomycin. 
Differentiation media: RPMI supplemented with 10 % FCS, 400µM L-glutamine, 0.2U/µl 
penicillin, 100 µg/µl streptomycin, and 20 ng/ µl M-CSF. 
These non-adherent cells were sub-cultured 1 in 10 roughly every 3 days to maintain 
cell health.  
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These cells could be differentiated into MØ: The cells were washed with RPMI three 
times; this involved removing the cells to a 50 ml centrifuge tube, centrifuging at 350 × 
g for 5 minutes, removing the supernatant by aspiration and re-suspending the pellet 
in 10 ml RPMI. After the last wash, the pellet was resuspended in 1 ml differentiation 
media and the cells counted. The cell number was adjusted to 0.64 × 106 cells per ml 
with differentiation media, and 1 ml was aliquoted into each well of a 6-well plate. The 
cells were incubated for 4 days, with the differentiation media topped up with an extra 
1 ml on day 2.  
 
2.5.6 – Culture of Jurkat-Eb.1 cells 
Complete media: RPMI supplemented with 10 % FCS, 400µM L-glutamine, 0.2U/µl 
penicillin and 100 µg/µl streptomycin. 
These non-adherent cells were sub-cultured 1 in 5 roughly every 2 days to maintain 
cell health. The cells were sub-cultured 1 in 10 if left for more than 2 days. 
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2.6 – Animal work 
2.6.1 – Animals used in this study 
Most animals were housed and maintained by Cardiff University’s Joint Biological 
Services (JBIOS) unit. C57BL/6 female mice were obtained from Harlan Olac. 
129S6/SvEv mice and 129S6/SvEv.Clec7a–/– (Dectin1-KO) (Taylor et al., 2007) were 
from Prof. Phil Taylor’s breeding colonies. The 129S6/SvEv.CD45.1 congenic mouse 
strain was bred from our own colonies (a kind gift from Prof. F. Powrie, Oxford). 
C57BL/6.Il4ra–/– mice were generated by backcrossing Il4ra–/– (Mohrs et al., 1999) onto 
the C57BL/6 genetic background for at least 9 generations (kindly provided by Prof. 
Frank Brombacher), and maintained in Edinburgh (by Dr. Steve Jenkins and Prof. Judith 
Allen). FoxP3-DTR-eGFP mice (Kim et al., 2007) were a kind gift from Prof. Alexander 
Rodensky (Memorial Sloan-Kettering Cancer Center, New York). Lysozyme M Cre 
recombinase (Cre) ‘knock-in’ congenic mice on the C57BL/6 background (‘Lyz2Cre’, 
B6.129P2-Lyz2tm1(cre)Ifo/J) (Clausen et al., 1999) and conditional ‘floxed’ Gata6 deficient 
mice (‘Gata6Fl’, Gata6tm2.1Sad/J) (Sodhi et al., 2006) were obtained from the Jackson 
Laboratories. Gata6-myeloid knockout (KOmye) mice (Lyz2+/CreGata6Fl/Fl), heterozygous 
KOmye mice (‘Het’, Lyz2+/CreGata6+/Fl) and ‘wild type’ (WT) littermates (Lyz2+/+Gata6Fl/Fl 
or Lyz2+/+Gata6+/Fl) were generated from crosses of two double heterozygous KO 
animals or crosses of KO animals and Lyz2+/+Gata6Fl/Fl mice, as appropriate (see figure 
6.5). All animal work was conducted in accordance with Institutional and UK Home 
Office guidelines under the project licenses 30/2401 (2010-2012) and 30/2938 (2012-
2014). All experiments were age and sex matched, unless specifically stated. For ex 
vivo culture, different strains of mice were used depending on availability, however 
these experiments were usually internally controlled (e.g. ± growth factor). 
 
2.6.2 – Intra-peritoneal (i.p.) injection 
Mice were restrained by pinching the loose skin above the neck with the thumb and 
side of the index finger of the left hand, holding the loose skin of the back with the two 
middle fingers pressed toward the palm, and by using the right hand to place the tail 
under the little finger of the left hand. The syringe needle (usually a 31 G, 0.5 ml insulin 
syringe) containing up to 500 µl of fluid was inserted into the lower left (posterior-left) 
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quadrant of the ventral abdomen at a 45° angle along the dorsoventral axis, when the 
mouse was tilted with its anterior pointed toward the table (to move the organs away 
from the injection point). The syringe was depressed to full, the needle removed, and 
the mouse returned. In the case of 4 % thioglycollate broth, a 27 gauge (G) needle in 
conjunction with a 2 ml syringe was used. 
Substances injected intra-peritoneally were: 100/ 200 µl zymosan in PBS (2 × 106-7 
particles) (Life technologies); 1ml 4 % Brewer’s thioglycollate broth (Sigma); 400 µl EdU 
in PBS (1 mg) (Life Technologies); αM-CSF, αIL-4 and IgG control (0.4 mg) in PBS 
(produced in house (no BSA) and from Bio X Cell (0.05 % BSA)); recombinant M-CSF 
(0.4 µg) in PBS containing 0.05 % BSA (Peprotech); and peritoneal/ BM cells (up to 1 × 
106 in up to 500 µl PBS). Additionally, lentiviral particles were injected; this was 
typically between 200-400 µl of 10-15 × concentrated lentivirus (see 2.9.2) in PBS or 
AimV media (Life Technologies).  
 
2.6.3 – Sub-cutaneous (s.c.) injection 
Mice were restrained by pinching the loose skin above the neck with the thumb and 
side of the index finger of the left hand, holding the loose skin of the back with the two 
middle fingers pressed toward the palm, and by using the right hand to place the tail 
under the little finger of the left hand. The syringe needle (31 G, 0.5ml insulin syringe) 
containing 400 µl EdU (1 mg) (Life Technologies) was inserted inside the loose skin of 
the posterior left of the abdomen (above the hip joint) at a shallow <45° angle along 
the dorsoventral axis. The syringe was depressed to full, the needle removed, and the 
mouse returned. 
 
2.6.4 – Genotyping 
A mouse ear disc (obtained using an ear punch – performed by JBIOS staff for 
genotyping purposes) was placed into a 1.5 ml microcentrifuge tube containing 50 µl 
of lysis buffer (100 mM Tris (pH 8.5), 5mM ethylenediaminetetraacetic acid (EDTA), 0.2 
% sodium dodecylsulphate (SDS) (w/v), 200 mM NaCl, 100 µg/ ml proteinase K – all 
from Sigma). The ear disc was submerged and the tube incubated at 50 °C for 1 hour 
(h) at 1200 revolutions per minute (rpm) in a shaking microcentrifuge tube heat block 
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(or 50 °C overnight with no revolutions). The reaction was terminated by incubation at 
72 °C for 15 minutes. The samples were diluted with 400 µl of clean deionised H2O 
(dH2O) to reduce the concentration of SDS. These samples could then be used in a 
polymerase chain reaction (PCR) (as in 2.8.5) at 0.8 µl per 20 µl reaction. The primers 
used are listed below.  
Cre F: CAGGCATGCTTTCTCTAGTCAG, R: TGATCCTGGCAATTTCGGCT.  
Gata6-Loxp: F: GTGGTTGTAAGGCGGTTTGT, R: ACGCGAGCTCCAGAAAAAGT.  
Lyz2-Cre: Cre-F: CCCAGAAATGCCAGATTACG,  
Lyz2-F: TTACAGTCGGCCAGGCTGAC, R: CTTGGGCTGCCAGAATTTCTC. 
Note: the Lyz2-Cre primer set was used for identification of Lyz2-Cre heterozygous/ 
homozygous mice during early breeding (figure 6.5). However, the newer Cre primers 
were used to assess the presence of Cre in Gata6-KOmye mice. These new primers were 
more efficient than the old when identifying Cre in genomic PCR. 
 
2.6.5 – Peritoneal lavage 
Mice were sacrificed in accordance with schedule one procedure (rising CO2 
concentration, followed by careful cervical dislocation to confirm death). The cadaver 
was turned upon its back, the loose skin of the abdomen was pinched together, and a 
sharp pair of scissors was used to cut a small incision in the skin at an upward 45° angle 
along the dorso-ventral axis (care was taken not to pierce the abdominal wall). The 
loose skin was then torn toward the hips (at a ≈45° angle along the left-right axis) on 
both sides to expose the abdominal wall (care was taken to avoid the navel, a weak 
point in the abdominal wall). A 5ml syringe containing 5ml of lavage solution (PBS + 
5mM EDTA) was loaded with a 21 G hypodermic needle. The needle was inserted into 
the peritoneal cavity at a low (≈20°) angle along the dorso-ventral axis (the bevelled tip 
pointing up), care was taken to avoid the intestines and blood vessels in the peritoneal 
wall. The needle was then rotated around 180° so that the bevelled tip pointed down. 
A small volume of solution was injected to give the needle room, then the angle of the 
needle was increased to 45-75° and the syringe depressed quickly to mix the 
peritoneum with all the lavage solution. The needle-syringe joint was held while 
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depressing the syringe to avoid separation, care was taken to keep the tip of the 
needle in the cavity, but not contact organs, such as the liver (which would result in 
bleeding). The peritoneal cavity was gently massaged with a finger and thumb to 
suspend the maximum number of cells. The needle was pulled left toward the user 
along the left-right axis and up against the peritoneal wall (making sure the bevel was 
still pointed toward the peritoneal cavity), the lavage solution was slowly drawn back 
up into the pipette, avoiding the intestines and fat. While drawing the liquid, the 
intestines were pushed back from the needle point with a finger to create a pocket of 
lavage fluid, which could be drawn off more efficiently. In the case of abdominal fat 
accidently entering the needle, the needle was withdrawn from the entry site, whilst 
still drawing the syringe to block the entry site with the abdominal fat. A new site was 
selected to withdraw the remaining fluid. The needle was removed from the cavity 
when most (≈4-4.5ml assuming no leakage) of the fluid was removed. The needle was 
then carefully removed from the syringe and disposed of. The fluid inside the syringe 
was ejected slowly into a 15ml centrifuge tube on ice. The freshly lavaged cells were 
stored on ice up to 5 hours before use if necessary (the smallest incubation time 
possible was preferable).  
 
2.6.6 – Pleural lavage 
Mice were sacrificed in accordance with schedule one procedure (rising CO2 
concentration, followed by careful cervical dislocation to confirm death). The cadaver 
was turned upon its back, the loose skin of the abdomen was pinched together, and a 
sharp pair of scissors was used to cut a small incision in the skin at an upward 45° angle 
along the dorsoventral axis (care was taken not to pierce the abdominal wall). The 
loose skin was torn toward the hips (at a ≈45° angle along the left-right axis) on both 
sides to expose the abdominal wall, then upward toward the thorax to expose the 
entire ribcage. A 2ml syringe containing 2ml of lavage solution (PBS + 5mM EDTA) was 
loaded with a 21G hypodermic needle. The needle was inserted into the pleural cavity 
at a low (≈20°) angle along the dorsoventral axis (the bevelled tip pointing up) between 
the lower two ribs, care was taken to avoid piercing the lungs and blood vessels in the 
pleural wall. The needle was then rotated around 180° so that the bevelled tip pointed 
down. The syringe was depressed quickly to mix the pleural contents with lavage 
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solution (the needle-syringe joint was held while depressing the syringe to avoid 
separation and care was taken to keep the tip of the needle in the cavity). The pleural 
cavity was tapped roughly with an index finger to suspend the maximum number of 
cells. The lavage solution was then slowly drawn back up into the pipette, with a slight 
movement of the needle if no liquid came out. The needle was removed from the 
cavity when most (≈1.5 ml assuming no leakage) of the fluid was removed. The needle 
was then carefully removed from the syringe and disposed of. The fluid inside the 
syringe was ejected slowly into a 15ml centrifuge tube on ice. The freshly lavaged cells 
were stored on ice up to 5 hours before use if necessary (the smallest incubation time 
possible was preferable). 
 
2.6.7 – Adoptive transfer 
Cells were lavaged (see 2.6.5, but using 1ml of lavage fluid) from CD45.1 129S6/SvEv 
congenic mice, counted (see 2.4) and injected intra-peritoneally (see 2.6.2) into CD45.2 
129S6/SvEv congenic mice. Typically, 200-400 µl of lavage fluid was transferred 
(between 2-10 × 105 cells). 
For adoptive transfer of BMMØ: BMMØs were cultured from femur bone marrow, and 
transduced with lentivirus (see 2.5.3 and 2.9.4). The media was aspirated from the 
cells, and the cells washed three times with PBS (aspirating after each wash). PBS (1 
ml) was added to each well and the transduced cells removed from the plate with a 
cell scraper. The cells were gently mixed by pipetting, and counted (see 2.4). Typically, 
1-2 × 105 cells were transferred in a volume of 200-400 µl. An aliquot of cells was kept 
for flow cytometric analysis and calculation of transfection efficiency (see 2.7). 
 
2.6.8 – Femur extraction 
Mice were sacrificed in accordance with schedule one procedure (rising CO2 
concentration, followed by careful cervical dislocation to confirm death). The cadaver 
was turned upon its back, the loose skin of the abdomen was pinched together, and a 
sharp pair of scissors was used to cut a small incision in the skin at an upward 45° angle 
along the dorsoventral axis (care was taken not to pierce the abdominal wall). The 
loose skin was torn toward the hips (at a ≈45° angle along the left-right axis) on both 
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sides to expose the abdominal wall, then toward both legs to expose the thigh 
muscles. A pair of sharp scissors was inserted between the femur and muscle (the 
scissor tip can be used to locate the bone) on the dorsal side of the upper leg and 
pushed through to the table. The scissors were slowly but forcibly opened (downward 
pressure toward the table) using the right hand; with the left hand index finger holding 
the mouse’s knee and the thumb holding the left flank of the mouse. This process 
either removed the bone from the knee or hip joint. If the femur was removed from 
the hip: the femur was dislocated from the knee joint by bending in the opposite way 
from the normal range of movement. If the femur was removed from the knee: the 
femur was held between finger and thumb and pulled away from the hip joint, using a 
sharp scissors to remove excess ligaments and tissue. In both cases, excess muscle was 
removed with a scissors, and the bone dried with tissue. The femur was finally placed 
in ice cold PBS for further processing (see 2.5.3). 
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2.7 – Flow Cytometry 
2.7.1 – Total cell staining 
Lavaged murine peritoneal cells were counted with a bright line haemocytometer 
(2.4.1), and the cells were aliquoted into a fresh 15 ml centrifuge tube. An equal 
volume of 2 % (v/v) formaldehyde solution in PBS was added to give a final 
concentration of 1 % (v/v) formaldehyde. This solution was stored for 20 minutes on 
ice to fix the cells. The tubes containing the cell suspension were centrifuged in a 
swivel rotor desktop centrifuge at 350 × g for 5 minutes at room temperature to pellet 
the cells (all subsequent centrifugations are performed at the same speed and time). 
The supernatant was removed by inverting the tube and blotting excess liquid with 
tissue. The pellet was resuspended in wash solution (PBS with 0.5 % (w/v) bovine 
serum albumin (BSA), 0.5 % (w/v) saponin, 5 mM EDTA and 2 mM sodium azide) to 
give a concentration of 2×107 cells/ ml, and 100µl of this was aliquoted to a well of a v-
bottom 96-well plate. This plate was centrifuged to pellet the cells. The supernatant 
was aspirated with a multi-channel pipette. The pellet was resuspended in 30 µl of 
block solution (wash supplemented with 5 % (v/v) rabbit serum and 4 µg/ ml rat anti-
mouse FcγRII/III (2.4G2)). The cells were incubated for 15 minutes on ice, in the dark. 
Antibody mixes were formulated (see table 2.1) and 20 µl was added to the 30 µl 
block/ cell solution to achieve a 1 × working concentration in 50 µl total staining 
volume. If no secondary (e.g. biotin-streptavidin) step was required, then dyes such as 
DAPI were added to the antibody mix at this stage. This mixture was incubated on ice 
for 1 hour in the dark. The plate was centrifuged and the supernatant removed. The 
cells were washed: the plate was centrifuged, the supernatant removed and pellet was 
resuspended in 150 µl wash solution, the plate was centrifuged again and the 
supernatant aspirated (this was repeated twice). If a biotin-conjugated antibody was 
used, then the cells were resuspended in 50 µl wash containing 2 µg/ ml of 
streptavidin-linked fluorochrome. If a DNA dye (e.g. DAPI) was required, it was added 
to this mixture. This solution was incubated on ice for 30 minutes in the dark. The cells 
were washed three times as described above, and the pellets resuspended in 150 µl 
wash. The cell solution (150 µl) was transferred by pipette into a labelled microtitre 
tube. To dilute the sample: 150 µl of wash solution or 25 µg/ ml of Draq5 (if required) 
in wash was added (Draq5 was incubated for 20 minutes at room temperature). The 
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microtitre tube was inserted into a 5 ml polypropylene tube and the sample was 
analysed using the Beckman-Coulter Cyan-ADP (9 colour) flow cytometer. 
 
2.7.2 – Use of nuclear isolation media (NIM)-DAPI for flow cytometry 
NIM-DAPI (Beckman-Coulter) was used to lyse the adherent cells, and release the 
nuclei (whilst staining with DAPI). NIM DAPI (400 µl) was added to the wells and 
scraped with a cell scraper to aid in cell lysis and recovery of nuclei. Cells were 
suspended and mixed by pipetting before incubation for 30 minutes at 4 °C in the dark. 
After incubation and mixing, only 350 µl of lysate was removed, which allowed for 
accurate nuclei numbers to be assessed (1.1429 times more than counted). The 350 µl 
lysate was transferred to a microtitre tube containing 5 µl cell counting beads 
(Beckman-Coulter) (approximately 5000 beads). This was mixed thoroughly with a 
pipette before analysing on a Cyan-ADP (9 colour) flow cytometer. The nuclei (DAPI+) 
were counted alongside beads (fluorescent in all channels, however red channels were 
used), and an equation was used to calculate total DAPI+ nuclei: (bead count/ bead 
total) × nuclei count = nuclei in 350 µl, nuclei in 350 µl × 1.1429 = total nuclei in well. 
Due to the analysis of individual nuclei, the complicating effects of non cell cycle-
associated DNA content were avoided (see chapter 3 of this thesis). 
 
2.7.3 – Flow cytometric cell sorting 
Cells were resuspended at 2 ×107 cells/ ml in ice cold wash solution without NaN3 (PBS 
with 0.5 % (w/v) BSA and 5 mM EDTA) supplemented with 5 % (v/v) rabbit serum and 4 
µg/ ml rat anti-mouse FcγRII/III (2.4G2). The cells were incubated on ice for 20 
minutes. Fluorescent antibodies (see table 2.1) were added directly to the cell block 
solution, which was gently pipetted to mix. This was incubated for 30 minutes on ice in 
the dark. The cells were centrifuged at 350 × g for 5 minutes at 4 °C, the supernatant 
removed by inversion and blotting with tissue, and the cells resuspended to 20 ×106 
cells/ ml in ice cold wash solution to wash. This step was repeated to wash the cells a 
second time. The cells were then transferred to either a 15 ml centrifuge tube 
(FACSAria III) or 10 ml polypropylene tube (MoFlo legacy), both were pre-blocked with 
FCS to limit unwanted cell adherence. The cells were sorted using the MoFlo legacy, 
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and FACSAria III as per instruments instruction. An example of cell sort gating is shown 
in figure 2.1. Cells were collected from the MoFlo legend in a 10 ml polypropylene tube 
stored on ice. The cells were kept cold in the FACSAria III by using the inbuilt 
refrigeration system, and collected in a 15 ml centrifuge tube. Purities were typically 
90-98 %. 
 
 
Figure 2.1. Example of gating in flow cytometric cell sorting 
Example density plots showing pooled cells stained with F4/80 and CD11b from the 
peritoneal cavities of 5 male 129S6/SvEv mice. The plots show sequential gating from 
the left to right, and this was used to charge droplets containing ResMØs for sorting on 
the MoFlo legacy. 
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2.8 – Lentiviral vector cloning 
The pHR’SIN-cPPT-SEW (Demaison et al., 2002) plasmid and an eGFP deficient version 
(pHR’SIN-cPPT-SXW) were kindly provided by Dr. Paul Brennan. 
 
2.8.1 – Primer design 
In-fusion cloning primers (ordered from Sigma) (table 2.2) were designed to include a 
15 base pair (bp) region which overlapped with the regions flanking the restriction 
endonuclease digestion site in the vector sequence. These primers were used to 
amplify target genes for expression vectors by PCR, or dimerised (forward and reverse) 
for short hairpin (sh) ribonucleic acid (RNA) constructs by heating to 98 °C for 5 
minutes and then slowly cooling to RT. The new templates formed were gel purified 
(see 2.8.3), and used in in-fusion cloning in conjunction with restricted starting vectors, 
to produce new vectors (see 2.8.6). 
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Starting 
Plasmid 
Restriction 
New 
Plasmid 
Primer Pairs / Synthetic templates 
SXW 
Xho I 
GATA6 
PCR F: 
GGATCCCGGGCTCGAGCCACCATGTACCAGACCCTCGCC 
PCR R: 
TACCAGGCCTCTCGAGTCAGGCCAGGGCCAGAGCA 
GATA6-Myc 
PCR F: 
GGATCCCGGGCTCGAGCCACCATGTACCAGACCCTCGCC 
PCR R: 
TACCAGGCCTCTCGAGTTACAGATCTTCTTCAGAAATAAG
TTTTTGTTCGGCCAGGGCCAGAGC 
Cre-Myc 
PCR F: 
GGATCCCGGGCTCGAGCCACCATGTCCAATTTACTGACC 
PCR R: TACCAGGCCTCTCGAGTCACAAGTCTTCTTC 
Mlu I 
T2A-rCD2 
Intermediate 
PCR F: : GCCTGGTACCACGCGTCTCGAGAGCGGCAGCGG 
PCR R: 
TCGCGGCCGCACGCGTTTACCGTTTTTTCCTCTTGCA 
T2A-rCD2 
Intermediate 
Xho I 
T2A-rCD2 
F: 
GGATCCCGGGCTCGACCACCATGCTCGAGAGCGGCAGC 
R: 
GCTGCCGCTCTCGAGCATGGTGGTCGAGCCCGGGATCC 
T2A-rCD2 
Gata6-T2A-
rCD2 
PCR F: GGATCCCGGGCTCGACCACCATGTACCAGACCCTC 
PCR R: CGCTGCCGCTCTCGAGGGCCAGGGCCAGAGC 
Cre-rCD2 
PCR F: 
GCTTGATATCGAATTCGATCCGACGCCGCCATCTCT 
PCR R: 
GGGGCTGCAGGAATTCGTTTAAACAAGGCTTTTCTCCAA
GGG 
SEW or T2A-
rCD2 
Eco RI 
U6 (eGFP or 
T2A-rCD2) 
PCR F: 
GCTTGATATCGAATTCGATCCGACGCCGCCATCTCT 
PCR R: 
GGGGCTGCAGGAATTCGTTTAAACAAGGCTTTTCTCCAA
GGG 
U6 (eGFP or 
T2A-rCD2) 
Pme I 
ICAM-1 
shRNA 
(eGFP) 
F: 
AGAAAAGCCTTGTTTGACGCTGACTTCATTCTCTATTCTCG
AGAATAGAGAATGAAGTCAGCGTCTTTTTCGTTTAAACGA
ATTCCTGCA 
R: 
TGCAGGAATTCGTTTAAACGAAAAAGACGCTGACTTCATT
CTCTATTCTCGAGAATAGAGAATGAAGTCAGCGTCAAAC
AAGGCTTTTCT 
Non-
Silencing 
shRNA (eGFP 
or T2A-rCD2) 
F: 
AGAAAAGCCTTGTTTGTCTCGCTTGGGCGAGAGTAAGTA
GTGAAGCCACAGATGTACTTACTCTCGCCCAAGCGAGAC
TTTTTCGTTTAAACGAATTCCTGCA 
R: 
TGCAGGAATTCGTTTAAACGAAAAAGTCTCGCTTGGGCG
AGAGTAAGTACATCTGTGGCTTCACTACTTACTCTCGCCC
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AAGCGAGACAAACAAGGCTTTTCT 
Gata6 shRNA 
(T2A-rCD2) 
F: 
AGAAAAGCCTTGTTTGCCACTACCTTATGGCGTAGAACTC
GAGTTCTACGCCATAAGGTAGTGGCTTTTTGTTTAAACGA
ATTCCTGCA 
R: 
TGCAGGAATTCGTTTAAACAAAAAGCCACTACCTTATGGC
GTAGAACTCGAGTTCTACGCCATAAGGTAGTGGCAAACA
AGGCTTTTCT 
Table 2.2. In-fusion cloning primers 
Table showing in-fusion cloning primers and the vectors/ restriction endonucleases 
used to produce new vectors. (Cre = Cre, F = forward oligonucleotide, R = reverse 
oligonucleotide, PCR = polymerase chain reaction primer). 
2.8.2 – Restriction endonuclease digestions 
Plasmids were cut by restriction endonucleases (NEB) using the appropriate buffer at 
37°C for 1 hour. Reactions were terminated by heating to 65°C for 20 minutes. 
Enzymes used were: Xho I, Mlu I, Eco RI and Pme I. Cut vectors were brought out of 
aqueous solution by adding 0.7 volumes of isopropanol and purified using columns 
from the QIAquick gel extraction kit (Qiagen) (see 2.8.4). 
 
2.8.3 – Agarose gel electrophoresis (AGE) 
Agarose powder (Sigma) was added to 0.5 × Tris-Borate EDTA (TBE) solution (Life 
Technologies) in an autoclave flask (1-2 % (w/v) agarose). The powder was dissolved by 
heating the solution in a microwave until boiling. This hot gel was left until cool 
enough to hold without scalding, but not to set. Ethidium bromide (100ng/ml) (Life 
Technologies) was added before the gel was poured into a gel caster with well moulds. 
Larger wells were created by placing tape over and between the wells. The gel was left 
to cool until set. This gel could be stored at 4°C for up to 48 hours. Additional agarose 
(without ethidium bromide) can be stored at room temperature and re-melted when 
required. The agarose gel was submerged in a gel tank filled with 0.5 × TBE. DNA 
loading dye (6 ×) (Promega) was added to the samples to achieve a final concentration 
of 1 × DNA loading dye. Up to 150 µl of sample was loaded into the wells via gentle 
pipetting. DNA ladders were loaded into an adjacent well to measure the size of the 
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DNA bands: 5-10 µl of 1kB (kilo base pair) (Invitrogen) or 100bp (base pair) (Promega) 
ladder was used. The gel was run at 100 volts for 30 minutes to separate DNA bands 
from contaminants and non-specific products. The gel was viewed under UV 
(ultraviolet) light where photographs were taken with the Auto-Chemi Darkroom 
Imaging System (UVP). 
 
2.8.4 – Gel extraction and DNA purification 
Gels were viewed on a UV transilluminator and targeted bands were dissected using a 
scalpel bade (this was carried out on separate sheets of saran wrap (VWR) to minimise 
contamination). The gel bands were deposited in pre-weighed 2ml microcentrifuge 
tubes, and weighed again; the new weight was used to calculate the mass of the gel. 
This mass was needed to perform DNA purification using the QIAquick gel extraction 
kit (Qiagen). This was used as per manufacturer’s instructions: The gel was dissolved 
and bound to a column membrane, this membrane was washed with ethanol to 
remove impurities and then the DNA was eluted with water. DNA concentration was 
measured using the Nanodrop spectrophotometer (this equipment calculates DNA 
concentration based on the equation: optical density at 260nm × 50 ng/ µl (constant) = 
ng/ µl of DNA). The kit was also used to purify DNA from a solution, by adding 0.7 
volumes of isopropanol (Thermo-Fisher) to the solution, and followed by binding the 
sample to the column membrane. DNA was stored at -20°C. 
 
2.8.5 – Polymerase chain reaction (PCR) 
PCRs were performed using a Peltier Thermal Cycler (PCT-200); the programme is 
shown in table 2.3 and was used unless otherwise stated. DNA was stored at -20°C. 
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Step Process Temperature (°C) Time Cycle 
1 Initial denaturisation/ Hot-start 98 5 minutes  
2 Denaturisation 98 30 seconds  
3 Annealing 60 30 seconds  
4 Extension 72 30 seconds per Kb  
to step 
2, × 30 
5 Final extension 72 10 minutes  
6 Resting 4 ∞  
Table 2.3. The PCR programme 
A table showing the times and temperatures of a PCR reaction, the programme cycled 
from step 2-4 thirty times. The extension step was 30 seconds per Kb of the PCR 
product. 
GoTaq green polymerase (Promega) was used for conventional PCR reaction mixes, 
and the reaction mix was as follows: 1× Buffer (MgCl2 final made up to 2.5 mM), 250-
500nM primers, 200nM of each dNTP, 0.05 Units/µl GoTaq DNA polymerase. The final 
volume was 20 µl per reaction. 
The Advantage High Fidelity or High Fidelity-2 kit (Clontech) was used for higher quality 
proofreading PCR. The reaction mix is as follows: 1 x Buffer, 250-500 nM primers, 1 × 
dNTP, 1 × Advantage High Fidelity or High Fidelity-2 DNA polymerase mix. The final 
volume was 50 µl per reaction. Three reactions were pooled after the PCR to obtain 
the necessary mass of product needed for efficient purification (150 µl). The DNA 
polymerase mix contained Titanium Taq, which works over a broad range of MgCl2 
concentrations, the kit did not disclose MgCl2 concentration; it was however optimised 
for high fidelity. 
 
2.8.6 – In-fusion cloning 
Cut vector (100 ng) was mixed with insert (50 ng) in 0.2 ml 8-strip tubes (STAR 
laboratories), and the total volume was made up to 4 µl with water. The In-fusion 
cloning reaction component (1 µl) (Clontech) was mixed into the solution by pipetting. 
The tubes were placed in a PTC-200 thermal cycler, and incubated at 50°C for 15 
minutes for the recombination reaction. The solutions were diluted by adding 20 µl of 
water and could be stored at -20°C. 
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2.8.7 – Escherichia coli (E. coli) transformation via heat shock 
Lysogeny broth (LB) Agar (Sigma) was formulated according to manufacturer’s 
instructions; this involved adding agar tablets to water inside an autoclave flask, and 
autoclaving to sterilise and dissolve the tablets. The agar could be stored at room 
temperature for up to a year.  
A 50 µl vial of one-shot Top10 competent E. coli cells (Life Technologies) was defrosted 
on ice for 15 minutes, and a vial of sterile super optimal broth with catabolite 
repression (SOC) (Life Technologies) was placed in a 37°C water bath. During this time, 
1 µl of the diluted In-fusion reaction solution (from 2.8.6) was aliquoted into 0.2 ml 8-
strip tubes (STAR laboratories). An aliquot (10-50 µl) of defrosted E.coli was mixed with 
the 1 µl solution and was incubated on ice for 30 minutes. The tubes were placed into 
a ready PTC-200 thermal cycler set at 42°C and held for exactly 30 seconds before 
transferring them directly back to the ice. The pre-warmed SOC media (100-200 µl) 
was added to the transformed cells before incubating in a shaking incubator (200 rpm) 
at 37°C for 1 hour. The tubes were adhered to a rack which was subsequently adhered 
to the floor of the shaker to promote maximal motion.  
During this incubation, the previously made agar solution was re-melted in a 
microwave and left until cool enough to hold without scalding, but not left to re-set. 
Ampicillin (100 µg/ ml) was added to the warm agar, and mixed well. The agar (≈20 ml) 
was poured into 85 mm Petri dishes (Thermo-Fisher) and left to set at RT.  
A range (10-100 µl) of transformed cells in SOC media was aliquoted onto separate 
agar plates and the liquid culture spread out on the agar using a plate spreader 
(Thermo-Fisher). The plates were then inverted (to prevent condensation) and 
incubated at 37°C for 12-18 hours. Plates were selected which had separate colonies 
and these could be stored at 4 °C for up to 1 month. 
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2.8.8 – E. coli culture 
LB broth was formulated according to manufacturer’s instructions; this involved adding 
LB tablets to water inside an autoclave flask, and autoclaving to sterilise and dissolve 
the tablets. The LB broth could be stored at room temperature for up to a year. 
A selected E. coli colony was touched gently with the end of a pipette tip (10/200 µl), 
and this tip was ejected into LB broth with ampicillin (100 µg/ ml). Larger volumes 
were used for plasmid Maxi kits (200 ml) and Midi kits (100ml) in autoclaved 1 L 
conical flasks, and smaller volumes were used for Mini kits (10ml) in 50 ml centrifuge 
tubes. These cultures were secured and incubated at 37°C for 18 hours in a shaking 
incubator (225 rpm). The lids of the centrifuge tubes were left loose, i.e. not screwed 
down, but loosely taped on, to allow air to enter the tubes. A loose fitting foil was 
placed over the top of the conical flasks.  
The large cultures were poured into 500 ml centrifuge flasks and the small cultures 
kept in their 50 ml centrifuge tubes. These were centrifuged at 3800 × g for 15 minutes 
at 4°C, to pellet the cells. The supernatant was poured off and disposed of; the pellet 
could be stored at -80°C if not used immediately (see below, 2.8.9). 
 
2.8.9 – Plasmid DNA extraction 
Qiagen Maxi, Midi and Mini plasmid prep kits were used to extract plasmid DNA from 
E. coli. The kits were used as per manufacturer’s instructions: The cell pellets were 
resuspended and lysed to release plasmid DNA, this was halted after 5 minutes to 
minimise contamination from bacterial DNA. The solution was centrifuged or sent 
through a filter to remove the protein-SDS aggregate from the lysate. The supernatant 
or eluate was placed onto a membrane to bind the DNA, which was then washed with 
ethanol. The DNA was eluted with water or elution buffer. For the larger kits this 
eluate was concentrated using isopropanol, then washed with ethanol and the DNA 
pellet partially dried (the tubes were left inverted over clean tissue for 5-10 minutes) 
and resuspended in water. DNA concentration was measured using the Nanodrop 
spectrophotometer (see end of section 2.8.4). DNA was stored at -20°C.  
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2.8.10 – DNA sequencing and validation 
DNA sequencing was carried out by Cardiff University Central Biotechnology Services 
(CBS). A primer (3.2 µl of a 1 µM solution) (see table 2.4) and 300 ng of vector or PCR 
product was needed per sequence read. The Chromas Lite software (Technelysium) 
was used to view sequence data and BLAST (basic local alignment search tool) 
(National Library of Medicine) was used to align and compare sequences. The 
algorithm parameters were always adjusted to remove the filter for low complexity 
regions. 
 
Name Sequence 
SXW Eco RI Forward GGTACAGTGCAGGGGAAAGA 
SXW Eco RI Reverse CAAACCTACAGGTGGGGTCT 
SXW Xho I Forward CTCTATAAAAGAGCTCACAACC 
SXW Xho I Reverse GGGCCACAACTCCTCATAAA 
Pre-trCD2 Reverse AGACGGTCCCACTGTCTCTG 
eGFP Sequencing Forward AGGACGACGGCAACTACAAG 
eGFP Sequencing Reverse CGATGTTGTGGCGGATCTTG 
Gata6 Sequencing Forward GTGATGTCTGCAGTGGGAGA 
Table 2.4. Sequencing primers 
Table showing the sequences of primers used for DNA sequencing. 
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2.9 – Viral particle production 
2.9.1 – Transfection 
Confluent 293-T cells were trypsinised and counted (See 2.5.4). Complete media (10 
ml) was aliquoted into T75 tissue culture flasks followed by 1.8×106 cells. The flasks 
were rocked gently whilst still vertical, then on the horizontal plane to mix well and 
ensure maximal seeding efficiency (care was taken not to get any fluid in the lid). The 
cells were incubated for 24 hours at 37°C. The supernatant was aspirated from the 
cells, and the cells were washed with 5 ml PBS: the PBS was added and gently rocked 
over the cells followed by aspiration; and then 12 ml of fresh complete media was 
added. The flask was briefly placed back into the incubator (37°C). 
Cells were transfected using the Effectene transfection kit (Qiagen): The lentiviral 
plasmid (1µg) was mixed with the pCMVΔ8.91 (750ng) and pMD2G (500ng) plasmid, 
and this solution was made up to 300 µl with condensation buffer EC. Enhancer (18 µl) 
was added to the buffer EC-DNA mix, vortexed briefly and left at room temperature for 
5 minutes to condense the DNA. Effectene transfection reagent (60 µl) was added and 
the solution vortexed for 10 seconds; this was left to incubate at room temperature for 
10 minutes to form micelle complexes around the condensed DNA. This solution was 
gently transferred to a 15 ml centrifuge tube containing 2.622 ml of complete media 
(to make 3 ml total volume), mixed gently with a 5 ml pipette and then added carefully 
to the flask containing 12 ml media on the cells to bring the total to 15 ml. This flask 
was rocked gently first vertically then on the horizontal plane to mix and ensure 
complete coverage of the flask. The flask was incubated at 37°C for 48 hours. The cell 
supernatant was transferred via pipette into a 50 ml centrifuge tube and centrifuged at 
500 × g for 10 minutes to remove cells and large cell debris. This new supernatant (15 
ml) was removed to a fresh 50 ml centrifuge tube and either stored at -80°C or 
concentrated (see 2.9.2). 
 
2.9.2 – Viral particle concentration 
The supernatant (15 ml) from above (2.9.1) was carefully poured into a 50 ml 
centrifuge tube containing 5 ml of Lenti-X concentrator solution (Clontech), the lid was 
closed and the tube inverted to mix. This step could have been doubled up within the 
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same tube (i.e. two flasks: 30 ml supernatant with 10 ml concentrator). This new 
solution was stored at 4°C for 2-24 hours (until the solution was thoroughly cooled) to 
enable binding of concentrator particles. The tube was centrifuged at 1500 × g for 45 
minutes at 4°C to pellet the virus/ concentrator. The supernatant was poured off 
carefully and the pellet resuspended gently in 1ml Aim-V media (Life Technologies) or 
PBS and stored at -80°C. This process resulted in a 15-fold increase in viral 
concentration. Lentivirus resuspended in Aim-V media could be used on cells in culture 
without dilution of the media and caused no significant inflammation when injected 
into mice (quantified by numbers of inflammatory cells, e.g. neutrophils, when 
compared to injection of PBS). 
 
2.9.3 – Multiplicity of infection (MOI) calculations 
The MOI of tagged (usually eGFP) lentiviruses was quantified using Jurkat cells and 
Poisson distribution (Zhou et al., 2003, Fehse et al., 2004). The number of Jurkat cells 
(see 2.5.6) seeded with a titrated volume (0-250 µl) of concentrated virus with 
complete media was kept constant: 0.3 × 106 cells in 250 µl total volume were 
aliquoted into each well of a 24-well plate. The plates were incubated at 37 °C in a 
humidified incubator. Cells were topped up with an additional 500 µl complete media 
(see 2.5.6) on day 1. The experiment was terminated on day 2 by pipetting an equal 
volume of 2 % formaldehyde (Sigma) into the wells and mixing gently. This was left for 
20 minutes at RT, to fix cells and virus. Cells were then analysed using flow cytometry 
and the percentage of infected cells calculated. A standard curve of Poisson 
distribution (probability of infection distribution) was used to calculate MOI based on 
the percentage of cells infected. These MOI values were for individual volumes of 
concentrated virus used; therefore an average MOI per µl of concentrated virus was 
formulated. The average MOI per µl could be used to calculate the number of viral 
particles per µl, by dividing the starting number of cells (0.3 × 106) by MOI. However, 
this value does not take into consideration the number of newly generated Jurkat cells 
during the 2 day incubation (which could have been >0.9 × 106) or the infection 
efficiency. Therefore the MOI per µl was only used to relatively compare viral titres. 
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2.9.4 – Use of lentiviral particles in culture 
Jurkat cells (0.3 × 106) in a volume of 150 µl of complete media were aliquoted into 
wells of a 24-well plate. Dilutions of concentrated virus (in Aim-V media) were added 
to the wells (100 µl total volume), and the plates incubated at 37°C for 72 hours. The 
viral media was topped up with 500 µl every 24 hours. After the 72 hour incubation, 
cells could then be set up for continued culture (see 2.5.6). 
Bone marrow MØs (see 2.5.3) were plated into wells of a 6 well plate (0.6 × 106 cells in 
1ml complete media supplemented with 20 ng/µl M-CSF), and incubated for 24 hours 
at 37°C. The media was aspirated, and 750 µl complete media supplemented with 20 
ng/ µl M-CSF was aliquoted onto the cells. Virus (250 µl of 10 × concentrate) was 
added gently to the wells, and the plate incubated for 5 days at 37°C. Media (500 µl) 
was added to wells every 24 hours. 
Lavaged murine peritoneal cells (lavaged with Aim-V instead of lavage solution, see 
2.6.5) were centrifuged at 350 × g for 5 minutes, and the supernatant aspirated with 
an aspirator pump. The cells were resuspended in 1ml of Aim-V and counted. The cell 
solution was made up to 2 × 106 cells per ml of Aim-V; and 0.25ml (0.5 × 106 cells) was 
aliquoted into each well of a 48 well Nunc UpCell plate (Thermo-Fisher), containing 
0.25ml of concentrated lentiviral particles (see 2.9.2). The cells were topped up with 
0.5 ml fresh complete media after 24 hours, and then every 48 hours. The cells were 
usually analysed 3-5 days after initial culture. 
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2.10 – Real-time PCR 
2.10.1 – RNA extraction 
The RNeasy mini and micro kits with or without optional on-column deoxyribonuclease 
digestion were used to extract RNA (Qiagen). In brief: Cells were lysed to free nucleic 
acids, which were brought out of solution with ethanol and bound to a membrane. The 
nucleic acids were washed to remove chromatin contaminants (with or without an 
optional deoxyribonuclease digestion), and then contaminating salts were washed 
away with ethanol. Finally, the ethanol was removed and the RNA eluted with 
ribonuclease-free dH2O (Life Technologies). 
RNA concentration was measured using the Nanodrop spectrophotometer (Thermo 
Scientific) as per manufacturer’s instruction. This equipment calculates RNA 
concentration based on the equation: optical density at 260 nm × 40 ng/ µl (constant) 
= ng/ µl of RNA. 
 
2.10.2 – Reverse transcription 
cDNA was synthesised using the reverse transcription kit (Primer Design) or the high 
capacity cDNA reverse transcription kit (Life technologies). Random hexamers were 
used to synthesise cDNA from the RNA obtained above using manufacturer’s 
instructions. The cDNA was diluted to 5 ng/ µl with clean dH2O, and could be used in 
real-time PCR (2.10.4). 
 
2.10.3 – Primer design 
Primers for real-time PCR were usually designed to be intron-spanning (with the 
exception of genomic real-time PCR) using Primer3 (Untergasser et al., 2012, Koressaar 
and Remm, 2007). The intron-spanning aspect ensured that only mRNA and not 
genomic DNA were amplified. The primer oligos were manufactured by Sigma. The 
sequences of the real-time PCR primers used in this thesis were: 
Gata6: F: AAAGCTTGCTCCGGTAACAG, R: TCTCCCACTGCAGACATCAC;  
Ywhaz: F: TGCAAAAACAGCTTTCGATG, R: CCTGCTTCTGCTTCATCTCC;  
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Spleen focus forming virus (SFFV) promoter:  
F: CCAACCCTCAGCAGTTTCTT, R: AAGCAGGCTGATTGGTTAATTC;  
Ywhaz-genomic: F: CCGTCCAGGAAGAGTAGCAG, R: TGAGATGAGAATGAAGGGGG. 
 
2.10.4 – Real-time PCR 
SYBR Green JumpStart Taq ReadyMix (without MgCl2) (Sigma) was used for real-time 
PCR. SYBR Green is a cyanine dye which greatly increases its fluorescence when bound 
to double stranded (ds) DNA. SYBR Green JumpStart Taq ReadyMix (10 µl) was added 
to 0.2 µl 6-carboxyl-x-rhodamine (ROX) solution, 2 µl of 25 mM MgCl2, 1.8 µl dH2O, and 
1 µl primer mix (0.5 µg/ ml each primer) to make a gene specific master-mix with a 
final MgCl2 concentration of 2.5 mM. A 5 µl volume of cDNA (5 ng/ µl) was aliquoted 
into a real-time PCR 96-well plate (Applied Biosystems - ABI) containing 15 µl of the 
gene specific master-mix. The plate was inserted into an ABI-7900HT fast real-time PCR 
system and the PCR amplification started as per instrument instruction. The 
amplification procedure started with 10 minutes at 98 °C (to activate the hot-start 
enzyme) followed by 40 cycles of: 98 °C for 15 seconds then 60 °C for 60 s. The 
quantity of DNA increases 2-fold every cycle of the reaction during the exponential 
phase (≈5-35 cycles) of a PCR reaction (assuming 100 % efficiency). The ABI-7900HT 
recorded this via the increase in SYBR green fluorescence over the time. An arbitrary 
SYBR fluorescence was chosen at the start of the exponential phase (≈4-5 cycles) for 
each gene specific PCR group, and the number of cycles taken to reach this arbitrary 
level was termed the cycle threshold value (Ct) (figure 2.2). Ct values were calculated 
for every gene specific reaction and normalised against the endogenous control 
Ywhaz. These values were expressed as a fold change (using the ΔΔ-Ct method (Livak 
and Schmittgen, 2001)). The ΔΔ-Ct method includes normalisation against an 
endogenous control and a chosen control group within the experiment (e.g. 0 hour 
time point), followed by a transformation (2^ΔΔ-Ct) to account for an assumed doubling 
in DNA product per cycle. After the last cycle, a dissociation stage (frequently termed a 
‘melt curve’) was performed. This was a gradual rise in temperature from 60 to 98 °C, 
and recorded the dissociation of SYBR green from dsDNA with ‘melting’ of the PCR 
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products. This melt curve was used to decipher whether single or multiple products 
were formed (example in figure 2.3). 
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Figure 2.2. Determination of Ct values 
An example graph showing change in fluorescence (Y) against PCR cycles (X), which can 
be used to determine Ct values. Reactions are indicated by the escalating thin lines on 
the graph. The thick horizontal green line denotes an arbitrary number for change in 
fluorescence. Ct values were generated for each reaction depending on where the 
green line intersected. This plot shows a Gata6 specific reaction from cDNA extracted 
from BMMØs infected with numerous lentiviruses. One of these lentiviruses expressed 
high levels of Gata6 and the duplicate reactions can be seen on the left side of the 
graph, exhibiting a lower Ct value. Therefore, fewer cycles were required to reach the 
arbitrary fluorescence, which translates as a higher level of original template. 
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Figure 2.3. Melt curve example 
Graph showing a derivative of change in fluorescence (Y) against temperature (X). The 
samples from figure 2.2 were sent though a dissociation stage. The ‘melting’ of the 
dsDNA products was recorded as a derivative of change in fluorescence (a decrease). 
The presence of a single peak in this plot suggests that the products were of the same 
structure/ size. If the plot showed multiple peaks, this would suggest that products 
with different structures were present. 
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2.11 – Immunocytochemistry 
2.11.1 – Cytospins, fixation and permeablisation 
Cells (0.4-1.2×105) in 100 µl PBS were centrifuged onto polylysine-coated glass slides 
(Fisher Scientific) using a cytospin 3 (Thermo Scientific). The cells were air-dried for a 
maximum of 5 minutes, while a circle was drawn tightly around the cells with an 
ImmEdge (hydrophobic) pen (Fisher Scientific). Three drops of freshly made (or freshly 
thawed) 4 % (w/v) paraformadehyde in PBS were added to the cells with a plastic 
Pasteur pipette to fix the cells. The cells were incubated for 20 minutes at RT. The 
slides were washed: the slide was inserted into a slide rack filled with fresh PBS 
(making sure the cells were covered), and left to rest for 1 minute; then the slides were 
removed and the excess liquid blotted off with tissue. Capillary action with a thin piece 
of dry tissue was used to remove the excess liquid from the cells, but care was taken 
not to touch the cells. Next, three drops of 0.1 % TritonX-100 (Sigma) in PBS were 
added directly to the cells, and left for 15 minutes at RT to permeablise the cells. The 
slide was inserted into the same slide rack filled with PBS (making sure the cells were 
covered), and left to rest for 1 minute. The cells could then be used for staining 
(2.11.2) or stored at 4 °C in the dark for up to three days before use (still in the PBS-
filled slide rack). 
 
2.11.2 – Staining 
Cell-containing slides (2.11.1) were removed from the PBS-filled slide rack and the 
excess liquid blotted off with tissue. Capillary action with a thin piece of dry tissue was 
used to remove the excess liquid from the cells, but care was taken not to touch the 
cells. The cells were covered with 30 µl of block (PBS with 0.5 % (w/v) BSA, 0.5 % (w/v) 
saponin, 5 mM EDTA, 2 mM sodium azide, 5 % (v/v) rabbit serum, 4 µg/ ml rat anti-
mouse FcγRII/III (2.4G2)) and left to incubate at 4°C for 20 minutes. To this block 
solution, 20 µl of 2.5× antibody mix was added to give a final concentration of 1× 
antibody (see table 2.1). This solution was incubated at 4 °C in the dark for 1 hour. The 
cells were washed (as in 2.11.1), before 50 µl of streptavidin mix (containing 25 ng/ ml 
DAPI and 2 µg/ ml streptavidin-flurochrome) was added. This was incubated for 30 
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minutes at 4 °C in the dark. Cells were then washed (as in 2.11.1) twice and mounted 
with a cover slip (2.11.3). 
 
2.11.3 – Slide mounting 
The stained slide (2.11.2) was dried with capillary action, taking care not to disturb the 
cells on the slide. Fluorescence mounting media (Dako) was pipetted onto the cells (3 
µl), and a 10 mm diameter thin glass cover slip (Fisher Scientific) carefully lowered on 
top. The cover slip was carefully flattened with the blunt end of a 200 µl pipette tip so 
that no air remained between the cover slip and slide. The cells on the slide were 
viewed by fluorescence microscopy (2.11.4). 
 
2.11.4 – Fluorescence microscopy 
The EVOS FL cell imaging system was used to take photographs of cells. This 
microscope contained bright field capabilities along with 4 light emitting diode (LED) 
light cubes suitable for imaging eGFP/ AlexaFluor488/ FITC, DAPI/ Pacific Blue, CY5/ 
APC/ AlexaFluor647, and TexasRed/ DyLight594. Pictures were taken using a 100× oil, 
40×, 20× and 10× objective lenses. LED power and exposure time were optimised on 
an experiment by experiment basis, but were kept constant during an experiment. The 
microscope was used as per manufacturer’s instructions. 
 
2.11.5 – Image processing 
Images were processed with GNU image manipulation programme (GIMP) 2.0 to 
optimise saturation levels, and analysed with image J (National Institutes of Health). 
Image J was also used to quantify nuclear content of Gata6 in F4/80+ cells. Images 
within the same experiment were processed and analysed using the same settings. 
2.12 – Statistics 
Statistical analyses were conducted using GraphPad Prism. The statistical tests used 
are indicated as appropriate within the text. P-values are summarised as: * = P≤ 0.05; 
** = P≤ 0.01; *** = P≤ 0.001. All analyses performed were two-tailed unless stated. 
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3.1 – Introduction 
3.1.1 – Zymosan peritonitis 
The peritoneal cavity is a vascular environment which has been widely used 
experimentally for the study of recruited inflammatory leukocytes, such as monocytes 
and neutrophils. These inflammatory cells can be recruited to the peritoneal cavity by 
intra-peritoneal administration of many inflammatory modulators. One such 
modulator: thioglycollate, has been used previously as a sterile initiator of 
inflammation, and is characterised by a large influx and retention of monocytes/ 
InfMØs (Hopper, 1986). However, due to the clinical relevance of infection, pathogen 
derived agents such as zymosan, a cell wall derivative of Saccharomyces cerevisiae (Di 
Carlo and Fiore, 1958), and Staphylococcus epidermidis cell free supernatant (SES) 
(Hurst et al., 2001) have been used to study inflammation in this environment. 
Zymosan peritonitis has been extensively used in Prof. Phil Taylor’s laboratory to study 
inflammation in the peritoneal cavity (Taylor et al., 2007, Rosas et al., 2010). 
The peritoneal cavity contains tissue resident cells which exist under normal 
homeostatic physiology. These cells include a high proportion of F4/80high ResMØs 
(Austyn and Gordon, 1981), with a lesser presence of F4/80low MHCIIhigh ResDCs/MØs 
(Dioszeghy et al., 2008), B and T lymphocytes (Carlow et al., 2009), eosinophils 
(Ohnmacht et al., 2007) and mast cells (Das et al., 1998). The primary roles of ResMØs 
in the peritoneal cavity are considered to be immune surveillance, innate defence 
(Dunn et al., 1985) and the clearance of apoptotic cells (Wong et al., 2010). 
Intra-peritoneal injection of zymosan particles triggers an innate immune response, 
with a characteristic elevation in the number of neutrophils recruited to the peritoneal 
cavity (Taylor et al., 2007, Rosas et al., 2010). The number of recoverable ResMØs 
drops after this initial inflammatory stimulus. This fall in ResMØ numbers is termed 
‘the disappearance reaction,’ and is defined as an experiential failure to recover the 
cells by lavage (Barth et al., 1995). As, mentioned in the general introduction (1.2.2), 
this could be due to increased adherence to the mesothelial tissues, cell migration to 
draining lymph nodes, or cell death (Barth et al., 1995). The number of recoverable 
ResMØs starts to increase during the resolution phase of zymosan induced 
inflammation, which is characterised by a fall in the number of neutrophils (Rosas et 
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al., 2010). The MØ element of this resolution phase includes ResMØs along with large 
numbers of recruited monocytes, which differentiate into inflammatory MØs (InfMØs) 
(Rosas et al., 2010). This provides circumstantial evidence for the prevalent model 
(Fogg et al., 2006, Geissmann et al., 2010, Gordon and Taylor, 2005) of ResMØ 
renewal: the mononuclear phagocyte system (van Furth et al., 1972). In spite of this, 
self renewal of MØs by proliferation has recently been identified in non-vascular 
environments; this has been speculated to evolve because leukocyte recruitment is 
restricted. These proliferating cells are: Langerhans cells of the skin (Chorro and 
Geissmann, 2010, Chorro et al., 2009) and microglia in the brain (Ajami et al., 2007, 
Mildner et al., 2007). These cells maintain their population via local proliferation in 
homeostasis and inflammation. They do not rely on recruited blood monocytes for 
their renewal and are self sufficient unless there is a catastrophic depletion of the 
population, such as UV irradiation in the case of Langerhans cells (Merad et al., 2002). 
 
3.1.2 –Proliferation 
Proliferation is frequently investigated using DNA content to identify stages of the cell 
cycle (Brown et al., 2010). Proliferating cells start in G1 with a 2N DNA content and 
synthesise new DNA throughout S phase, reaching a 4N DNA content in G2 before cell 
division by mitosis (a.k.a. M phase). Studying the proliferation of MØs using DNA 
content alone would be difficult due to the relatively common presence of 
multinucleated cells, and the potential for phagocytosis of apoptotic bodies (which 
includes the degrading nuclei). These factors will skew the normal DNA content of 
cells, giving false positives for S, G2 and M phases. However, there are many molecular 
markers which can be used to identify cells in the active phases of the cell cycle (G1, S, 
G2 and M), which include: Ki67, phospho-histone H3 (pHH3), aurora A kinase and the 
various cyclins (A, D E, B); the specific expression of these markers is described below.  
Ki67 is expressed only by cells in the active cell cycle phases (G1, S, G2 and M) (Scholzen 
and Gerdes, 2000). Histone H3 is selectively phosphorylated from prophase to early 
anaphase during cell division (Hans and Dimitrov, 2001, Hendzel et al., 1997), 
therefore pHH3 can be used (in conjunction with 4N DNA content) as a marker of 
active mitosis. Aurora A kinase is required for mitotic spindle formation during cell 
division (Crane et al., 2004). The cyclins are required for progression through the cell 
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cycle and their expressions and activities increase at specific checkpoints, cyclins D and 
E are required for G1-S transition, A for S-G2 and B for progression into M (Sanchez and 
Dynlacht, 2005). However, using these cyclins as markers would be difficult, as they 
maintain low levels of expression even when not required. 
Microarray analysis of monocyte and MØ populations during inflammation was 
performed by Dr. Marcela Rosas (see general introduction, 1.3.1) and revealed that 
transcription factors and soluble mediators linked to proliferation or associated with 
stem cells were expressed by ResMØs; which suggested that ResMØs may not be 
terminally differentiated and could share a capacity for self renewal with MØs in non 
vascular environments, such as Langerhans cells. This generated the hypothesis 
examined in this chapter. 
 
3.1.3 – Hypothesis 
The hypothesis tested in this chapter is that peritoneal ResMØs have the capacity for 
proliferation in homeostatic growth and are capable of self-renewal after 
inflammatory depletion. 
 
3.1.4 – Aims 
 To establish a model for the investigation of the cell cycle in peritoneal ResMØs 
 To investigate the level of homeostatic ResMØ proliferation in the post-natal 
period and in the adult peritoneal cavity 
 To investigate peritoneal ResMØ renewal during acute inflammation 
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3.2 – Results 
3.2.1 – Doublet discrimination in complex polychromatic flow cytometry 
In order to study proliferation on an individual cell basis, it was first necessary to 
establish a robust flow cytometric assay. Doublets are adhered cell clumps and 
coincidental events and are generally characterised as events which have an 
abnormally high signal area to linear ratio, or pulse width to signal ratio. Doublets are 
frequent artefacts of flow cytometry and contribute to false positives, especially in cell 
cycle analysis. Doublets were excluded during flow cytometric analysis of cell 
populations by three methods, which are shown as consecutive gating on forward 
scatter (FSc)Linear vs FScArea, DNALinear vs DNAArea, and Pulse Width vs DNAArea (figure 3.1). 
 
 
Figure 3.1. Doublet discrimination in complex multi-parameter flow cytometry 
Representative density plots showing doublet discrimination achieved by consecutive 
gating on FSCLinear vs FScArea (G1), DNALinear vs DNAArea (G2), and pulse-width (G3). Data 
shown is from peritoneal lavaged cells and is representative of 6 individual 2 week old 
female 129S6/SvEv naϊve mice from two independent experiments; however this 
strategy of using the FSCLinear vs FScArea ratio and pulse-width to exclude doublet events 
was applied to all cells analysed by flow cytometry in this thesis. DNALinear and DNAArea 
parameters were only used when a DNA stain was present. In the absence of a DNA 
dye pulse-width vs FScArea was used, with the same gating strategy as pulse-width vs 
DNAArea. 
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3.2.2 – Definition of ResMØs in complex inflammatory environments 
ResMØs are defined by their F4/80high phenotype in the peritoneal cavity (Austyn and 
Gordon, 1981), however they were indistinguishable from eosinophils using F4/80 
alone when the cells were fixed and permeabilized (figure 3.2a: left panel). The ResMØ 
marker Tim4 helped to discriminate between ResMØs and eosinophils (figure 3.2a: left 
panel). Tim4 is a phosphatidylserine receptor expressed by CD11b+ cells in various 
tissues (Miyanishi et al., 2007). It was identified as a marker primarily restricted to 
ResMØs by Dr. Marcela Rosas who validated its expression by ≥95 % of ResMØs in the 
peritoneal cavity of C57BL/6 and 129S6/SvEv mice. Tim4– eosinophils have a distinct 
FSc/ side scatter (SSc) profile after fixation/permeabilization (Taylor et al., 2003), which 
facilitated their separation from ResMØs and other cells (figure 3.2a: right panels). 
F4/80low MHCIIhigh Res DCs/MØs and InfMØs arriving during inflammation also 
complicated the classification of ResMØs (utilising F4/80 and CD11b) (figure 3.2a: left 
panels). However, after eosinophil removal via their FSc/SSc profile, the F4/80high 
phenotype was sufficient for discrimination between these populations, which was 
confirmed by expression of the restricted ResMØ marker Tim4 (figure 3.2b: right 
panels). 
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Figure 3.2. Definition of ResMØs in complex inflammatory environments 
A) Representative density plots showing Tim4 expression, which was found to be 
associated with the F4/80high ResMØ profile, separating them from F4/80+ eosinophils 
(left panel). The distinctive FSc/ SSc profile of eosinophils after fixation/ 
permeabilization (right panels) was used to exclude them from further analysis (G4).  
B) Density plots showing gating of F4/80+ CD11b+ MØ populations in naϊve mice, and 
mice 48 hours after intra-peritoneal injection of 2×106 zymosan particles (left panels). 
The ResMØ and ResDC gate includes both F4/80high ResMØs and F4/80low MHCIIhigh Res 
DCs/MØs, while the ResMØ and InfMØ gate includes both F4/80high ResMØs and 
F4/80low InfMØs. The MØ populations were further examined using Tim4 expression; 
the majority of F4/80high ResMØs showed positive staining (right panels), whereas 
F4/80low MHCIIhigh DCs/MØs (ResDCs) and InfMØs were negative. All plots were gated 
for single events as shown in figure 1 and eosinophils were excluded as shown in (A) 
(G4). Data shown is representative of 6-7 week old female C57BL/6 mice from one of 
three similar experiments (n= 5 per group).  
  
F
4
/8
0
-A
P
C
S
S
c
A
re
a
FScAreaTim4-PE
0 32 64 96 128
FS Area
0
32
64
96
128
S
S
 A
re
a
100 101 102 103 104
PE Log Comp
10 0
10 1
10 2
10 3
10 4
A
P
C
 L
o
g
 C
o
m
p
0 64 128 192 256
FS Area
0
64
128
192
256
S
S
 A
re
a
0 64 128 192 256
FS Area
0
64
128
192
256
S
S
 A
re
a
ResMØ
Eos
ResMØ EosA
Naϊve 48h Zymosan
CD11b-APC-Cy7 Tim4-PE
100 101 102 103 104
PE Log Comp
10 0
10 1
10 2
10 3
10 4
A
P
C
 L
o
g
 C
o
m
p
100 101 102 103 104
APC-Cy7 Log Comp
10 0
10 1
10 2
10 3
10 4
A
P
C
 L
o
g
 C
o
m
p
100 101 102 103 104
APC-Cy7 Log Comp
10 0
10 1
10 2
10 3
10 4
A
P
C
 L
o
g
 C
o
m
p
100 101 102 103 104
PE Log Comp
10 0
10 1
10 2
10 3
10 4
A
P
C
 L
o
g
 C
o
m
p
ResMØ
and ResDC
ResMØ
and InfMØ
F
4
/8
0
-A
P
C
F
4
/8
0
-A
P
C
B
Naϊve 48h Zymosan
G3
G4
G4 G4
G3
ResMØ and InfMØResMØ and ResDC
80 
 
3.2.3 – Identification of non cell cycle-associated DNA content and ResMØs in cell 
cycle 
Cell cycle analysis was complicated in ResMØs due to the presence of non cell cycle-
associated DNA content and irregular nuclear morphology, which included: 
multinucleate MØs, multi-lobed nuclei, and the presence of phagocytic bodies, the 
latter more evident during inflammation (figure 3.3). 
 
 
Figure 3.3. Description of non cell cycle-associated DNA content in ResMØs 
Photographs showing a representation of ResMØs that are: A) mononucleate ‘fried 
egg’, B) bilobed C), binucleate, D) multinucleate, E) phagocytic (containing zymosan 
particles in this picture, but this could theoretically be apoptotic cell debris) and F) 
mitotic. Cells were purified by flow cytometric cell sorting (Moflo, Beckman Coulter) of 
F4/80high CD11bhigh peritoneal cells from lavages pooled from five 7 week old C57BL/6 
female mice, 48 hours after intra-peritoneal injection of 2×106 zymosan particles. The 
cells were centrifuged onto slides in a cytospin-3 and fixed, then stained with 
hematoxylin and eosin. Pictures were taken using a Leica light microscope at 100 × 
objective magnification under oil. 
A B C
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Flow cytometric analysis of DNA content using nuclear stains was not affected by 
irregular nuclear shape, but was unable to discriminate between non cell cycle-
associated DNA content and those cells in active cell cycle. Therefore, markers for the 
active stages of the cell cycle were pursued for use in flow cytometry. DNA content 
staining was used in conjunction with pHH3 in Hoxb8 immortalised MØ precursors (a 
fast growing cell line) (Rosas et al., 2011) to confirm its selectivity in cells with a 4N 
DNA content (figure 3.4). This confirmation enabled the use of pHH3 expression to 
detect a small window of cell mitosis (prophase to early anaphase). The 1.64 ± 0.17 % 
(mean ± SEM, n= 5) of cells with 4N DNA content that expressed pHH3 in this fast 
growing cell line gave an ‘unnaturally high’ level of pHH3 (only 1.64 %), which provided 
a basis to evaluate the results from MØ proliferation in vivo (see below). 
 
 
Figure 3.4. Identification of definitive mitotic events by phosphorylation of histone 
H3 in cells with 4N DNA content 
Representative density plot showing phospho-histone H3 (pHH3) and DNA (DAPI) 
staining of a Hoxb8 immortalised MØ precursor cell line made from the bone marrow 
of 129S6/SvEv mice (Rosas et al., 2011). Data shown is from three independent 
experiments (n= 5). 
ResMØs were stained with anti-pHH3 following successful staining of mitosis in the 
precursor cell line. Positive staining in the 4N DNA population showed that a small 
number of ResMØs in the adult were mitotic (figure 3.5: left panel). The proliferative 
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marker Ki67 (Kubbutat et al., 1994) was also used to highlight ResMØs in the active cell 
cycle phases (G1, S, G2 and M), and was able to distinguish them from the Ki67
- cells in 
G0, ‘binucleate’ cells with 4N DNA content and those cells with >2N, but less than 4N 
DNA content, which could represent phagocytic events (figure 3.5: right panel). 
Positive staining of pHH3 coincided with a high level of Ki67 staining (figure 3.5: middle 
panel), which provided conclusive evidence for a low level of active proliferation in 
resting peritoneal ResMØs. This data supported the method for quantification of 
mitotic events with Ki67high staining in addition to pHH3 expression; when bearing in 
mind that pHH3 is only expressed in a small window in mitosis. The combination of 
both markers was used to accurately quantify the cell cycle of ResMØs from the resting 
peritoneal cavity of adult mice (figure 3.6). 
 
 
Figure 3.5. Use of Ki67 and phospho-histone H3 to discriminate between MØs with 
non cell cycle-associated DNA content and those in cell cycle 
Representative density plots showing ResMØs from the peritoneal cavity. Cells were 
gated to remove doublets (3.1), eosinophils (3.2) and gated on ResMØs as shown in 
3.2b. The cells were stained for DNA content (DAPI), phospho-histone H3 (pHH3) and 
Ki67. pHH3 labels mitotic cells with 4N DNA content (left panel) and coincides with 
Ki67high staining (middle panel). Ki67 staining of ResMØs (right panel) shows cells 
within specific stages of the cell cycle. The red line marks the maximal staining from a 
matched isotype control; cells above this line are positive for Ki67 and are in the active 
phases of the cell cycle (S, G2 and M), while the cells below this are negative and 
therefore not in active cell cycle phases (G0, ‘phagocytic’ and ‘binucleate’). Data is 
representative of one of three similar experiments with 6-7 week old female C57BL/6 
mice (n= 5 per group). 
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Figure 3.6. Quantification of cell cycle in adult mice 
Bar graph depicting the percentage of ResMØs in different stages of the cell cycle 
determined as shown above (figure 3.5). The data is from one experiment with 14 
week old 129S6/SvEv (n= 5) and similar results were obtained with 7 week old C57BL/6 
(n= 3) female mice in an independent experiment; error bars denote the mean ± SEM. 
3.2.4 – ResMØs expand by proliferation during the neonatal period 
During the neonatal period a mouse will grow rapidly and dramatically increase in size 
until growth slows toward adulthood. The peritoneal cavity in these mice also 
increases in size and volume, therefore the number of cells it can support will increase. 
Cell quantification was performed during the neonatal period (2 weeks, P14-15), 
through young adulthood (5 weeks) and into full adulthood (12-16 weeks). The total 
number of ResMØs increased with age (figure 3.7a). The number started off relatively 
low in neonate mice (0.62 ± 0.09×106, mean ± SEM, n= 6) when the MØs were the 
dominant cell in the cavity (76.8 ± 1.4 % of total cells). However, this number rapidly 
increased as the mice grew, and by 4-5 weeks of age 2.17 ± 0.28×106 ResMØs were 
present in the peritoneal cavity (mean ± SEM, n= 6). This expansion slowed, giving a 
stable number of ResMØs (2.8 ± 0.18×106), with a reduced dominance in the cavity 
(38.9 ± 5 %) by 12-16 weeks of age (mean ± SEM, n= 5). The proliferation of ResMØs 
during growth was quantified using DNA content and pHH3. The level of proliferation 
in ResMØs was high in neonatal mice and fell rapidly with age (figure 3.7b). This was 
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quantified as an over 20-fold increase in pHH3+ cells in neonatal mice compared with 
that of older (12-16 week old) mice (0.25 ± 0.07 % vs 0.011 ± 0.003 %, mean ± SEM, n= 
5-6). However the percentage with DNA >2N only dropped 5-fold from neonate to 
older mice (5.15 ± 1.65 % vs 1.16 ± 0.12 %); this indicated that pHH3 has a greater 
resolution when quantifying proliferation. When these values were correlated (figure 
3.8), it was revealed that DNA content >2N correlated well with proliferation (pHH3) in 
younger mice (2 and 4-5 weeks), but did not in older (12-16 weeks) mice, which 
emphasised the problem of non cell cycle-associated DNA content in the adult mouse. 
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Figure 3.7. ResMØs proliferate during neonatal growth 
A) Graphs showing the total number of ResMØs (left), and ResMØs as a percentage of 
cells recovered (right) in the peritoneal lavage of mice at different ages. B) Graphs 
showing the proportion of ResMØs of mice at different ages that are either DNA 
content >2N (left), or pHH3
+ (right). Horizontal bars denote means. Data were analyzed 
by one-way ANOVA, with Bonferroni post tests to determine the significance of 
differences between groups, significance values for the effect of age are indicated, and 
Bonferroni post tests are shown: ** = P≤ 0.01, *** = P≤ 0.001. Each symbol represents 
an individual 2-16 week old 129S6/SvEv female mouse, and data were pooled from 
two similar experiments.  
analysis
pooled
2dna 4-5dna12-16dna
0.1
1
10
100
2dna
4-5dna
12-16dna
analysis
pooled
2H3 4-5H312-16H3
0.001
0.01
0.1
1
2H3
4-5H3
12-16H3
% analysis
pooled
2 4-5 12-16
0
20
40
60
80
100
2
4-5
12-16
number
analysis
pooled
2 4-5 12-16
0
1
2
3
4
2
4-5
12-16
M
Ø
 (
x1
0
6
)
M
Ø
 (
%
 o
f 
to
ta
l 
c
e
lls
)
D
N
A
 c
o
n
te
n
t 
>
G
0
/1
(%
 o
f 
M
Ø
)
p
H
is
to
n
e
H
3
+
(%
 o
f 
M
Ø
)
Age (wk)
-
Age (wk)
-
Age (wk)
2 4-5
Age (wk)
2 4-5 -
***
***
***
***
**
A
B
One –way ANOVA
P = <0.001
One –way ANOVA
P = 0.0478
One –way ANOVA
P = 0.002
One –way ANOVA
P = <0.001
l i
l
2dna 4-5dna12-16dna
0.1
1
10
100
2dna
4-5dna
12-16dna
l i
l
2H3 4-5H312 16H3
0.001
0.01
0.1
1
2 3
4-5 3
12-16 3
 l i
l
2 4-5 12-16
0
20
40
60
80
100
2
4-5
12-16
r
l i
l
2 4-5 12-16
0
1
2
3
4
2
4-5
12-16
M
Ø
 (
x1
0
6
)
M
Ø
 (
%
 o
f 
to
ta
l 
c
e
lls
)
D
N
A
 c
o
n
te
n
t 
>
G
0
/1
(%
 o
f 
M
Ø
)
p
H
is
to
n
e
H
3
+
(%
 o
f 
M
Ø
)
ge ( k)
-
ge ( k)
-
ge ( k)
2 4-5
ge ( k)
2 4-5 -
ne – ay 
P = <0.001
ne – ay 
P = 0.0478
ne – ay 
P = 0.002
ne – ay 
P = <0.001
One-way ANOVA
P< 0.001
One-way ANOVA
P< 0.001
One-wa  ANOVA
P= 0.048
One-way ANOVA
P= 0. 02
A
Data 2
14
-1
5d
ay
s
4-
5w
ee
ks
12
-1
6w
ee
ks
0.1
1
10
1 0
Data 1
14
-1
5d
ay
s
4-
5w
ee
ks
12
-1
6w
ee
ks
.001
0.01
0.1
1
86 
 
 
Figure 3.8. DNA content does not readily correlate with proliferation in older mice 
Graph showing the correlation between percentages of ResMØs with DNA content >2N 
and those that are pHH3+. Data were analyzed by linear regression, and r2 values are 
indicated alongside significance testing for a non-zero slope (***= P≤0.001). Each 
symbol represents an individual 2-16 week old 129S6/SvEv female mouse, and data 
were pooled from two similar experiments. 
3.2.5 – ResMØs recover from acute inflammation by proliferation 
The numbers of recoverable ResMØs drop in the first few hours after the initiation of 
inflammation by 2×106 zymosan particles; this number starts to recover during the 
resolution phase seen at 48 hours and 72 hours after initiation. InfMØs are also 
present in the cavity at these time points, and make up a large component of the total 
MØ population in this model (figure 3.9). 
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Figure 3.9. Recovery of ResMØ population during acute inflammation 
Graph showing the number of recoverable ResMØs and InfMØs in the peritoneal 
lavage of mice at different time points after intra-peritoneal injection of 2×106 
zymosan particles. Error bars denote the mean ± SEM of data obtained from one of 
three similar experiments with 6-7 week old female C57BL/6 mice (n= 5 per group). 
The dotted line represents a ≈93 % reduction in recoverable ResMØs observed 4 hours 
after zymosan.  
The proliferative marker pHH3 was utilised along with MØ gating strategies to 
investigate proliferation during inflammation. The gating strategies shown in figure 
3.10 are the definitions of F4/80high ResMØs and F4/80low InfMØs in mild acute 
inflammation, which was previously shown to be based on Tim4 expression on ResMØs 
(figure 3.2). These strategies are used throughout this thesis, and are frequently 
referred to within figure legends. ResMØs experienced a burst in proliferation at a 
specific time point during inflammation (48 hours after 2×106 particles of zymosan), 
which coincided with the recovery of their numbers during the resolution (figure 3.10). 
InfMØ populations (including a small number of F4/80low MHCIIhigh Res DCs/MØs) did 
not follow this same proliferative pattern, and showed lower levels of proliferation. 
This data (pHH3+ %) was quantified (figure 3.11a) and showed that the burst in ResMØ 
proliferation at 48 hours was over 12-fold higher than the proliferation at baseline 
(0.64 ± 0.07 % vs 0.05 ± 0.01 %, mean ± SEM respectively, n= 5), and the level of 
proliferation was reduced again at 72 hours (0.13 ± 0.09 %,       n= 5). Proliferation was 
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also quantified using DNA content (figure 3.11a), which was shown to correlate well 
with proliferation in younger mice (figure 3.8); it also correlated well during 
inflammation in these 6-7 week old mice (figure 3.11b). 
 
Figure 3.10. Identification of a proliferative burst in ResMØs during acute 
inflammation 
Density plots depicting cells stained with F4/80, CD11b, DNA (DAPI) and pHH3 in naϊve 
mice and mice after intra-peritoneal injection of 2×106 zymosan particles. Cells were 
pre-gated to remove doublets and eosinophils (as shown in figures 3.1 and 3.2). 
Representative gating of ResMØ and InfMØ populations is shown in the top panels and 
their respective pHH3+ gates (boxes) are shown in the bottom and middle panels. Cells 
to the right of the dotted vertical lines were described as having >2N DNA content. 
Note: the InfMØ gate also contains F4/80low MHCIIhigh Res DCs/MØs (ResDC) in animals 
after zymosan. Data is representative of the mice used in figure 3.9. The gating 
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strategies used (ResMØ, ResDC and InfMØ) are reminiscent of all experiments carried 
out in this thesis. 
 
Figure 3.11. Quantification of phospho-histone H3 expression and increased DNA 
content of MØs during acute inflammation 
A) Graphs showing percentage of cells with DNA content >2N (left), or those that are 
pHH3+ with 4N DNA content (right) in naϊve mice and mice after intra-peritoneal 
injection of 2×106 zymosan particles. Data were analyzed by two-way ANOVA with 
Bonferroni post tests to determine the influence of cell type and zymosan treatment 
on MØ proliferation, and significance values are indicated: I= interaction between cell 
type and zymosan effects, C= cell type, T= effect of zymosan treatment over time, and 
Bonferroni post tests: *** = P≤ 0.001. B) Graph showing the correlation between 
percentage of ResMØs with DNA content >2N and those which were pHH3+ after 
zymosan injection. Data were analyzed by linear regression and the r2 values and the 
significance of tests for a non-zero slope are indicated (** = P≤ 0.01). In both cases (A 
and B), error bars denote the mean ± SEM of data obtained from one of three similar 
experiments with 6-7 week old female C57BL/6 mice (n= 5 per group). 
The cell cycle could be further investigated using DNA content due to the excellent 
correlation with proliferation during inflammation. The Dean-Jett-Fox algorithm in 
Flowjo was used to quantify cell cycle stages 48 hours after inflammation (figure 3.12). 
This algorithm uses mathematical modelling to calculate the number of cells in phases 
of the cell cycle on the assumption that cells in the G2M peak have twice the DNA 
fluorescence compared with G0/1, and assumes equal coefficients of varience. 
However this algorithm had a restricted ability to only detect higher levels of 
proliferation; so could not be used to quantify low levels of proliferation, such as that 
seen basally. Therefore, proliferation was characterised in inflammation using the 
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proliferation marker Ki67. A clear increase in the percentage of total Ki67+ ResMØs was 
identified during the proliferative burst at 48 hours vs baseline (41.4 ± 7.0 % vs 3.8 ± 
0.9 %, mean ± SEM, n= 5), and this level was still relatively high 72 hours after 
inflammation (27.3 ± 2.4 %, n= 5) (figure 3.13a). The percentage of Ki67+ InfMØs did 
not change significantly throughout inflammation, but started off higher than ResMØs 
at baseline (13.7 ± 0.6 % vs 3.8 ± 0.9 %, mean ± SEM respectively, n= 5) (figure 3.13a). 
The cell cycle stages were characterised with the use of Ki67 along with DNA content 
as in figure 3.5 to additionally highlight this burst in proliferation (figure 3.13b). 
 
 
Figure 3.12. Quantification of cell cycle stages using DNA content during acute 
inflammation 
Histogram (left) showing the DNA content of ResMØs, this was quantified into stages 
using the Dean-Jett-Fox cell cycle algorithm in Flowjo, and presented as a bar graph 
(right). The blue peak denotes G0/ 1, the red area is S phase and the green peak shows 
G2/ M. Error bars denote the mean ± SEM of data obtained from one of three similar 
experiments with 6-7 week old female C57BL/6 mice, 48 hours after intra-peritoneal 
injection of 2×106 zymosan particles (n= 5 per group). 
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Figure 3.13. Quantification of cells in cell cycle using Ki67 during acute inflammation 
A) Bar graph showing the percentage of total Ki67+ ResMØs and InfMØs in naϊve mice 
or mice after intra-peritoneal injection of 2×106 zymosan particles. Data were analyzed 
by two-way ANOVA, with Bonferroni post tests to determine influence of cell type and 
zymosan treatment on Ki67 expression, significance values are indicated: I= interaction 
between the effects of cell type and zymosan treatment, C= cell type, T= effect of 
zymosan treatment over time, and Bonferroni post tests: * = P≤ 0.05, *** = P≤ 0.001. 
B) Bar graphs showing the percentage ResMØs and InfMØs in different cell cycle 
phases using Ki67 and DNA staining in naϊve mice or mice after intra-peritoneal 
injection of 2×106 zymosan particles. Data was quantified using gating described in 
figure 3.5. Error bars denote the mean ± SEM of data obtained from one of three 
similar experiments with 6-7 week old female C57BL/6 mice (n= 5 per group). 
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3.2.6 – ResMØs in the naïve tissue survive inflammation and proliferate 
Previous unpublished experiments by Prof. Phil Taylor, showed that during a model for 
adoptively transferring peritoneal cells using congenic CD45.1 and CD45.2 mice 
(Komuro et al., 1975) (129S6/SvEv), the ResMØs survived relatively well, with 50 % of 
the transferred ResMØs still present in the cavity five days after transfer. An adapted 
model for adoptive transfer was established (figure 3.15) to investigate the origins of 
proliferating ResMØs. Donor CD45.1+ cells were retrieved via lavage from the naϊve 
peritoneal cavity. These cells were injected into the peritoneal cavity of host CD45.2+ 
mice and left for 24 hours. Following this, inflammation was initiated with intra-
peritoneal injection of 2×106 zymosan particles, and left to proceed for 4 hours or 48 
hours before cell recovery via lavage. Mice which did not receive zymosan were used 
as a baseline control to monitor both the transfer and the disappearance reaction seen 
at 4 hours. This model allowed for comparison between the responses of both donor 
(CD45.1) and host (CD45.2) cells. 
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Figure 3.14. Establishing a model for adoptive transfer of ResMØs prior to acute 
inflammation 
Summary of the adoptive transfer strategy used to study the cellular responses during 
acute inflammation (2×106 zymosan particles). Donor CD45.1+ cells (retrieved via 
lavage, see 2.6.7) were injected into the peritoneal cavity of host CD45.2+ mice. 
Zymosan induced inflammation was initiated (or not) 24 hours later, and peritoneal 
cells were recovered at 28 or 72 hours. 
The recovery of donor cells was examined during acute inflammation using specific 
antibodies against CD45.1 and CD45.2, to separate the donor and host populations 
during flow cytometric analysis (figure 3.15). The number of MØs retrieved was 
quantified and showed a good survival rate 28 hours after transfer (baseline) (76.67 ± 
14.71 %, mean ± SEM, n= 5). The majority of InfMØs retrieved 48 hours after 
inflammation (2×106 zymosan particles) were host derived (92.96 ± 1.77 %, mean ± 
SEM, n= 7) (figure 3.16). The remaining cells in this InfMØ gate were most likely 
F4/80low MHCIIhigh Res DCs/MØs (45375 ± 535 injected vs 21803 ± 2543 seen in the 
InfMØ gate at 48 hours, mean ± SEM). Donor ResMØs mimicked host ResMØs during 
inflammation (figure 3.17: left graph), with a substantial disappearance reaction 4 
hours after inflammation (73.28 ± 3.21 % vs 74.72 ± 5.68 %, mean ± SEM, n= 7), 
followed by recovery of ResMØ numbers at 48 hours. This correlation in cell behaviour 
was also supported by a stable donor to host ratio over the inflammatory time course 
(figure 3.17: right graph). This data indicated that donor ResMØs were recovering their 
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lost numbers during the resolution of inflammation, and this was independent from 
bone marrow-derived monocyte recruitment. 
 
 
Figure 3.15. Determination of the persistence of adoptively transferred ResMØs 
during acute inflammation 
Representative density plots showing CD45.1+ donor vs CD45.2+ host cells within the 
gates for ResMØs and InfMØs from 129S6/SvEv mice (from fig 3.17) 48 hours after 
intra-peritoneal injection of 2×106 zymosan particles. F4/80 and CD11b expression 
were used to discriminate MØs obtained via peritoneal lavage. Cells were gated as in 
figures 3.1 and 3.2 to remove doublets and eosinophils. Data is representative of 7 
mice at the indicated time point. 
 
Figure 3.16. InfMØs are host derived 
Graph showing the CD45.2+ host InfMØs as a proportion 
of total InfMØs in the peritoneal lavage of mice, 48 hours 
after intra-peritoneal injection of 2×106 zymosan particles. 
Error bars denote the mean ± SEM of data obtained from 
5-7 week old donor 129S6/SvEv CD45.1+ cells and 10-12 
week old host 129S6/SvEv (CD45.2+) mice (n= 7) pooled 
from two independent experiments. 
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Figure 3.17. Comparable restoration of host and donor ResMØs after acute 
inflammation 
Graph (left) showing the number of recoverable donor and host ResMØs in the 
peritoneal lavage of mice at different time points during zymosan induced 
inflammation (2×106 zymosan particles). White symbols depict CD45.1+ donor, and 
black depicts CD45.2+ host cells. Graph (right) showing the survival of donor ResMØs as 
a proportion of total ResMØs, this number was additionally made relative to the 
proportion of donor ResMØs observed in mice that did not receive zymosan. Error bars 
denote the mean ± SEM of data obtained from 5-7 week old donor 129S6/SvEv 
CD45.1+ cells and 10-12 week old host 129S6/SvEv (CD45.2+) mice in the peritoneal 
lavage of mice at different time points after zymosan. Data was pooled from two 
independent experiments (n= 5-7 per group). 
Proliferation of ResMØs was investigated using pHH3 and DNA content analysis. Both 
donor and host cells were proliferating, and there was no significant difference 
between the proliferation of donor and host ResMØs (figure 3.18). The proliferation of 
donor and host ResMØs at baseline was relatively high (e.g. donor = 0.16 ± 0.03 % 
pHH3+, mean ± SEM, n= 5), which was most likely due to the inflammation caused by 
the injection of the cells 28 hours previously. 
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Figure 3.18. Comparable proliferative response of host and donor ResMØs after 
acute inflammation 
Graphs showing the percentage of ResMØs that are pHH3+ (left) or have DNA content 
>2N (right) in mice at different time points after receiving 2×10
6 zymosan particles. 
Data were analyzed by two-way ANOVA with Bonferroni post tests to determine 
differences between groups, and significance values are indicated: I= interaction 
between the effects of cell type and zymosan treatment, C= cell type, Z= effect of 
zymosan treatment over time. Error bars denote the mean ± SEM. The data is pooled 
from two independent experiments with 5-7 week old donor 129S6/SvEv CD45.1+ cells 
and 10-12 week old host 129S6/SvEv (CD45.2+) mice (n= 5-7 per group). 
3.2.7 – A significant proportion of ResMØs are generated by proliferation during 
inflammation 
The methods used for looking at active proliferation in situ using Ki67 and pHH3 
staining give a good indication of active proliferation, but do little to quantify how 
much proliferation has occurred and how many new daughter cells are generated by 
this process. The level of ResMØ proliferation observed during inflammation (as 
measured by % pHH3+) was approximately a third of that seen in a fast growing MØ 
precursor cell line (0.64 ± 0.07 % vs 1.64 ± 0.17 %, mean ± SEM, n= 6), as shown in 
figure 3.4. This indicated that a significant number of cells would be generated in situ. 
To quantify the level of ResMØ proliferation in the peritoneal cavity 
Bromodeoxyuridine (BrdU) was used. BrdU is a synthetic compound which can be 
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incorporated into DNA during DNA replication instead of thymidine; and an antibody 
against BrdU can be used to label cells that have been through S phase of the cell cycle 
(Gratzner et al., 1975). BrdU was introduced to the drinking water of the mice at the 
initiation of inflammation (2×106 zymosan particles). ResMØs reported a significant 
uptake of BrdU (mean of ≈50 %), showing that roughly half of the recovering ResMØs 
are generated via proliferation, 72 hours after intra-peritoneal injection of 2×106 
zymosan particles. InfMØs had a lower level of BrdU uptake (mean of less than 20 %) 
(figure 3.19), which could have occurred in the bone marrow. This experiment was 
carried out and analysed by Dr. Marcela Rosas, and is included here because of its 
relevance. 
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Figure 3.19. Determination of the number of newly generated ResMØs after acute 
inflammation by in vivo BrdU incorporation 
A) Mice were fed BrdU in drinking water (+BrdU) immediately after intra-peritoneal 
injection of 2×106 zymosan particles. Density plots (top) show representative BrdU 
incorporation in gated MØ populations 72 hours after zymosan, and histograms 
(bottom) showing the proportion of MØs that are BrdU+ in these mice. Cells were 
gated as in 3.1 to remove doublets and 3.2 to remove eosinophils. F4/80 and CD11b 
expression were used to distinguish MØ populations. The data is representative of 6-7 
week old C57BL/6 mice from one of two independent experiments. B) Graphical 
representation of the data from (A) above showing BrdU incorporation in ResMØs and 
InfMØs. Each symbol represents an individual 6-7 week old C57BL/6 mouse from two 
independent experiments and horizontal bars denote means. Data were analyzed by a 
paired t-test. As stated in the text, this experiment was conducted by Dr. Marcela 
Rosas. 
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3.3 – Discussion 
The aim of this chapter was to investigate the potential for ResMØs to self renew via 
proliferation during homeostasis and inflammation. Firstly, a model was established to 
investigate cell cycle in peritoneal MØs. Then proliferation was examined during 
homeostasis and neonatal growth through to adulthood when ResMØ numbers were 
expanding. Finally, proliferation was investigated during acute inflammation, when the 
number of recoverable ResMØs drops after initial stimulus and is eventually restored 
during the resolution of inflammation.  
 
3.3.1 – Flow cytometric analysis of MØ populations 
A model to investigate ResMØ proliferation was established through the use of 
polychromatic flow cytometry. Specific markers and precise gating strategies were 
employed to accurately dissect MØ populations during homeostatic and complex 
inflammatory conditions. Doublets were frequent artefacts of flow cytometry, but 
great care was taken to exclude these from analysis via gating around their abnormal 
signal area to linear ratio and pulse width to signal ratio. These ratios were subtly 
different depending on cell type, for example: lymphocytes are small spherical cells so 
will have a different ratio from large globular MØs with irregular shapes. Therefore, 
the order of flow cytometric gating (i.e. whether doublets were removed first then 
MØs were gated) was decided on a case by case basis, to avoid the removal of large, 
complex, and potentially proliferating cells.  
ResMØs have been extensively studied in Prof. Phil Taylor’s group, and are typically 
classified by their F4/80high CD11bhigh phenotype (Rosas et al., 2010), which can be used 
to distinguish them from all other cell types in the peritoneal cavity. However, the 
fixation and permeabilization procedure (required for analysis of the cell cycle) slightly 
altered the flow cytometric profile of the cells. The implications of this were that other 
cell types now complicated flow cytometric analysis of MØ populations. Eosinophils 
are highly auto-fluorescent and also express the F4/80 antigen, which was used to gate 
for MØ populations. Fortunately eosinophils have a distinct FSc/SSc profile after 
fixation/permeabilization, which was used to exclude them from analysis. This was 
confirmed by staining of peritoneal cells with Siglec-F (supplemental figure S1), which 
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is selective for eosinophils in the peritoneal cavity (Ohnmacht et al., 2007), and also 
negative staining for Tim4 in naϊve mice; Tim4 is largely restricted to ResMØs in the 
peritoneal cavity (confirmed by Dr. Marcela Rosas). The Tim4– FSc/SSc profile of 
eosinophils is also shared by mast cells. However, mast cells were CD11blow/– 
(supplemental figure S2), while eosinophils had a higher expression of CD11b in the 
peritoneal cavity; this facilitated their separation during differential counts. This was 
confirmed with CD117 expression by Dr. Marcela Rosas, which is primarily expressed 
by mast cells in the peritoneal cavity (Hsu et al., 2010, Miettinen and Lasota, 2005). 
More eosinophils are recruited to the peritoneal cavity during acute inflammation, 
along with neutrophils and InfMØs. After fixation and permeabilization, neutrophils 
become smaller and less granular (supplemental figure S2), this was used in 
conjunction with their F4/80– and CD11bhigh phenotype to distinguish them from MØs. 
F4/80low MHCIIhigh Res DCs/MØs in the naϊve peritoneal cavity and the InfMØs that 
arrive during the first few days of inflammation (induced by 2×106 zymosan particles) 
have a different F4/80-CD11b profile to ResMØs, even when fixed/ permeabilized. The 
ResMØ restricted Tim4+ staining confirmed the F4/80high phenotype of ResMØs and 
the F4/80low phenotype of F4/80low MHCIIhigh Res DCs/MØs and InfMØs, as a 
consequence the F4/80 antigen was used to distinguish between these MØ subsets. 
 
3.3.2 – Nuclear profile of ResMØs 
The nuclear profile of ResMØs was found to be complicated by the presence of multi-
nucleate MØs, and the potential for phagocytic events. This non cell cycle-associated 
DNA content concealed the accurate measure of cell cycle. To definitively identify 
active phases of the cell cycle in situ, select markers of proliferation were employed in 
complex polychromatic flow cytometry. Ki67 and pHH3 were chosen over other 
markers of proliferation (eg. the cyclins) due to the availability of directly conjugated 
antibodies for use in flow cytometry, and the specificity of the markers themselves. 
Ki67 is expressed in all active cell cycle phases, while pHH3 is selective for certain 
phases of mitosis. Mitotic events were identified in ResMØs from the resting 
peritoneal cavity using pHH3+ staining; and this was found to coincide with high Ki67 
staining. The specific association of pHH3 with high Ki67 staining may be a sign of Ki67 
relocation during mitosis (Scholzen and Gerdes, 2000) or greater antigen availability 
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due to the breakdown of the nuclear envelope during mitosis. The absence of Ki67+ 
expression was also able to distinguish cells with non cell cycle-associated >2N DNA 
content, such as that found in multinucleate cells. The high levels of non cell cycle-
associated DNA content further demonstrates the limitations of cell cycle analysis of 
ResMØs using DNA content alone. However, Ki67 enabled quantification of the cell 
cycle stages in adult mice, and confirmed a low-level of homeostatic ResMØ 
proliferation.  
 
3.3.3 – ResMØs proliferate in homeostasis and neonatal growth 
Langerhans cells of the skin are a MØ population that is seeded prenatally. Langerhans 
cells increase their numbers by a high level of local proliferation in the neonate; and 
they maintain their numbers through a low level of proliferation in the adult (Chorro et 
al., 2009). However, this was suggested to be restricted to tissues with limited 
vasculature. Microarray data of MØ populations during inflammation from Prof. Phil 
Taylor’s group revealed transcripts linked to proliferation or associated with stem cells 
that were expressed by ResMØs (see 1.3.1). Therefore, the proliferation of ResMØs 
was examined in the neonate and adulthood to test the hypothesis: that peritoneal 
ResMØs are akin to Langerhans cells, in that their population is established by a high 
level of proliferation in the neonate and maintained throughout adulthood. Younger 
mice have significantly less cells and ResMØs in the peritoneal cavity than older mice. 
However, younger mice have substantially higher levels of proliferation than the older 
mice, measured by the definitive mitotic marker pHH3+. This proliferation coincides 
with the expansion of ResMØ numbers; which indicates that peritoneal ResMØ 
numbers are established in the adult via local proliferation of cells present at, or soon 
after birth. This has recently been confirmed by fate mapping studies, which show that 
peritoneal ResMØs are seeded during development (Yona et al., 2012). The level of 
mitosis correlated with >2N DNA content in the younger mice; but did not correlate in 
the older mice. This highlights that analysing DNA content alone in ResMØs is 
insufficient, and explains the need for these specific markers of proliferation (pHH3 
and Ki67), especially in older mice. 
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3.3.4 – ResMØs proliferate during acute inflammation to restore depleted numbers 
ResMØ numbers are depleted during zymosan peritonitis and cells with the same 
phenotype recover approximately 72 hours later (in this mild model of 2×106 zymosan 
particles (Rosas et al., 2010)). This ‘disappearance’ has been attributed to increased 
adherence, migration to draining lymph nodes, or cell death (Barth et al., 1995). 
Experiments utilising aliphatic dyes have been interpreted to claim that the cells 
present before inflammation are the same as those present after (Melnicoff et al., 
1989); however this does not acknowledge the transfer of dyes via phagocytosis, or 
other inflammatory kinetics such as inflammation induced by dye injection. For more 
definitive understanding, the level of ResMØ proliferation was examined during the 
recovery phase of inflammation with specific markers of proliferation (pHH3 and Ki67). 
This identified a burst in proliferative activity in ResMØs 48 hours after zymosan insult. 
The proportion of ResMØs in this stage of mitosis was approximately a third of that of 
a fast growing cell line, however the burst in proliferation seen in ResMØs is likely 
more synchronous than that of the cell line, because it was only recently initiated, and 
perhaps under stricter physiological control. The extent of ResMØ proliferation was 
quantified using BrdU incorporation by Dr. Marcela Rosas. Over half the ResMØs 
incorporated BrdU which shows that half of the end-point population was produced 
via proliferation in this mild model. This demonstrated that proliferation is a major 
mechanism for MØ renewal during the resolution of inflammation, but also indicates 
that much of the initial disappearance reaction could be attributed to increased tissue 
retention, leading to reduced recovery during lavage. 
 
3.3.5 – ResMØs renew in situ, without the need for blood monocyte precursors 
Adoptive transfer experiments were used to test for in situ proliferation. These 
experiments mathematically confirmed that the vast majority of proliferating ResMØs 
in the resolution phase of zymosan induced inflammation (48 hours), were the same as 
those present in the naϊve tissue before challenge. This, along with data from BrdU 
incorporation shows that the majority of the recovered ResMØ population consists of 
cells present before zymosan insult; which must have remained adherent to the tissue 
or lost from the tissue, with the rest (roughly 50 %) reconstituted via proliferation. The 
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adoptive transfer also confirmed that the InfMØs in the peritoneal cavity were from 
the periphery, as the vast majority were host derived. 
 
3.3.6 – Conclusion 
In conclusion, the studies in this chapter, which have now been published (Davies et 
al., 2011), showed that: 1) ResMØs contain non cell cycle-associated DNA content, 
nevertheless precise markers of proliferation can be used to show that there is a low 
level of homeostatic proliferation in the peritoneal cavity of adult mice; 2) ResMØ 
numbers are expanded in the neonate and maintained in the adult mouse via local 
proliferation; and 3) ResMØs restore their population during the resolution of a mild 
acute inflammation via a burst in local proliferation, that can be independent from 
blood monocytes, and contributes to the restoration of MØ numbers after acute 
inflammation. This redefines our understanding of MØ renewal in a vascular tissue 
(peritoneal cavity), challenging the dogma of the MPS, and opens up new avenues to 
investigate MØ function in homeostasis and inflammation. 
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Chapter 4 – InfMØs proliferate in situ during inflammation
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4.1 – Introduction 
4.1.1 – Ly-6B+ InMØ persistence 
Zymosan peritonitis has been extensively used by our research group to study 
inflammation in the peritoneal cavity (Taylor et al., 2007, Rosas et al., 2010) (and 
chapter 3 of this thesis). Monocytes recruited to the peritoneal cavity during acute 
inflammation differentiate into InfMØs and can persist for weeks after the 
inflammatory stimulus (figure 4.01) (Rosas et al., 2010).  
 
 
Figure 4.01. Kinetics of acute zymosan induced peritonitis 
Graphs showing the numbers of neutrophils and eosinophils (left panel), and total 
monocyte/ MØs and ResMØs (right panel) present at the indicated times after intra-
peritoneal administration of 2x106 zymosan particles. The difference in numbers 
between total monocyte/MØs and ResMØs represents numbers of InfMØs and 
monocytes. Data represents mean ± SEM of 3-5 C57BL/6 female mice (6 weeks old) per 
time point, taken from one of two similar experiments carried out by Dr. Marcela 
Rosas (Davies et al., 2013b), and is included because of its relevance. 
These InfMØs coexist with a recovering ResMØ population and are heterogeneous. Dr. 
Marcela Rosas identified differential expression of the antigen 7/4 which is 
synonymous with Ly-6B on InfMØs. Ly-6B+ InfMØs also showed differences in the 
expression of other surface markers, including: CD200R, CD9 and CD11b in comparison 
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to Ly-6B– InfMØ/ResMØs (Rosas et al., 2010). Ly-6B was originally identified on 
neutrophils (Hirsch and Gordon, 1983), but is also expressed on monocytes and 
InfMØs that arrive during acute inflammation (Henderson et al., 2003, Taylor et al., 
2003). After intra-peritoneal challenge with 2×106 particles of zymosan, InfMØs are 
recruited to the peritoneal cavity and maintain their numbers for at least 14 days. This 
Tim4– population of InfMØs contains a proportion of cells that are Ly-6B+, which show 
myeloid cell morphology with an irregular nucleus and large cytoplasm (figure 4.02). 
 
 
Figure 4.02. Presence and persistence of Ly-6B+ InfMØ 
 A) Representative flow cytometric profiles showing Tim4 and Ly-6B expression on 
MØs gated using the ResMØ and InfMØ gate (as in figure 3.10), and pre-gated to 
remove doublets (figure 3.1) and eosinophils (figure 3.2a). It shows that Ly-6B+ InfMØs 
are clearly distinct from Tim4high ResMØ. The box gates denote Ly-6B+ and Ly-6B– 
InfMØ populations. B) Approximately one fifth of cells classified as InfMØs are Ly-6B+ 
and they are detectable for several weeks after induction of a mild inflammatory 
challenge. Data represents mean ± SEM of 3-5 C57BL/6 female mice (6 weeks old) per 
time point, taken from one of two similar experiments. C) The Ly-6B-expressing MØs 
were gated as indicated (A) and purified (>90 %) by flow cytometric cell-sorting on a 
Moflo legend (Beckman Coulter). Cells were centrifuged onto slides using a Cytospin 3, 
then fixed and stained with eosin and methylene blue. Images were acquired on a 
Leica light microscope at 40× objective magnification. Cells were pooled from 10 (6 
week old) female C57BL/6 mice 7 days after intra-peritoneal zymosan (2x106 particles) 
(Davies et al., 2013b). This experiment was carried out by Dr. Marcela Rosas, and is 
included because of its relevance. 
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4.1.2 – Prospect of Ly-6B+ InfMØ proliferation 
Dr. Marcela Rosas also showed that a large proportion of Ly-6B+ InfMØs were newly 
generated by proliferation by utilising BrdU incorporation (Rosas et al., 2010) (also see 
3.2.7). This proliferation could have occurred in MØ progenitors in the bone marrow, 
so only showed that Ly-6B+ InfMØs were recently generated. However, in the previous 
chapter of this thesis, it was shown that ResMØs have the capacity to proliferate to 
establish and maintain their population during homeostatic growth and also to renew 
their population after inflammatory depletion by a rapid proliferative burst. BrdU was 
used to quantify this level of proliferation in inflammation (figure 3.19). This 
proliferation was confirmed to occur in situ via the use of adoptive transfer 
experiments (figures 3.17 and 3.18) and definitive identification of cells in mitosis 
(figure 3.5). During these and similar experiments the proliferation of InfMØs was 
measured alongside that of ResMØs. Although, the InfMØs did not show the same 
pattern of a proliferative burst, they did exhibit a definitive, quantifiable low-level of 
proliferation (figure 3.11); and confirmed the overall low level of BrdU incorporation in 
total InfMØs as seen in Dr. Rosas’ previous study (Rosas et al., 2010). 
Microarray analysis of monocyte and MØ populations during inflammation (initiated 
by 2x106 particles of zymosan) was performed by Dr. Marcela Rosas as described in the 
general introduction (1.3.1). Comparison of transcripts differentially expressed 
between day 7 Ly-6B+ and Ly-6B– MØs identified an enrichment of transcripts that 
were associated with proliferation in Ly-6B+ MØ. Notably however, proliferation of 
ResMØs was substantially attenuated 7 days after 2x106 particles of zymosan (both in 
genes associated with proliferation and in cell cycle studies, for an example see the 
future results chapter 6 - figure 6.19). This information was combined with the low 
level proliferation of InfMØs, and the enrichment of BrdU incorporation in Ly-6B+ 
InfMØs seen during inflammation (Rosas et al., 2010). This derived the hypothesis: that 
Ly-6B+ InfMØs may not be terminally differentiated and could also have the capacity to 
proliferate like that of ResMØs, although potentially with distinct control mechanisms. 
Importantly in situ proliferation of monocyte-derived MØs has never been definitively 
reported. 
This cellular proliferation would most-likely be governed by growth factors and other 
soluble mediators. At the same time that the experiments in chapter 3 of this thesis 
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were completed (Davies et al., 2011), Jenkins et al. reported a high level of ResMØ 
proliferation in the peritoneal cavity during helminth infection. This proliferation was 
dependent upon the cytokine IL-4 (Jenkins et al., 2011). IL-4 is is produced by a number 
of cells including: Th2 lymphocytes, eosinophils and mast cells (Voehringer et al., 2004). 
It is known to promote both Th2 differentiation through STAT6 (Kaplan et al., 1996) 
and ‘alternative activation’ of MØs: enhancing expression of molecules such as 
mannose receptor (Stein et al., 1992). There are other cytokines which have also been 
shown to promote MØ proliferation. M-CSF is frequently used to expand and 
differentiate MØs from bone marrow progenitors (Hume and Gordon, 1983). M-CSF is 
essential for the proliferation of these differentiated progenitors and it’s also essential 
for the formation of osteoclasts from monocytic precursors (Hattersley et al., 1991). A 
deficiency in M-CSF, such as that seen in the naturally occurring mutation in the 
osteopetrotic (op/op) mouse causes a marked deficiency in many MØ populations, 
including peritoneal ResMØs (Wiktor-Jedrzejczak et al., 1990), which could be a result 
of impaired differentiation or proliferation. 
The quantity of zymosan (2×106 particles) used in the majority of this thesis promotes 
a mild, acute model of inflammation that is unlikely to trigger an IL-4 rich Th2 
environment as seen with helminth infection (Jenkins et al., 2011), although this does 
not exclude innate sources of IL-4. Whilst it is possible that IL-4 is required for MØ 
proliferation in the acute zymosan model, it has been suggested that the small 
proliferative responses of MØs brought about by IL-4 treatment could be a result of 
stimulated autocrine signalling from M-CSF (Gordon, 2003). Given the marked impact 
of the op mutation on detectable peritoneal MØ numbers, M-CSF appears a strong 
target for investigating the control mechanisms for MØ proliferation in homeostasis 
and acute inflammation. 
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4.1.3 – Hypothesis  
The hypothesis tested in this chapter is that peripherally recruited Ly-6B+ InfMØs have 
the capacity to proliferate in situ, as an alternative mechanism of generation during 
the resolution of inflammation; and that proliferation of ResMØs and Ly-6B+ InfMØs is 
under the control of the growth factor M-CSF in inflammation. 
 
4.1.4 – Aims 
 To determine whether Ly-6B+ InfMØs proliferate during acute inflammation 
 To investigate the origins of Ly-6B+ InfMØs in acute inflammation 
 To evaluate the roles of IL-4 and M-CSF in MØ proliferation in homeostasis and 
inflammation 
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4.2 – Results 
4.2.1 – Definition of Ly-6B+ InfMØs in complex inflammatory environments 
Acute inflammation was initiated by injection of zymosan particles (2x106) into the 
peritoneal cavity. During the resolution of this inflammation the cellular kinetics alter 
drastically, with a short spike in neutrophil numbers followed (and overlapped) by a 
sustained influx of monocytes, which have the potential to differentiate into InfMØs 
(see previous figure 4.01). Newly arrived monocytes share an F4/80low Ly-6B+ profile 
with Ly-6B+ InfMØs (figure 4.1a), however, their physical size (measured by FScAREA) 
and lower CD11b expression could be used to remove them when analysing Ly-6B+ 
InfMØs (figure 4.1b and c).  
 
 
Figure 4.1. Classification of Ly-6B+ InfMØs during inflammation 
Representative density plots showing MØs and monocytes from mice 72 hours after 
the induction of peritonitis with 2x106 zymosan particles. Plots A and B have been 
gated using the ResMØ and InfMØ gate (as described in figure 3.2b) and pre-gated to 
remove eosinophils and doublets (figures 3.1 and 3.2a). Plot C has been additionally 
gated with the MØ gate in B, and shows the gating strategy for the identification of 
ResMØs, Ly-6B+ and Ly-6B– InfMØs after the removal of monocytes. The plots are from 
a 6-7 week female C57BL/6 mouse, but is representative of all C57BL/6 and 
129S6/SvEv mice analyzed in these studies. 
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4.2.2 – Ly-6B+ InfMØs proliferate during the resolution of zymosan induced 
peritonitis 
The methods of analysing cell cycle from chapter three were also applied in this 
chapter; however a high level of Ki67 expression did not always correlate with high 
levels of mitosis (figure 4.2a). This was due to variations in the proportion of cells in 
the G1 phase of the cell cycle, indicating that using measures for the ‘active’ phases of 
the cell cycle were most reliable in identifying MØ proliferation. Therefore, the S, G2 
and M phases of the cell cycle were combined into an ‘SG2M’ measure (figure 4.2b), 
which gave an accurate reading of active proliferation that is not restricted to certain 
phases of mitosis (as seen with pHH3 staining). During zymosan peritonitis (2x106 
particles) most ResMØs are not recoverable during the first few hours, but recover by 
a burst in proliferation 48 hours after stimulus. By 72 hours the proportion of ResMØs 
in the SG2M phases of the cell cycle decreases to near basal levels and is comparable to 
that of InfMØs (figure 3.11). At this time point InfMØs have a low level of proliferation 
classified and quantified as: 1) >G0/1 DNA content of 4.36 ± 0.52 % (mean ± SEM, n= 5); 
2) SG2M of 3.06 ± 0.50 %; and 3) 0.08 ± 0.05 % pHH3
+ (quantified from mice in figure 
4.3). However, Ly-6B+ MØs have a clearly enriched level of proliferation when 
compared with Ly-6B– MØs in all measures of proliferation: 15.20 ± 1.15 % vs 3.64 ± 
0.50 % >G0/1 DNA content, 10.8 ± 1.48 % vs 2.52 ± 0.45 % SG2M and 0.34 ± 0.05 % vs 
0.06 ± 0.01 % pHH3+ respectively (quantified from mice in figure 4.3). 
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Figure 4.2. Considerations for the use of Ki67 as a measure of cell division 
A) A linear correlation plot showing total Ki67 expression vs indicators of active mitosis 
(4N DNA content associated with pHH3 or Ki67high phenotype) in naïve mice and mice 
48 and 72 hours after the induction of peritonitis with 2x106 zymosan particles. All 
mice used were 6-7 week female C57BL/6 and each symbol represents an individual 
mouse pooled from 3 independent experiments. Linear correlation analysis was 
performed and P-values showing significance testing for a non-zero slope are indicated 
(***= P≤ 0.001). B) Representative density plot showing the stages of the cell cycle 
after staining with Ki67 and DAPI (DNA). The boxes indicate active cell cycle stages 
(SG2M) which are Ki67
+ with >2N DNA content, the ‘inactive’ cell cycle stages with 2N 
DNA G1 (Ki67
+) and G0 (Ki67
–), but do not include non cell cycle-associated DNA content 
as shown in figure 3.5. Note that high Ki67 staining with 4N DNA content always 
correlated with pHH3 staining, so could be used as an additional comparative measure 
of mitosis. SG2M gating is highlighted in blue. The data shown is of Ly-6B
+ InfMØs (as 
shown in figure 4.1) 72 hours after the induction of peritonitis with 2x106 zymosan 
particles in 6-7 week C57BL/6 female mice, however the gating strategy shown is 
representative of all proliferating cells in this thesis. 
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Figure 4.3. Ly-6B-expressing InfMØs are actively dividing in situ 
A) Representative density plots showing cells stained for Ki67 and DNA (DAPI), cells 
were gated on MØ populations as shown in figure 4.1 and also pre-gated to remove 
eosinophils (figure 3.2a) and doublets (figure 3.1). The plots show total InfMØ 
populations (left), Ly-6B+ cells (middle) and their Ly-6B– counterparts (right) 72 hours 
after the induction of peritonitis with 2x106 zymosan particles. The boxes indicate the 
cell cycle stages as shown in figure 4.2b. Data was derived from individual mice and are 
representative of at least 3 experiments with 6-7 week old C57BL/6 female mice 
(typically 3-5 mice per experiment). B) The levels of proliferation within the two 
populations of InfMØs from one of the experiments shown above (A) was measured by 
the proportion of cells with >2N DNA content (left), >2N DNA content with Ki67 
expression (‘SG2M’, middle), and pHH3+ (right). Data is expressed as mean ± SEM of 5 
mice per group. Data were analyzed by a paired t-test and significance values are 
indicated. 
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4.2.3 – Proliferation of Ly-6B+ InfMØs is not restricted to zymosan peritonitis 
A higher number of zymosan particles (2x107) or 1 ml of 4 % (w/v) thioglycollate broth 
were used as alternative initiators of peritoneal inflammation, to determine whether 
Ly-6B+ MØ proliferation is restricted to a lower dose of zymosan (2x106 particles). The 
higher dose of zymosan resulted in increased numbers of InfMØs, with a substantial 
presence of Ly-6B+ MØs, but it also resulted in a reduced number of recoverable 
ResMØs when compared to the low dose, as expected (Taylor et al., 2003, Taylor et al., 
2005b) (figure 4.4). The Ly-6B+ MØs are also proliferating during inflammation caused 
by this high dose and at a significantly higher level than the Ly-6B– InfMØs (figure 4.5). 
In contrast, the thioglycollate broth resulted in a near complete depletion of ResMØs 
compared to that of low dose zymosan (0.17 ± 0.03x106 vs 2.15 ± 0.42x106 mean ± SEM 
respectively, n= 3) and no evident Ly-6B+ InfMØ population 72 hours after injection 
into the peritoneal cavity (figure 4.4). However, if cells were lavaged 1 week after 
thioglycollate injection, small numbers of both Ly-6B+ InfMØ and ResMØ populations 
could be identified (figure 4.6), with the Ly-6B+ InfMØs having high (0.67 ± 0.12 % 4N 
DNA content, Ki67high, mean ± SEM, n= 5) and comparable levels of proliferation to that 
of the high dose zymosan model after 72 hours (0.66 ± 0.13 % pHH3+) (figure 4.5). 
115 
 
 
Figure 4.4. MØ populations during peritonitis 
A) Representative flow cytometric profiles showing F4/80 and Ly-6B expression in MØs 
gated using the ResMØ and InfMØ gate (as described in figure 3.2b), and also pre-
gated to remove eosinophils (figure 3.2a) and doublets (figure 3.1)). Cells were taken 
from mice 72 hours after induction of peritonitis with zymosan (both 2x106 and 2x107 
particles) or 1ml of 4 % (w/v) thioglycollate broth, as indicated. The presence of Ly-6B+ 
monocyte and Ly-6B+ InfMØ populations are shown. Flow cytometric plots are 
representative of at least 3 C57BL/6 female mice per group from one of two similar 
experiments. B) Bar graph showing a quantification of Ly-6B+ and Ly-6B– MØ numbers. 
Note that Ly-6B+ InfMØs were undetectable 72 hours after thioglycollate broth. C) Bar 
graph showing a quantification of ResMØ numbers analysed by one-way ANOVA with 
Bonferroni post tests (* = P≤ 0.05) to define the significance of differences between 
the groups, the ANOVA P-value is indicated. Data in both B and C are from the 
experiment described in A. 
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Figure 4.5. MØ proliferation during high dose zymosan peritonitis 
A) Graph showing numbers of Ly-6B+ and Ly-6B– InfMØs recovered from mice 72 hours 
after intra-peritoneal injection of 2x107 particles of zymosan. B) Graphs showing 
proliferation of Ly-6B+ and Ly-6B– InfMØs 72 hours after the induction of peritonitis 
with 2x107 zymosan particles. The level of proliferation within the two populations of 
InfMØs was measured by the proportion of cells with >2N DNA content (left), >2N DNA 
content with Ki67 expression (‘SG2/M’, middle), and pHH3
+ (right). Data were analyzed 
by a paired t-test and significance values are indicated. Data (A and B) are expressed as 
mean ± SEM of 5 mice per group (7-9 week old female 129S6 mice) and is from one of 
2 similar experiments.  
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Figure 4.6. MØ proliferation during thioglycollate peritonitis 
A) Representative density plot showing F4/80 and Ly-6B expression in MØs from the 
peritoneal cavity of mice 7 days after intra-peritoneal injection of 1ml of 4 % (w/v) 
thioglycollate broth. The plot has been pre-gated using the ResMØ and InfMØ gate (as 
described in figure 3.2b) and to remove eosinophils and doublets (figures 3.1 and 
3.2a). The cell populations are indicated. B) Bar graph showing quantification of the 
total cell numbers of 3 populations from A, and their levels of proliferation, measured 
by Ki67 and DNA (DAPI) staining. Ki67high cells with 4N DNA content were classified as 
mitotic. Data shown is from five 9 week old 129S6 mice from one of two independent 
experiments. 
4.2.4 – Both Ly-6B+ and Ly-6B– InfMØs are derived from the bone marrow. 
The adoptive transfer experiments in chapter three of this thesis (figures 3.15 and 
3.16) indicated that InfMØs were not derived from the cells present in the naϊve 
peritoneal cavity, so are likely recruited from the periphery. To definitively determine 
whether InfMØs (specifically those expressing Ly-6B) were peripherally recruited cells, 
derived from the bone marrow, a collaborative study was performed with Prof. Judith 
Allen and Dr. Steven Jenkins in Edinburgh. Partial bone marrow chimeric mice were 
constructed for these studies by Dr. Steven Jenkins who: shielded the abdomen of 
anaesthetized C57BL/6 CD45.1 mice with a 2-inch lead screen before exposing them to 
a single dose of 9.5 Gy radiation. This was followed by intra-venous injection of 6x106 
donor bone marrow cells from congenic C57BL/6 CD45.2 mice. Chimeric mice were left 
for 6 weeks before analysis of the chimerism in myeloid populations in the blood. After 
this time, the chimeric mice showed a good level of blood myeloid cell chimerism of 
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around 15-40 % (figure 4.7a), and were subsequently injected intra-peritoneally with 
2x106 particles of zymosan a day after the blood testing to initiate acute inflammation. 
Peritoneal cells were recovered 72 hours after initiation of the inflammation by lavage. 
ResMØs showed very low levels of chimerism (0.29 ± 0.09 %, mean ± SEM, n= 6), while 
Ly-6B+ and Ly-6B– InfMØs showed substantial levels of chimerism (figure 4.7b), which 
correlated well with the chimerism seen in the Ly-6Chigh blood monocytes from the 
same animals 4 days previously (figure 4.7c). 
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Figure 4.7. Both Ly-6B+ and Ly-6B– InfMØs are derived from the bone marrow and are 
quite distinct from ResMØ, which have the potential to self-renew 
A) Graph showing analysis of blood myeloid cell chimerism one day before induction of 
peritonitis (see below), a stable chimerism is seen in all partial chimeras generated by 
Steve Jenkins (described in 4.2.4). Each line links the data from an individual mouse. B) 
Representative flow cytometric plots gated from the populations as gated in figure 4.1 
stained with antibodies against CD45.1 and CD45.2 to determine the level of 
chimerism between CD45.1 recipient cells and CD45.2 donor cells, 72 hours after the 
induction of peritonitis by intra-peritoneal administration of 2x106 zymosan particles. 
The dashed line represents the divide between donor and recipient cells. C) Graphical 
representation of the chimerism in all of the experimental animals, correlating the 
chimerism of the 3 peritoneal MØ subsets with that of Ly-6Chigh blood monocytes 
within the same animal. Data were analyzed by linear regression, and r2 values are 
indicated alongside significance testing for a non-zero slope (***= P≤ 0.001). Each 
symbol represents an individual irradiation chimera.  
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4.2.5 – M-CSF is required but not sufficient for substantial ResMØ proliferation 
M-CSF is a cytokine required for growth and differentiation of MØ progenitors in bone 
marrow (Hume and Gordon, 1983); therefore the role of M-CSF was investigated in 
peritoneal MØ proliferation. Exogenous recombinant M-CSF was added to cultured 
ResMØs to determine whether M-CSF could stimulate ResMØ proliferation ex vivo. 
Peritoneal cells were cultured for 7 or 12 days, with or without M-CSF. M-CSF 
treatment resulted in increased numbers of recovered, intact MØ nuclei (figure 4.8a); 
and an over three fold increase in proliferation measured by >2N DNA content. For 
example, at 7 days of culture ‘media only’ had 3.87 ± 0.42 % >2N DNA (mean ± SEM, n= 
3) while M-CSF addition had 12.3 ± 0.24 %. The higher cell numbers seen in M-CSF 
treated cells compared with media alone could be accounted for by this higher level of 
proliferation (figure 4.8a) or an increase in cell survival; as typically only 200,000 
ResMØs were seeded, and the number recovered in the M-CSF treatment was 187,345 
± 35,307 nuclei (mean ± SEM) at 12 days. However, active proliferation with M-CSF 
treatment in vitro was confirmed by 5-ethynyl-2'-deoxyuridine (EdU) uptake into 
proliferating cells. EdU is an alternative to BrdU, it will be incorporated during DNA 
synthesis instead of thymidine in S phase (Buck et al., 2008). EdU was added to culture 
media (± M-CSF) on day 6 of a 7 day adherent peritoneal cell culture to assess the 
proliferation. In one day 4.9 ± 0.92 % (mean ± SEM, n= 4) of cells incorporated EdU 
(figure 4.8b), which provides evidence for proliferation in a small percentage of the 
cells. When EdU was added every day in a 3 day culture 21.88 ± 8.72 % (mean ± SEM, 
n= 3) of the cells incorporated EdU (figure 4.8c). This suggests that only a small number 
of cells have the potential to proliferate in vitro, but that their daughter cells 
accumulate in the culture. Additionally, this proliferation coupled with cell death could 
explain the stagnation of cell numbers in M-CSF supplemented culture (200,00 cells 
cultured vs 187,345 ± 35,307 cells recovered). 
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Figure 4.8. Exogenous M-CSF promotes ResMØ proliferation ex vivo 
A) Bar graphs showing the number of nuclei (left) and % DNA >2N (right) retrieved 
from adherent peritoneal cells (the vast majority being ResMØs) cultured for 7 or 12 
days ± 20 ng/ml M-CSF. Data were analysed by two-way ANOVA with M-CSF treatment 
and time as the two groups. The interactions between the effects of M-CSF and time in 
culture was non-significant, however the effect of M-CSF treatment was statistically 
significant on both numbers P= 0.0007 (left) and proliferation P≤ 0.0001 (right). There 
was also a significance in proliferation with the time that cells were cultured (7 or 14 
days), P= 0.0158. Data is from one of two similar experiments using separate wells (n= 
3) of cultured peritoneal cells from a pool of three 15 week old female 129S6/SvEv 
Dectin-1–/– mice (different strains of mice were used depending on availability – see 
methods 2.6.1). 
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B) (from previous page) Bar chart showing the level of EdU incorporation in ResMØs 
after culture for 7 days ± 20 ng/ml M-CSF. EdU (1.25 µg/ml) was added on day 6 of 
culture to assess the proliferation at this late stage. Data were analysed by a one tailed 
Student’s t-test and the significance value is indicated (** = P≤ 0.01). Data is from one 
experiment using separate wells of cultured peritoneal cells from two 10 week old 
male 129S6/SvEv mice (duplicate wells were used per mouse for ± M-CSF treatment, 
n= 4). C) Bar chart showing the level of EdU incorporation in ResMØs (gated as in figure 
3.10) after culture for 3 days ± 20 ng/ml M-CSF. EdU (1.25 µg/ml) was added (media 
refreshed, including M-CSF) every day of culture to assess the total proliferation. Data 
were analysed by a one tailed Student’s t-test and the significance value is indicated (* 
= P≤ 0.05). Data were pooled from two independent experiments (n = 3 per group) 
from individual Gata6-WT mice (different strains of mice were used depending on 
availability – see methods 2.6.1). 
To determine whether M-CSF could also promote ResMØ proliferation in vivo, 0.4µg of 
recombinant M-CSF was administered to mice via intra-peritoneal injection. Exogenous 
M-CSF caused an increase in proliferation compared to the carrier control (0.5 % BSA 
in PBS (w/v)), as measured by: total Ki67+, >2N DNA content, >2N DNA content that 
were Ki67+, and pHH3+ ResMØs (figure 4.9). The trend showed increased proliferation 
with all measures. The minimum was a 40 % increase in mean total Ki67 expression, 
and the maximum was a 116 % increase in mean pHH3 expression (n= 10). However, 
only >2N DNA content and pHH3+ values were significant by Student’s t-test. Media = 
media alone 
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Figure 4.9. M-CSF is not sufficient for substantial ResMØ proliferation in vivo 
Bar graphs showing the proliferation (measured by Ki67, pHH3 and DNA) of ResMØs 24 
hours after intra-peritoneal administration of 0.4 µg of recombinant M-CSF or carrier 
control. SG2M shows Ki67
+ cells with >2N DNA content. Data shown represents mean ± 
SEM of 10 mice per group (7 week old female C57BL/6) pooled from 2 identical 
experiments. Data were analyzed by a Student’s t-test and significance values are 
indicated.  
A neutralising antibody against M-CSF (clone 5A1) was administered intra-peritoneally 
to determine whether M-CSF is needed for ResMØ proliferation. The antibody binds to 
M-CSF in situ and blocks its biological activity (Lokeshwar and Lin, 1988). All measures 
of peritoneal ResMØ proliferation were completely ablated 48 hours after intra-
peritoneal administration of 0.5mg anti-M-CSF (figure 4.10). For example, the 
percentage of cells in SG2M (Ki67
+ >2N DNA) was 1.23 ± 0.1 % in IgG injected mice and 
0.07 ± 0.01 % in M-CSF neutralised mice (mean ± SEM, n= 3 and 4 respectively). The 
number of ResMØs was also significantly reduced after anti-M-CSF treatment (figure 
4.10) compared to IgG control, reduced from 4.12 ± 0.64x106 to 2.5 ± 0.24x106 (mean ± 
SEM). The antibody against M-CSF was additionally administered at the same time as 
2x106 zymosan particles, and the proliferation examined after 48 hours. The ResMØ 
proliferative burst usually seen 48 hours after zymosan was still intact with IgG control, 
but was entirely blocked by anti-M-CSF treatment (figure 4.11b, c). The numbers of 
recoverable ResMØs 48 hours after zymosan were also reduced by anti-M-CSF, to only 
66 % (based upon means, n= 5) of the level seen with the IgG control (figure 4.11a). 
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Figure 4.10. M-CSF is required for homeostatic ResMØ proliferation 
Bar graphs denoting ResMØ numbers (top left) and various measures of proliferation 
calculated using DNA (DAPI), Ki67 and pHH3 48 hours after 0.5mg anti-M-CSF or IgG 
isotype control antibody. Data were analyzed by Student’s t-test and significance 
values are indicated, ** = P≤ 0.01, *** = P≤ 0.001. Data is from one experiment with 9-
12 week 129S6/SvEv female mice (n = 3-4 mice per group), but similar results were 
obtained with Gata6-WT mice (different strains of mice were used depending on 
availability – see methods 2.6.1). 
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Figure 4.11. M-CSF is required for ResMØ proliferation during acute inflammation 
A) Bar graph showing the numbers of ResMØs and InfMØs 48 hours after the intra-
peritoneal injection of 2x106 zymosan particles in conjunction with 0.5 mg of either 
anti-M-CSF or rat IgG isotype control (as indicated). B) Representative flow cytometric 
plots showing cells gated for ResMØs as previously described (figure 3.10 and also 
figures 3.1/3.2 for doublet/ eosinophil discrimination), after the same treatment as in 
(A). Cells were stained for Ki67 and DNA to measure proliferation, the diagonal dashed 
line represents the maximal staining seen with a matched isotype control for Ki67 C) 
Bar graphs showing quantification of proliferation from (A) measured by Ki67, pHH3 
and DNA. SG2M shows Ki67
+ cells with >2N DNA content. Data shown represents the 
mean ± SEM of 5 mice per group (7 week old female C57BL/6) from one of 2 similar 
experiments. Data were analyzed by a Student’s t-test and significance values are 
indicated, * = P≤ 0.05, *** = P≤ 0.001. 
The number of InfMØs seen 48 hours after acute peritonitis induced with 2x106 
zymosan particles was examined with anti-MCSF treatment or IgG isotype control. The 
number of recoverable InfMØs was significantly reduced after M-CSF treatment 
compared with isotype control, which included both Ly-6B– and Ly-6B+ MØs 
(figure4.12). Due to two strains of inbred mice being used, the data was analysed by a 
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two-way ANOVA using M-CSF treatment as one group and strain of mice the other 
group, which showed significant reductions in cell numbers with M-CSF treatment. 
 
 
Figure 4.12. Ly-6B-expressing InfMØs are M-CSF-dependent 
Bar graphs showing quantification of InfMØ numbers 48 hours after acute peritonitis 
induced with 2x106 zymosan particles in conjunction with 0.5 mg of either anti-M-CSF 
or rat IgG isotype control. Data shown represents the mean ± SEM of two independent 
experiments, one conducted with 7-8 week old female C57BL/6 mice (n= 5 per group) 
and the other with 9-12 week old female 129S6/SvEv (n= 3-6 per group). Data was 
analyzed by two-way ANOVA with the significance of the effects of both M-CSF 
blockade and strain of mouse indicated, ** = P≤ 0.01, *** = P≤ 0.001. 
The M-CSF dependence of ResMØ proliferation could be attributed to availability of M-
CSF in the peritoneal cavity. Therefore, the quantity of M-CSF was assessed from 
lavage fluid. The level of M-CSF quantified in the peritoneal cavity of naϊve mice was 
(in the majority, n= 10) between 1 and 1.5 ng, this number did not significantly change 
48 hours after 2x106 zymosan particles (figure 4.13). 
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Figure 4.13. Measurement of M-CSF in homeostasis and inflammation 
Column scatter plot showing M-CSF in the lavage fluid of naïve mice and mice 48 hours 
after the induction of peritonitis with 2x106 zymosan particles measured by enzyme-
linked immunosorbent assay. Data is adjusted for lavage volume and expressed as 
total M-CSF in the peritoneal cavity. Each symbol represents an individual 6 week old 
C57BL/6 female mouse and data was pooled from 2 independent experiments. The 
horizontal bars denote the means. The enzyme-linked immunosorbent assay was 
carried out by Dr. Selinda Orr for incorporation into this thesis. 
4.2.6 – IL-4 is not essential for MØ proliferation during acute inflammation 
The high level of ResMØ proliferation in the peritoneal cavity during a helminth 
infection seen by Jenkins et al., was dependent upon the cytokine IL-4 (Jenkins et al., 
2011). Therefore IL-4 was investigated during the proliferative activity of MØs after 
peritonitis induced by 2x106 zymosan particles. The proliferative burst of ResMØs was 
investigated 48 hours after intra-peritoneal zymosan in conjunction with a neutralising 
antibody against IL-4 (clone 11B11) or rat IgG isotype control. The 11B11 antibody 
binds to IL-4 and inhibits its biological activity (Ohara and Paul, 1985). ResMØ numbers 
and levels of proliferation measured by Ki67, pHH3 and DNA were not significantly 
different between anti-IL-4 treatment and control (figure 4.14). The populations of 
both Ly-6B+ and Ly-6B– InfMØs were also investigated 48 hours after zymosan. Note: 
the numbers of Ly-6B+ InfMØs (figure 4.15a) seen 48 hours after 2x106 zymosan 
particles are much lower than after 72 hours (figure 4.4). However, these cells were 
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still proliferating at a relatively high level, which was around 3-fold higher than the Ly-
6B– InfMØs (figure 4.15b). IL-4 blockade caused a significant but relatively mild 
reduction in proliferation in both populations of InfMØs (figure 4.15b). The number of 
Ly-6B+ InfMØs was also significantly reduced (figure 4.15a) from 76x103 ± 17x103 to 
33x103 ± 6x103 (mean ± SEM, n= 8 and 11 respectively), although not to the same 
effect as seen in M-CSF blockade (figure 4.12). The number of Ly-6B– InfMØs was not 
significantly altered. 
 
 
Figure 4.14. No role for IL-4 on ResMØ proliferation during acute inflammation 
Bar graphs showing the number of ResMØs, and measurements for proliferation, 48 
hours after intra-peritoneal injection of 2x106 zymosan particles in conjunction with 
0.5 mg of either anti-IL-4 or rat IgG isotype control. SG2M phases of the cell cycle were 
measured by Ki67+ cells with >2N DNA content. Data were analysed by two-way 
ANOVA as indicated. Data shown represents the mean ± SEM of 5 mice per group (7 
week old female C57BL/6) from one of 2 similar experiments. 
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Figure 4.15. IL-4 blockade has a limited effect on InfMØ proliferation during acute 
inflammation 
A) Bar graphs showing quantification of InfMØ numbers, 48 hours after acute 
peritonitis induced with 2x106 zymosan particles in conjunction with 0.5 mg of either 
anti-IL-4 or rat IgG isotype control. B) Bar graphs showing analysis of proliferation in 
InfMØ subsets in mice after the same treatment as in (A). Proliferation was measured 
with Ki67 and DNA, SG2M shows Ki67
+ cells with >2N DNA content. Data shown for (A) 
and (B) represents mean ± SEM from two-independent experiments with 7-8 week old 
female C57BL/6 n= 5 mice per group and 9-12 week old female 129S6 mice (n= 3-6 
mice per group). Data were analyzed by a Two-way ANOVA with the significance of the 
effects of IL-4 neutralization and mouse strain indicated, *= P≤ 0.05 ***= P≤ 0.001. 
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The apparent effects of IL-4 blockade with 11B11 were further investigated using IL-4 
receptor α knockout mice (Il4ra–/–). Il4ra–/– mice were originally generated by gene 
targeting in BALB/c mice (Noben-Trauth et al., 1997), but were backcrossed onto a 
C57BL/6 background recently by Prof. Frank Brombacher in Cape Town. These 
C57BL/6· Il4ra –/– mice were kindly supplied by Prof. Judith Allen, Dr. Steven Jenkins 
assisted in experimental procedures. No significant differences were seen in ResMØ or 
InfMØ cell numbers and proliferation between WT C57BL/6 mice and Il4ra–/– mice, 72 
hours after intra-peritoneal administration of 2x106 zymosan particles. 
 
 
Figure 4.16. Lack of an essential role for IL-4/ IL-4 receptor α on MØ proliferation 
during acute inflammation 
Bar charts showing the number and proliferation of ResMØ and InfMØ subsets, 72 
hours after induction of peritonitis with 2x106 zymosan particles in wild type and IL-4 
receptor α deficient mice on the C57BL/6 background. Proliferation was measured by 
Ki67 and DNA. SG2M shows Ki67
+ cells with >2N DNA content. Data shown represents 
mean ± SEM of one experiment with 6 week old female mice (n= 9-10 per group). Data 
were analysed by two-way ANOVA, no significant differences were observed. 
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4.3 – Discussion 
The aims of this chapter were to: 1) investigate whether Ly-6B+ InfMØs have the 
capacity to proliferate in situ; 2) investigate the origins of Ly-6B+ InfMØs; and 3) 
investigate the role of M-CSF and IL-4 in the control of ResMØ and InfMØ proliferation. 
 
4.3.1 – Ly-6B+ InfMØs 
In 2010, Dr. Marcela Rosas identified the antigen recognised by the 7/4 antibody as Ly-
6B (Rosas et al., 2010). Ly-6B is a member of the Ly-6 family of proteins, however this 
family’s functional activities are poorly categorised (Lee et al., 2013). In vivo treatment 
with the 7/4 antibody leads to a reduction in neutrophil and monocyte numbers in the 
blood (Rosas et al., 2010) similar to the neutropenia seen with Ly-6G blockade, 
however blockade of Ly-6B does not affect the migration of neutrophils seen with a 
limited blockade of Ly-6G (Wang et al., 2012a). The function of Ly-6B on monocytes or 
MØs is not known (Lee et al., 2013) and is purely used here as a marker for MØ 
subsets. Dr. Rosas found that Ly-6B+ InfMØs that arrived during inflammation were 
newly generated, and had incorporated substantially higher levels of BrdU compared 
with their Ly-6B– counterparts in the resolution phase of inflammation (Rosas et al., 
2010). This incorporation was assumed to occur in the bone marrow. However the 
results from chapter 3 of this thesis show that ResMØs can proliferate in the peritoneal 
cavity; this provides an alternate hypothesis for the origin of BrdU incorporation seen 
in Ly-6B+ InfMØs: in situ proliferation. 
Ly-6B+ InfMØ populations elicited during inflammation were examined using flow 
cytometry. The cells needed to be fixed and permeabilized in order to subsequently 
look at the cell cycle. After removing doublets (figure 3.1) and eosinophils (figure 3.2) 
and broadly gating on MØs (shown in figure 3.2b), monocytes were frequently seen in 
the population. These Ly-6B+ monocytes exhibited less F4/80 expression as shown in 
F4/80 vs Ly-6B flow cytometric plots (figures 4.1, 4.4a and 4.6a), however there was 
sometimes a slight overlap with the Ly-6B+ InfMØ population, when shown in this 
fashion. Fortunately, these monocytes could be excluded from analysis via their lower 
expression of CD11b and a slightly smaller FSc profile (figure 4.1). Excluding the 
monocytes here allowed for accurate separation of these populations and refined 
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analysis when viewed as F4/80 vs Ly-6B expression, the monocytes are only included in 
the representative plots to emphasise their existence in this complex inflammatory 
environment. 
 
4.3.2 – Ly-6B+ InfMØs proliferate during inflammation 
Having established an accurate gating strategy for Ly-6B+ InfMØ, the cell cycle was 
investigated as in chapter 3 of this thesis. However, the measure of cell cycle using 
‘SG2M’ calculations was now frequently chosen over pHH3
+ or Ki67high calculations. 
SG2M is calculated by gating on cells that have >2N DNA content and are Ki67
+. This 
measure of proliferation includes all active levels of the cell cycle and can be more 
sensitive than pHH3+ or Ki67high staining when a low level of proliferation is observed. 
Therefore, the ‘all inclusive’ SG2M calculation was used for a more holistic analysis of 
MØ proliferation. 
Intra-peritoneal injection of 2x106 zymosan particles causes inflammation 
characterised by an early influx of neutrophils followed by an accumulation of InfMØs, 
including Ly-6B+ InfMØs (Rosas et al., 2010). The new gating strategies and cell cycle 
calculations were applied to Ly-6B+ InfMØs 72 hours after zymosan. This revealed that 
Ly-6B+ InfMØs have a significant capacity for proliferation; these levels of proliferation 
(measured by DNA, Ki67 and pHH3) were in some cases (figures 4.5 and 4.6) higher 
than the proliferative burst of ResMØs seen 48 hours after 2x106 zymosan (figure 
3.11), and notably this occurs at different time points during inflammation. The 
proliferation was also much higher than the low levels seen in Ly-6B– InfMØs. This 
matches the data from the microarray (1.3.1), which showed an enrichment of genes 
associated with proliferation in Ly-6B+ InfMØs.  
 
4.3.3 – Ly-6B+ InfMØ and ResMØ proliferation is a general phenomenon in 
inflammation 
A higher dose (2x107 particles) of zymosan and thioglycollate broth were used to show 
that both the existence of Ly-6B+ InfMØs, and the MØ proliferation seen with the low 
dose of zymosan (2x106 particles) are not restricted to one model. The higher dose of 
zymosan resulted in a similar number of Ly-6B+ InfMØs, but less ResMØs than the low 
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dose, due to the increased zymosan load on the ResMØs, and a higher more sustained 
influx of neutrophils (Taylor et al., 2003, Taylor et al., 2005b). The thioglycollate broth 
injection resulted in a more substantial recruitment of monocytes from the blood, but 
with no detectable Ly-6B+ InfMØs, and only a small number of ResMØs 72 hours after 
injection. Injection of 1ml 4 % thioglycollate is the standard practice for eliciting 
InfMØs (Hopper, 1986); however it causes greater peritoneal inflammation than the 
doses of zymosan used in this study. It is possible that a smaller dose of thioglycollate 
would be more akin to the low doses of zymosan used. If thioglycollate inflammation is 
left to resolve for a longer time (7 days), then ResMØs are recoverable in greater 
numbers than 72 hours, and Ly-6B+ InfMØs are detectable. Both of these MØ 
populations were proliferating, which means that proliferation of ResMØs and Ly-6B+ 
InfMØs is a general characteristic of the resolution of peritoneal inflammation and is 
not just restricted to mild doses of zymosan. 
 
4.3.4 – Ly-6B+ InfMØs are bone marrow-derived 
The adoptive transfer experiments in chapter three of this thesis (figures 3.15-19) 
showed that InfMØs were primarily host derived, not originating from the naϊve 
peritoneal cavity, and were therefore likely peripherally recruited. To verify this, a 
collaborative study was established with Prof. Judith Allen and Dr. Steven Jenkins in 
Edinburgh in order to assess the origins of Ly-6B+ InfMØs. Partial bone-marrow 
chimeras were created by Dr. Steven Jenkins (Jenkins et al., 2011). Six weeks later, 
after confirming chimerism, zymosan peritonitis was initiated in these mice and left to 
resolve for 72 hours. Both Ly-6B– and Ly-6B+ InfMØs were chimeric (which correlated 
well with blood chimerism), so were likely bone-marrow derived. ResMØs were not 
chimeric, which supported conclusions made from the adoptive transfer experiments 
carried out in chapter 3 of this thesis (figures 3.14-3.18), in that ResMØs do not rely on 
blood monocytes for their renewal, but self-renew via local proliferation. 
 
4.3.5 – M-CSF dependency of MØs 
M-CSF addition is used to expand bone marrow MØ cultures ex-vivo (Hume and 
Gordon, 1983). Therefore, exogenous M-CSF was added to cultured peritoneal cells. 
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M-CSF addition caused increased proliferation and/ or survival of the adherent 
peritoneal cells, the vast majority are likely ResMØs (Davies and Gordon, 2005). The 
level of >2N DNA content could be used as a good measure for active proliferation due 
to the nature of the NIM-DAPI used to extract the cell nuclei. Over 10 % of the cells 
were in active phases of the cell cycle (SG2M) 7 and 12 days after culture with M-CSF 
(figure 4.8a); however these could have been adherent cells other than MØs. EdU 
incorporation in vitro could be used in conjunction with expression of the MØ markers 
F4/80 and CD11b in flow cytometry, to accurately identify MØ proliferation. EdU 
incorporation showed that only around 5 % of the ResMØs had actively proliferated on 
the last day of a 7 day culture with M-CSF (figure 4.8b). This was supported by a ≈20 % 
EdU incorporation after 3 days of culture (figure 4.8c). Additionally, Jessica Llewellyn (a 
master’s student in our laboratory) showed that roughly 50 % of cells had incorporated 
BrdU 7 days after culture (unpublished data). This data suggests that only a small 
proportion of <5 % of peritoneal MØs have the capacity to proliferate in culture in 
these experiments, and that their daughter cells accumulate in culture, but this needs 
to be formally addressed. Either a form of contact inhibition could be limiting the 
proliferation, or perhaps stem cell-like subset of ResMØs was proliferating. A method 
of testing these hypotheses would be to try different seeding densities, measuring EdU 
uptake daily, and pulse-chase labelling the cells with both EdU and BrdU. However, the 
specific processes in vitro were not a focus of this thesis, especially when the 
physiological relevance of these observations was uncertain. This uncertainty is due to 
the loss of homeostatic controls, such as the transcription factor Gata6 mentioned 
later in this thesis (chapter 6).  
The effect of M-CSF was tested in vivo by a single intra-peritoneal injection of 
recombinant M-CSF. This caused a significant, but small increase in ResMØ 
proliferation, which was not as high as that seen in the proliferative burst 48 hours 
after zymosan peritonitis (chapter 3 of this thesis). Daily intra-venous injection of 
recombinant M-CSF has previously been shown to increase the number of peritoneal 
MØs, which was attributed to a 10-fold increase in circulating monocytes (Hume et al., 
1988). However on reflection, this could also be a result of increased local 
proliferation. The peritoneal cavity itself contains high levels of constitutive M-CSF in 
naϊve animals and similar levels were present 48 hours after zymosan. This suggests 
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the proliferative burst is not primarily controlled by the availability of M-CSF, but by 
other factors, perhaps the levels and/ or the function of the M-CSF receptor, or 
alternative regulatory mechanisms.  
Blockade of M-CSF with the 5A1 antibody caused a complete ablation of all measures 
of proliferation in naϊve mice and on the proliferative burst seen in mice 48 hours after 
intra-peritoneal zymosan. This shows that M-CSF is essential for proliferation, but its 
addition is not sufficient to replicate the high levels of ResMØ proliferation seen after 
peritonitis, again implicating additional proliferative controls. Anti-M-CSF treatment 
also caused a substantial decrease in ResMØ numbers; which could be a result of the 
failure of ResMØs to recover via proliferation from the inflammation caused by intra-
peritoneal injection of anti-M-CSF (plus carrier). Indeed similar losses of ResMØs were 
seen in conjunction with anti-M-CSF 48 hours after zymosan. The numbers of InfMØs 
were also severely reduced after zymosan in conjunction with anti-M-CSF, specifically 
the numbers of Ly-6B+ InfMØs; which were reduced by a higher proportion relative to 
Ly-6B– InfMØs. However, this could be due to the presence of F4/80low MHCIIhigh Res 
DCs/MØs (which are still present during inflammation) ‘contaminating’ the Ly-6B– 
InfMØs gate. The general reduction in InfMØs could be attributed to either: i) a 
reduction in recruitment, ii) in situ differentiation (although significant numbers of 
monocytes were not seen in the peritoneal cavity), iii) proliferation (at least with the 
Ly-6B+ InfMØs), or iv) survival. Continuous blockade of M-CSF after birth results in 
most of the defects seen in the op mouse: including reduced levels of tissue MØs and 
growth defects (Wei et al., 2005). Additionally, M-CSF blockade in the adult has been 
shown to deplete tissue MØs and ‘non classical’ Gr1- (Ly-6C-/low) monocytes but 
increase the numbers of ‘classical’ Gr1+ (Ly-6C+/high) monocytes (MacDonald et al., 
2010). These studies have attributed the reduction of tissue MØs to the loss of 
differentiation from ‘non-classical’ monocytes (Hume and MacDonald, 2012), which 
were assumed to be the precursors of ResMØs. However, the loss of tissue MØs could 
also be attributed to the ablation of homeostatic maintenance by in situ proliferation. 
These previous blockade studies could have also explained the preferential loss of Ly-
6B+ InfMØs seen with anti-M-CSF treatment during zymosan peritonitis; in that the 
precursors of Ly-6B+ InfMØs could be ‘non classical’ monocytes. However, it has 
recently been shown that ‘classical’ monocytes are precursors to ‘non-classical’ 
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monocytes (Yona et al., 2012), therefore investigating the monocytic origin of these 
cells would be difficult and impractical in the inflammatory setting. After taking these 
findings into account, it is more likely that the peripheral recruitment of the whole 
InfMØ population has been inhibited by M-CSF blockade. 
 
4.3.6 – MØ proliferation is not dependent upon IL-4 
The cytokine IL-4 was implicated in proliferation of peritoneal ResMØs after helminth 
infection (Jenkins et al., 2011). However, the environment created 48 hours after intra-
peritoneal administration of 2x106 particles of zymosan was considered to be different 
from the IL-4 rich Th2 environment seen in the Jenkins et al. study. Hence the role of IL-
4 in this model was expected to be minimal. IL-4 was blocked with the antibody 11B11 
in the peritoneal cavity of mice 48 hours after zymosan. This blockade did not affect 
ResMØ proliferation or numbers, but had a small but significant reducing effect on Ly-
6B+ InfMØ numbers and proliferation of InfMØs as a whole. 
The effects of using blocking antibodies can be variable due to the way they are 
produced (i.e. levels of endotoxin and other contaminants) and potential secondary 
effects in the inflammatory process, so a second collaborative study was established 
with Prof. Judith Allen and Dr. Steven Jenkins in Edinburgh in order to test the findings 
when using the blocking antibody 11B11 on Ly-6B+ InfMØs. Zymosan was injected into 
WT and Il4ra–/– mice. There was no significant difference between MØ numbers or any 
measures of proliferation between the two groups. This clearly demonstrates that IL-4 
is not essential for MØ proliferation in the zymosan model. Either way, the effect of IL-
4 on Ly-6B+ InfMØs during an acute inflammatory response is limited at best and not 
necessary for proliferation. In contrast, M-CSF was an essential growth factor for MØ 
proliferation. Perhaps there is a homeostatic feedback loop for ResMØs, under the 
control of the M-CSF receptor; which limits proliferation in homeostasis where there 
the number of ResMØs are sufficient, but drives proliferation when there is a loss in 
normal homeostatic numbers as seen in zymosan induced inflammation. IL-4 
seemingly has the ability to bypass this mechanism during helminth infection to drive 
proliferation and expand ResMØ numbers beyond homeostatic levels (Jenkins et al., 
2013). 
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Interestingly, the times at which ResMØs and Ly-6B+ InfMØs are actively proliferating is 
distinct. ResMØs undergo a burst in proliferation 48 hours after 2x106 zymosan 
particles, and this returns to near homeostatic levels 72 hours after zymosan. On the 
other hand Ly-6B+ InfMØs continue to proliferate at high levels 72 hours after zymosan 
and beyond. This indicates that there are alternative and distinct intrinsic control 
mechanisms between these two populations. These specific mechanisms have been 
largely undetermined; however one mechanism for the proliferative control of 
ResMØs is explored in chapter six of this thesis. 
 
4.3.7 – Conclusion 
In conclusion, the studies in this chapter, which have now been published (Davies et 
al., 2013b), showed that: 1) a subset of InfMØs that are Ly-6B+ proliferate during 
inflammation; 2) these Ly-6B+ InfMØs are derived from the bone marrow and are 
recruited to the inflammatory lesion; 3) M-CSF is required but not sufficient for ResMØ 
proliferation; 4) M-CSF is required for either recruitment, survival or proliferation of 
Ly-6B+ InfMØs; 5) IL-4 receptor α is not necessary for ResMØ or InfMØ proliferation; 
and 6) proliferation of these different MØ populations is under distinct mechanistic 
control. This demonstrates that blood monocyte (bone marrow)-derived MØs are 
capable of proliferation and are not terminally-differentiated, which additionally 
challenges the dogma of the MPS (as with chapter 3 of this thesis). The identification 
that local MØ proliferation is ablated by anti-M-CSF treatment should be considered 
when targeting M-CSF for treatment of diseases like rheumatoid arthritis (Korkosz et 
al., 2012) and cancer (Hume and MacDonald, 2012); and also when designing novel 
strategies to combat these chronic diseases. 
 
 
 
 
 
138 
 
 
 
 
 
 
Chapter 5 – Lentiviral modification of MØ gene expression
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5.1 – Introduction 
5.1.1 – Lentiviral vectors 
Lentiviruses are a type of retrovirus (RNA containing virus) which can infect non-
dividing cells (Naldini, 1998). A well known lentivirus is the human immunodeficiency 
virus (HIV) which causes acquired immunodeficiency syndrome (AIDS). Lentiviral 
vectors have been used to deliver target genes to non-dividing cells and are frequently 
derived from the genome of HIV-1 (Naldini, 1998). Retroviral vectors in general are 
valued because they do not force translation of any viral proteins, meaning they can be 
accepted in most cellular systems. The pHR’SIN-cPPT-SEW (SEW) (Demaison et al., 
2002) vector and an enhanced green fluorescent protein (eGFP) deficient version 
(pHR’SIN-cPPT-SXW) (SXW) were kindly provided by Dr. Paul Brennan. These vectors 
had been modified to lack virulent proteins, which were: the group antigens (gag), 
reverse transcriptase-containing pol, regulator of expression of viron proteins (rev), 
envelope protein (env), viral infectivity factor (vif), viral protein R (vpr), viral protein 
unique (vpu), trans-activator of transcription (tat), and negative factor (nef). This left 
the viral vector unable to infect or replicate without help. Therefore, helper constructs 
are required to generate infectious viral particles. The pCMVR8.91 (pCMVΔ8.91) 
(containing gag, pol, and rev) and pMD2G (containing vesicular stomatitis virus G 
protein (VSV-G)) expression vectors can be used in combination with the lentiviral 
vector to produce infectious lentiviral particles (albeit they are still unable to replicate) 
(Zufferey et al., 1997). The supplemented VSV-G envelope protein is valued for its 
ability to infect a broad range of cell types in multiple species (Burns et al., 1993). The 
lack of the tat protein in the lentiviral vector also means that the long terminal repeats 
(LTRs) of the vector were unable to be transcribed into foreign viral RNA. Therefore, a 
new transcriptional initiation system was introduced; consisting of the SFFV promoter 
and Woodchuck post-transcriptional regulatory element (WPRE) (an enhancer) to 
facilitate the transcription of the transgenes (Demaison et al., 2002). The SFFV 
promoter is from the Friend strain of SFFV virus, which usually infects erythrocytes, 
however this strong promoter is frequently used in retroviral vectors to enforce 
transgene expression (Demaison et al., 2002). The WPRE is known to enhance the 
expression of retroviral transgenes (Zufferey et al., 1999). The formation of this SEW 
construct (Demaison et al., 2002) resulted in a safe lentiviral delivery system, which 
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can infect a broad range of cell types (including myeloid cells) and can efficiently 
express genes of interest in infected cells. 
 
5.1.2 – RNA interference 
RNA interference can been delivered through lentiviral vectors, to achieve sustained 
knockdown of target gene expression (Abbas-Terki et al., 2002). RNA interference 
describes a wide range of RNA silencing processes in which RNA can be degraded or its 
action inhibited (Meister and Tuschl, 2004). One such method is via the production of 
dsRNA, usually through sh (short hairpin) RNA; where complementary RNA folds into a 
hairpin structure and base-pairs to form ds-shRNA. These shRNAs are processed by the 
ribonucleases Drosha (Lee et al., 2003) and Dicer (Bernstein et al., 2001) and loaded 
into RNA silencing complexes (RISC), which target specific RNA structures/ sequences 
for degradation (Hammond et al., 2000). 
 
5.1.3 – Markers used to identify infected cells 
Lentivirally delivered transgenes usually contain a tag or marker, which can be used to 
identify infected cells. The artificial protein eGFP is frequently chosen as a marker for 
viral infection, because it can be readily detected using its fluorescent properties. GFP 
was originally identified in Aequorea victoria jellyfish in the 1960s as the protein which 
absorbed bioluminescent blue light from aequorin and re-emitted this as green light 
(Shimomura et al., 1962, Morise et al., 1974). An enhanced version of GFP was created 
30 years later by introducing the S65T and F64L mutations, which enhanced brightness 
and thermo-stability of the protein at 37 °C (Heim et al., 1995, Cormack et al., 1996). 
However, this new eGFP protein was further improved in brightness and thermo-
stability (at 37 °C) with introduction of the V164A and S175G mutations (Siemering et 
al., 1996), to produce what will be referred to in this thesis as eGFP. Numerous, slightly 
different versions of eGFP exist within the literature, and their nomenclature has been 
poorly categorised. Apart from eGFP, several hundred diverse GFP derivatives have 
now been formulated with colours ranging from cyan and yellow to orange and red 
(Rizzo et al., 2009). 
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Other markers can also be used to track viral infections, such as Myc-tags, poly-
histidine-tags (6 histidine residues) and proteins such as truncated rat CD2 (trCD2). The 
Myc-tag is a 10 amino acid long sequence based upon the c-Myc protein, which has 
been used extensively to tag proteins since its first use (Munro and Pelham, 1986). The 
rat CD2 (rCD2) protein was truncated at the cytoplasmic tail to produce trCD2 (King et 
al., 1998). This protein is not able to mediate CD2 cytoplasmic signalling in infected 
cells, and infected cells expressing rat CD2 can be detected with a monoclonal 
antibody (which will not bind to mouse CD2). 
 
5.1.4 – Hypothesis 
The hypothesis tested in this chapter is that lentiviruses can be used to efficiently 
modulate gene expression in ResMØs in vivo. 
 
5.1.5 – Aims 
 To create an efficient method for quantifying viral titre 
 To infect ResMØs with lentivirus in vitro 
 To infect ResMØs with lentivirus in vivo 
 To produce lentiviral vectors that express and/ or knockdown genes of interest 
 To investigate the efficacy of ResMØ lentiviral infection in vivo 
  
142 
 
5.2 – Results 
5.2.1 – Lentiviral titre calculations in vitro 
Methods for quantifying viral titre were investigated to allow comparison between 
different viral preparations. Flow cytometry was used to quantify the level of eGFP 
expression in Jurkat cells infected with virus produced from the SEW plasmid. Jurkat 
cells are considered to be an ‘easy target’ for viral infection (Zhou et al., 2003), and 
were used to efficiently measure viral titre. The level of infection was quantified as 
total median fluorescent intensity (MFI) and the proportion of eGFP+ cells (figure 5.1). 
Real-time PCR (with a standard curve) was used to calculate the viral integration in 
these infections to give copy number per pg of DNA (figure 5.1). A relative MOI was 
also calculated using the proportion of eGFP+ cells and Poisson distribution (see 
methods 2.9.3). The MOI calculated from infected Jurkat cells was used when 
necessary for relative quantification of viral titre in specific lentiviral productions. 
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Figure 5.1. eGFP viral titre using flow cytometry and real-time PCR 
A) Scatter plot showing MFI (left Y) and the percentage of cells infected with an eGFP-
expressing lentivirus (right Y) vs the copy number of virus detected per pg of DNA (X). 
Non linear regression analysis was used to create the dotted line (eGFP+ %) (R2= 
0.9987), and linear regression was used to create the solid line (MFI) on the graph (R2= 
0.9949, P-value for significantly non-zero slope = 0.0002). Copy numbers per pg of DNA 
were calculated using genomic real-time PCR, using the integrated viral SFFV promoter 
and making this relative to genomic Ywhaz. A known quantity of lentiviral plasmid was 
used to create a standard curve, from which copy number values were calculated. Data 
represents a pilot experiment conducted prior to infection of MØs. B) Confirmation of 
eGFP infection of Jurkat cells from (A) using fluorescence microscopy. Image was 
captured using the 20× objective lens on the EVOS microscope, and is an overlay of 
phase contrast and eGFP expression. 
5.2.2 – Lentiviral infection of BMMØs and ResMØs in vitro 
After confirming that the SEW virus was able to transduce Jurkat cells, mature BMMØs 
and ResMØs were infected with the SEW lentivirus in vitro. Both BMMØ and ResMØ 
cultures exhibited eGFP+ cells 3 days after transduction with SEW (figure 5.2a). The 
ResMØs cultures (adherent peritoneal cell cultures) also included lymphocytes (SSclow), 
interestingly these cells had noticeably less eGFP+ expression compared with that of 
the ResMØs (SSchigh) (figure 5.2b). The SEW virus was titrated in ResMØ cultures and 
showed non-linear regression with a maximal infection of 68.8 % eGFP+ cells (figure 
5.3), using 250 µl of 10 × concentrated virus containing supernatant (see methods 
2.9.2). 
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Figure 5.2. Lentiviral infection of BMMØs and ResMØs 
A) Representative histograms showing the percentage of infected BMMØs and 
ResMØs (calculated using Overton channel by channel subtraction – the filled 
histogram) 3 days after transduction with an eGFP-expressing virus. The black 
histogram shows autofluorescence from an empty vector virus, and the green outline 
histogram shows fluorescence from cells infected with the eGFP-expressing virus. 
Note: the BMMØ and ResMØ infection levels are not directly comparable, as they 
were separate experiments with different conditions. B) Representative density plots 
depicting the prevalence of ResMØ infection over lymphocytes 3 days after lentiviral 
infection in vitro. In general, ResMØs have a higher FSc/ SSc profile than other resting 
peritoneal cells, albeit a small percentage of eosinophils and DCs were included in the 
ResMØ population and were not distinguished in this initial study. Lymphocytes and 
cell debris had a lower FSc/ SSc profile (bottom left of plots). BMMØs and peritoneal 
cells were seeded in vitro from 129S6/SvEv mice (see methods 2.5). Data is 
representative of a single preliminary experiment using 6 titrations of lentivirus, the 
plots shown used 250 µl of 10 × concentrated virus. SXW = empty vector virus, SEW = 
eGFP expressing virus. 
ResMØ
SXW
89.6%BMMØ
68.8%
SEW
eGFP
SS
c A
R
E
A
C
o
u
n
ts
A
B
145 
 
 
 
Figure 5.3. eGFP viral titre in ResMØs in vitro 
Scatter plot showing the percentage of ResMØs infected with an eGFP-expressing 
lentivirus vs the µl of virus used. Non linear regression analysis was used to create the 
line on the graph (R2= 0.9937). Data shown is from the same experiment as figure 5.2. 
5.2.3 – Specific lentiviral infection of ResMØs in vivo 
Following the successful infection of in vitro cultured peritoneal ResMØs, virus was 
injected into the peritoneal cavities of mice in order to assess the level of peritoneal 
cell infection. In vivo injection of SEW resulted in a high level of infection selective for 
ResMØs in the lavage retrieved from the peritoneal cavity (figure 5.4). Two additional 
repeats of the experiment shown in figure 5.4 showed that there was 50.27 ± 4.062-
fold (mean ± SEM) enrichment of ResMØ infection in vivo, when compared to all other 
cells in the peritoneal cavity (n= 5 total). 
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Figure 5.4. Specific lentiviral infection of ResMØs in vivo 
A) Representative density plot showing peritoneal cells stained with F4/80, 7 days after 
in vivo intra-peritoneal infection with an eGFP-expressing lentivirus. The overlaid 
contour plot indicates the representative autofluorescence seen in an uninfected 
mouse. Data shown is from a single preliminary experiment with 129S6/SvEv mice (n= 
1 per group), but the selective in vivo infection of ResMØs (F4/80high) is representative 
of all experiments carried out in this thesis. 
5.2.4 – Lentiviral knockdown of target gene expression in ResMØs in vivo 
Having achieved efficient in vivo infection of ResMØs, lentiviruses were produced to 
modify gene expression. A murine U6 promoter was inserted into the Eco RI site of the 
SEW lentiviral vector, and shRNA hairpin sequences were inserted into the Pme I site 
immediately following the promoter generated by this cloning. This created a system 
where RNA polymerase III would produce shRNAs from this sequence after viral 
integration (Kunkel et al., 1986); and the shRNAs would target mRNA for degradation 
(Hammond et al., 2000). Lentiviruses containing shRNA against Icam1 mRNA and non-
silencing control were formulated using this method. Transduction of ResMØs in vivo 
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with the Icam1 shRNA targeting lentivirus resulted in a drastic decrease in ICAM-1 
protein expression, when compared to the non-silencing control (figure 5.5).  
 
 
Figure 5.5. Lentiviral knockdown of ICAM-1 expression in ResMØs in vivo 
Representative density plots showing knockdown of ICAM-1 protein levels in ResMØs 
(gated as in figure 3.10), 7 days after intra-peritoneal delivery of a shRNA (eGFP-
tagged)-expressing lentivirus. The overlaid contours show the fluorescence of the 
ICAM-1 IgG isotype control. The bar graph shows quantification of ICAM-1 MFI in cells 
infected with ICAM-1-targeting and non-silencing shRNA-expressing lentiviruses. Data 
shown is representative of one of two independent experiments using 14 week old 
female 129S6 mice (n= 2/group). 
5.2.5 – Validation of a lentiviral expression vector 
As with the knockdown vectors (above), expression vectors were produced as a 
modulator of gene expression. For this thesis (specifically chapter 6), the short form of 
the transcription factor Gata6 (Takeda et al., 2004) was inserted into the Xho I 
restriction site of the SXW (eGFP deficient) vector. This new Gata6-expressing virus 
was used to transfect cultured BMMØs. Upon transfection, the level of Gata6 mRNA 
(measured by real-time PCR) increased over 10,000-fold when compared to SXW 
infection (figure 5.6). 
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Figure 5.6. Validation of the Gata6-expressing lentivirus 
Bar graph showing the fold change in Gata6 mRNA expression in BMMØs, 3 days after 
infection with a Gata6-expressing lentivirus. Data shown was made relative to both the 
endogenous control Ywhaz, and control SXW lentiviral infection. Data (n= 2) is from 
one of two independent experiments using 129S6/SvEv mice. 
5.2.6 – Lentiviral vectors constructed for this thesis 
Using similar strategies as mentioned above, other expression and knockdown vectors 
were produced from the SEW and SEW vectors (figure 5.7). Some of the expression 
vectors included a trCD2 tag linked to the expressed gene via a T2A (the template T2A-
CD2 was kindly supplied by Dr. James Mathews). The 2A sequence was originally 
identified in the foot-and-mouth disease virus and was found to be ‘self-cleaving’ 
(Ryan et al., 1991). This has been used in viral vectors to produce two protein products 
from one mRNA transcript (Szymczak et al., 2004). Other vectors included a Myc-tag, 
which can be detected with an antibody. These vectors were used for work carried out 
in chapter 6 of this thesis. 
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Figure 5.7. Schematic of lentiviral vectors produced for this thesis 
Schematic showing the content between the long terminal repeats (LTRs) of some of 
the lentiviral plasmids produced in this thesis. Individual sequence units are labelled: 
cPPT = central polypurine tract, SFFV = spleen focus forming virus promoter, WPRE = 
woodchuck post-transcriptional regulatory element, mU6 = mouse U6 promoter, eGFP 
= enhanced green fluorescent protein, trCD2 = truncated rat CD2. 
5.2.7 – Preferential inflammatory loss of infected ResMØs in vivo 
The efficacy of the lentiviral vectors in ResMØs was examined in vivo over a longer 
time course (up to two weeks), to determine whether viral integration and expression 
of transgenes was stable, or whether infected cells or were lost over time. The level of 
infection seen two weeks after intra-peritoneal injection of SEW or trCD2-expressing 
lentiviruses decreased significantly from the level seen 1 week after infection (figure 
5.8a). This was accompanied by a sharp increase in the number of recruited InfMØs 
(figure 5.8b), which is indicative of a post inflammatory environment (chapters 3 and 4 
of this thesis).  
This loss in expression levels was attributed to immune rejection of the trCD2 or eGFP 
tags, which are not native proteins to the mouse. Therefore, mice which had been 
genetically modified to contain an eGFP gene were acquired. Foxp3-eGFP mice were 
bred in-house by the JBIOS facility and were a kind gift from Prof. Alexander Rodensky 
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(Memorial Sloan-Kettering Cancer Center, New York). These mice express low levels of 
eGFP in regulatory T-cells (Kim et al., 2007), and therefore would have gained immune 
tolerance to eGFP. These Foxp3-eGFP mice were used in combination with eGFP-
expressing lentiviral vectors. Unlike WT 129S6/SvEv mice, Foxp3-eGFP mice maintain a 
constant level of infected peritoneal ResMØs for up to 3 weeks, with no signs of 
inflammation (figure 5.9). However, the infected cells were again lost when the mice 
were left for 6 weeks (42 days) after lentiviral infection (figure 6.10).  
 
 
Figure 5.8. Preferential inflammatory loss of infected ResMØs in vivo 
A) Bar graphs showing the ratio of infection 7 and 14 days after intra-peritoneal 
delivery of trCD2 and eGFP-expressing lentiviruses. Data was made relative to the 
infection levels seen in mice 7 days after lentiviral delivery. Data shown for trCD2 and 
eGFP are from two separate experiments in 129S6/SvEv mice (n= 2 per group).            
B) Bar graph showing the number of InfMØs quantified from the eGFP infected mice in 
(A). Data shown is from a single experiment in 129S6/SvEv mice (n= 2 per group), but 
similar results were obtained (for both A and B) 14 days after intra-peritoneal delivery 
of ICAM-1 and non-silencing shRNA (eGFP-tagged)-expressing lentiviruses (n= 4). 
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Figure 5.9. Preferential inflammatory loss of infected ResMØs is prevented in Foxp3-
eGFP mice 
A) Bar graph showing the ratio of infection 7, 14 and 21 days after intra-peritoneal 
delivery of eGFP-expressing lentivirus. Data was made relative to the infection levels 
seen in mice 7 days after lentiviral delivery. B) Bar graph showing the number of 
InfMØs quantified from (A), which includes MHCIIhigh MØ/ DCs (Dioszeghy et al., 2008). 
Data shown is from one preliminary experiment in Foxp3-eGFP mice (n= 1-2 per 
group). 
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Figure 5.10. Foxp3-eGFP mice only offer limited protection from the loss of infected 
ResMØs in vivo 
A) Bar graph showing the ratio of infection 7 and 42 days after intra-peritoneal delivery 
of eGFP-expressing lentivirus. Data was made relative to the infection levels seen in 
mice 7 days after lentiviral delivery. B) Bar graph showing the number of InfMØs 
quantified from (A) which includes MHCIIhigh MØ/ DCs (Dioszeghy et al., 2008). Data 
shown is from one preliminary experiment in Foxp3-eGFP mice (n= 2 per group). 
  
In
fe
ct
io
n
 R
at
io
 %
7 42
In
fM
Ø
 ×
1
0
6
7 42
A B
6wk egfp
1w
k
6w
ks
0
1
2
3
4
In
fm
a
c
s
 m
il
li
o
n
s
6wk egfp
1w
k
6w
ks
0
50
100
%
 e
G
F
P
+
Days after Infection
InfMacs / DCs
eG
FP
 1
w
k
eG
FP
 2
w
k
C
e
ll
s

1
0
6
Marker Ratio
rC
D
2 
1w
k
rC
D
2 
2w
k
R
a
ti
o
153 
 
5.3 – Discussion 
The aims of this chapter were to: 1) create an efficient method for quantifying viral 
titre; 2) infect ResMØs with lentivirus in vitro; 3) infect ResMØs with lentivirus in vivo; 
4) produce lentiviral vectors that express and/ or knockdown genes of interest; and 5) 
investigate the efficacy of ResMØ lentiviral infection in vivo. 
 
5.3.1 – Viral titre 
Viral titre could be quantified a number of ways: the MOI could be calculated using 
infection of Jurkat cells and Poisson distribution, viral RNA could be extracted and 
quantified with real-time PCR, or viral integration into the genomic DNA could be 
investigated with real-time PCR. Viral integration was quantified against a standard 
curve using lentiviral plasmid to produce a value for viral copy number (figure 5.1). 
However, this value was not considered to be accurate, due to the difference in PCR 
efficiency using a plasmid or extracted DNA. Therefore, the value was considered 
relative, so could only be used to relatively compare viral titre. This however, was not 
considered the most efficient method for viral titre measurement. Due to the relative 
ease of infection of Jurkat cells: Poisson distribution could be applied to calculate viral 
titre (see methods 2.9.3). Tagged (eGFP/ trCD2/ Myc) virus could be detected in cells 
using flow cytometry; this gave a value for the percentage of cells infected. This 
percentage could be extrapolated from a Poisson distribution curve to give a relative 
number for MOI. Multiple titres were extrapolated this way to give an average MOI per 
µl of virus, which could be used to compare different viral productions. 
Viral titre used in vivo was not usually quantified or kept consistent due to the natural 
variability of injections and individual mice. An infection percentage of 5-95 % was 
considered acceptable, as both infected and non-infected cells could be analysed 
reliably by flow cytometry. However, this did not take into account any secondary 
effects, such as a change in secreted factors or other juxtacrine effects. For example, if 
a secreted factor such as adenosine was reduced with lentiviral knockdown of an 
important enzyme (e.g. CD73), then the level of infection would have an impact on the 
total availability of adenosine in the system. Therefore, in some circumstances it would 
be important to keep infection levels consistent. In this chapter infection percentages 
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were typically between 40-60 % when using 200-400 µl of concentrated virus per intra-
peritoneal injection. 
The lentiviruses used in this thesis frequently showed non-linear regression between 
viral titre used and measures of infection (MFI, %+ cells) when infecting different cell 
types with lentivirus in vitro. The non linear regression leading to a maximal infection 
level (68.8 % seen in the ResMØ cultures (figure 5.3)) in vitro could be attributed to 
toxic effects of the virus, lentiviral concentrator or 293T proteins and/ or debris that 
may have inevitably been concentrated with the virus; which could lead to cell death. 
However, this was not further investigated in this thesis, as in vivo delivery of virus 
could infect a larger proportion of cells (figure 5.4). This could be attributed to the 
presence of a ‘clearance system’ in an in vivo environment, which was not present in 
vitro. 
 
5.3.2 – Selective infection of ResMØs 
Interestingly, even though the SEW lentivirus has been shown to infect myeloid cells 
and B cells alike with similar efficiencies (Demaison et al., 2002), the SEW lentivirus 
used in this thesis selectively infected MØs over other peritoneal cells (including B 
cells), both in and ex vivo. This could be attributed to the Lenti-X Concentrator 
(Clontech) used to concentrate the virus. This concentrator contains polyethylene 
glycol (PEG), which is known to be recognised by MØ scavenger receptors (Shibuya-
Fujiwara et al., 2001). This scavenger receptor mediated phagocytosis of what could 
potentially be PEGylated clusters of viral particles, could explain the selectivity for 
infection of professional phagocytes (MØs). However, investigation into the 
mechanism of the selective viral uptake was not an objective of this thesis. 
 
5.3.3 – Immune rejection of infected ResMØs 
The number of eGFP/ trCD2-tagged lentivirally infected cells in vivo dropped 
dramatically 2 weeks after infection. This was associated with inflammation, 
suggesting host rejection of foreign proteins (eGFP/ trCD2). The rat CD2 protein was 
truncated to prevent downstream signalling (King et al., 1998), however this was only 
in the cytoplasmic region. Truncated rat CD2 has the additional disadvantage that it is 
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homologous to mouse CD2 (76 % identity (Yagita et al., 1988)). Therefore, it could still 
have bound to receptors, activated juxtacrine signalling and altered cell adhesion. The 
76 % identity also meant that foreign peptides (24 %) would have been presented to 
cells of the adaptive immune system, which could trigger an immune response against 
trCD2-expressing cells. The eGFP used is a synthetic protein, originally found in jellyfish 
(Shimomura et al., 1962). This would have also produced foreign peptides and 
triggered an immune response. The use of transgenic eGFP mice (Foxp3-eGFP) 
overcame this rejection at 2 weeks, and no loss in eGFP-expressing cells was observed 
up to 3 weeks after infection (figure 5.9). This supports the theory for immune 
rejection of ResMØs expressing foreign proteins. It has also been reported that VSV-G 
coated lentiviruses cannot efficiently infect myeloid cells, due to the SAM domain and 
HD domain-containing protein 1 (Bobadilla et al., 2012, Hrecka et al., 2011, Laguette et 
al., 2011). However, the data presented herein suggests that this cannot fully restrict 
lentiviral integration, even in vivo (figure 5.9). The lack of InfMØs seen 6 weeks after 
SEW infection (figure 5.10) could be attributed to a non-inflammatory loss of cells, or 
that the cells were lost between 3 and 6 weeks after infection when InfMØs could be 
cleared. The loss of eGFP expression could also be explained by gene silencing 
mechanisms, such as epigenetic modification (He et al., 2005). However, the in vivo 
model of infecting peritoneal ResMØs of transgenic eGFP mice with eGFP-expressing 
lentiviruses could be used efficiently for up to 3 weeks. 
 
5.3.4 – Conclusion 
In conclusion, the methodology produced in this chapter shows that ResMØs can be 
efficiently infected with lentiviruses both in and ex vivo to modulate gene expression. 
Gene expression was modulated through the use of expression cassettes for transgene 
expression, and shRNA to induce RNA silencing of target mRNA. These lentiviral 
vectors provide a powerful tool to dissect specific MØ functions in vivo, and can be 
applied to investigate the role of MØs in homeostasis and inflammation. 
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Chapter 6 – Gata6 controls ResMØ renewal
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6.1 – Introduction 
Previously, this thesis has examined ResMØ phenotype (chapter 3), and the renewal of 
MØs during inflammation (chapters 3-4). Additionally, an efficient, specific system for 
the in vivo lentiviral manipulation of ResMØs was established (chapter 5). This work 
creates a platform from which specific gene function can be probed in vivo in a 
physiological context. During this chapter, this knowledge is applied to the functional 
analysis of Gata6. 
As previously mentioned (general introduction, 1.3.1), microarray analysis of monocyte 
and MØ populations during peritoneal inflammation was performed by Dr. Marcela 
Rosas in Prof. Phil Taylor’s group. This identified a list of ≈800 ResMØ restricted genes, 
which included Tim4 (Miyanishi et al., 2007), SignR1 (Taylor et al., 2004) and CRig (He 
et al., 2008); but also revealed atypical transcription factors with unknown functions in 
MØs. One such transcription factor was Gata6. This zinc finger transcription factor is 
described in more detail in the general introduction (1.3.2), but has been implicated in 
proliferation and differentiation in a different cellular context (Beuling et al., 2011). 
 
6.1.1 – Pleural ResMØs 
In this chapter pleural ResMØs were also investigated. Pleural ResMØs exist in the 
serous membrane of the pleural cavity, which is similar to the peritoneal membrane 
(Negrini et al., 1993). Both the pleural and peritoneal ResMØs from these membranes 
share an F4/80high CD11bhigh phenotype, and have the ability to proliferate in Th2 
mediated inflammation (Jenkins et al., 2011). These comparable phenotypes, 
responses and environments could suggest that both serosal MØ populations are likely 
regulated by similar mechanisms. 
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6.1.2 – Hypothesis 
The hypothesis tested in this chapter is that both the proliferation and phenotype of 
peritoneal and pleural ResMØs is mediated by the transcription factor Gata6. 
 
6.1.3 – Aims 
 To determine whether Gata6 is selectively expressed by peritoneal and pleural 
ResMØs 
 To investigate the effect of Gata6 on peritoneal ResMØ proliferation and 
phenotype 
 To investigate the effect of Gata6 on pleural ResMØ proliferation and 
phenotype 
 To determine the effect of Gata6 deficiency on the inflammatory response 
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6.2 – Results 
6.2.1 – Gata6 is expressed selectively by peritoneal ResMØ 
Previous microarray experiments carried out by Dr. Marcela Rosas in Prof. Phil Taylor’s 
laboratory showed that ResMØs selectively express the transcription factor Gata6, 
when compared to multiple populations of MØs and monocytes during inflammation. 
This result was supported by quantitative real-time PCR analysis of Gata6 mRNA 
expression in ResMØs. Gata6 expression was 6210 ± 1462-fold higher in ResMØs 
(mean ± SEM; n= 3) than cultured BMMØs (see methods 2.5.3) (figure 6.1a). However 
to confirm it’s selectivity to ResMØs specifically in the peritoneal cavity, inflammation 
was initiated by 2x106 particles of zymosan which resulted in mixed populations of 
MØs including InfMØs. The expression of Gata6 was 10.44 ± 0.76-fold higher in naϊve 
ResMØs than InfMØs retrieved from the peritoneal cavity 48 hours after this 
inflammation. The ResMØs from the same inflammatory environment had a 
comparable level of Gata6 expression with naϊve ResMØs (figure 6.1b). 
Immunostaining of peritoneal cells confirmed selective Gata6 expression at the protein 
level, with a visible, nuclear rich content of Gata6 in F4/80high ResMØs (figure 6.1c). 
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Figure 6.1. Gata6 is selectively expressed by ResMØ 
A) Bar graph showing relative mRNA expression of Gata6 in purified (by flow 
cytometry) ResMØs and cultured BMMØs (see 2.5.3). Expression data for Gata6 was 
made relative to BMMØs and the endogenous control Ywhaz, and represents the 
mean ± SEM of 3 independent samples per group. B) Graph showing relative mRNA 
expression of Gata6 in flow cytometrically purified InfMØs and ResMØs isolated 48 
hours after acute inflammation induced with zymosan (2x106 particles) and compared 
with ResMØs from naïve animals. Expression data for Gata6 was made relative to 
InfMØs and the endogenous control Ywhaz, and represents the mean ± SEM of 2 
independent samples per group. C. Pictures showing cytospun peritoneal cells stained 
with Gata6 (green), F4/80 (red) and DAPI (blue), shown as three separate images and a 
merge (overlay). The control picture represents residual binding from streptavidin-
AlexaFluor488 in the absence of the Gata6 biotin antibody. Data is representative of 8 
‘Gata6-WT’ mixed sex mice (4 slides per mouse and 4 pictures per slide) from 2 
independent experiments. The scale bar is indicated. APC = Allophycocyanin, A488 = 
AlexaFluor488. 
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6.2.2 – Knockdown of Gata6 expression results in a reduction in F4/80 protein 
To determine the impact of a reduction in Gata6 expression: lentiviruses were 
constructed (see chapter 5, 5.2.6) to introduce stable production of shRNA molecules 
against Gata6 mRNA into ResMØs. Stable transduction of peritoneal ResMØs with 
Gata6 targeting shRNA was performed via intra-peritoneal injection. This infection 
significantly reduced F4/80 levels in ResMØs compared with non-silencing control 
(figure 6.2) after 7 days. Due to the alteration in the normal F4/80high phenotype of 
ResMØ, the ResMØ specific marker Tim4 (Miyanishi et al., 2007) was used to identify 
ResMØ populations, and this applies to all the experiments conducted in this chapter. 
 
 
Figure 6.2. Knockdown of Gata6 causes a reduction in F4/80 protein expression 
A) Representative flow cytometry plot comparing F4/80 expression in 12-16 week 
male 129S6/SvEv ResMØ, 7 days after intra-peritoneal infection with a Gata6-specific 
shRNA or non-silencing (Non-sil) control (indicated by expression of the trCD2 tag). The 
boxes show trCD2– and trCD2+ cell populations. The plot was gated on Tim4+ CD11bhigh 
cells and pre-gated to remove eosinophils and doublets as previously shown (figures 
3.1 and 3.2). B) Quantification of the impact of Gata6 shRNA on F4/80 expression 
compared to non-silencing shRNA. Data was made relative to uninfected cells in the 
same environment and represents mean ± SEM of n= 3 mice per group from one of 
two independent experiments. Statistical analysis was performed using a Student’s t-
test, the P-value is indicated on the graph (P≤ 0.01 = **). 
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6.2.3 – Knockout of the Gata6 gene causes a marked reduction in the F4/80 
phenotype of adult ResMØ 
Mice which contained a floxed Gata6 allele (Gata6tm2.1Sad) have been generated 
previously (Sodhi et al., 2006). Cre could be employed to recombine the flanking loxP 
sites (floxed) and delete exon 2 of the Gata6 gene, this resulted in more than half of 
the protein length being lost which translates to a loss of function (Sodhi et al., 2006). 
These mice (Gata6tm2.1Sad) were used in conjunction with a Cre-expressing lentiviral 
vector to stably knock out normal Gata6 expression in adult peritoneal MØ in vivo. 
Gata6 knockout resulted in a marked reduction in the canonical F4/80high profile of 
ResMØs (figure 6.3), which could be rescued by reconstitution with Gata6-expressing 
lentiviruses (figure 6.4). Infection of WT 129S6/SvEv mice with Cre-expressing 
lentivirus did not alter F4/80 expression (figure 6.3). 
 
 
Figure 6.3. Selective knockout of Gata6 in ResMØs results in a reduction of F4/80 
expression 
Representative density plots showing infection of Gata6tm2.1Sad mice with a lentiviral 
vector encoding a Myc-tagged Cre (Cre-Myc) over a week time course (left panels), 
compared with 129S6 mice at day 7 (far right panel). The plots show F4/80 and Cre-
Myc expression, the blue gates indicate two separate populations of Cre– F4/80high and 
Cre+ F480low ResMØs. Plots were pre-gated to remove eosinophils and doublets as 
previously described (figures 3.1 and 3.2a). Data was compiled from preliminary 
experiments with at least 2 mice per time point. 
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Figure 6.4. Gata6 reconstitution in Gata6-KOmye ResMØs restores F4/80 expression 
A) Representative 3D bubble plots showing F4/80 expression in Gata6tm2.1Sad mice co-
infected with a Myc-tagged Cre (Cre-Myc), and either control or Gata6-expressing virus 
(indicated by expression of the trCD2 tag) for 7 days. The persistence of the F4/80high 
phenotype in Cre-Myc+ trCD2+ cells can be seen with the Gata6-expressing virus 
(white/grey dots, right panel) in comparison to the F4/80low Cre-Myc+ trCD2+ 
population seen when control virus was used (magenta dots, left panel). Data 
represents 3-4 mice per group from one of three similar experiments. B) A bar graph 
showing quantification of the phenotype conversion shown in (A). The prevalence of 
F4/80high Cre+ cells was compared between Gata6 reconstitution (+) and control virus 
(–) by Student’s t-test with the P-value indicated. C. Representative density plots 
showing F4/80 expression on cells co-infected with the Cre-Myc lentivirus and a non-
tagged Gata6-expressing lentivirus (right panel) or empty vector control (left panel) for 
7 days. Data shown is from Gata6tm2.1Sad 8-14 week old male mice (n= 4/group). Plots 
(A, C) were gated on F4/80+ CD11bhigh cells and pre-gated to remove eosinophils and 
doublets as previously described (figures 3.1 and 3.2a). 
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6.2.4 – Gata6 knockout in the myeloid lineage gives viable ResMØs with an altered 
F4/80 phenotype 
Gata6 is essential for the formation of major organs during development, thus the loss 
of Gata6 in all cells is lethal during embryogenesis (Morrisey et al., 1996). Therefore, 
Lysozyme M (Lyz2) Cre ‘knock-in’ congenic mice (‘Lyz2Cre, B6.129P2-Lyz2tm1(cre)Ifo) 
(Clausen et al., 1999) were crossed with conditional KO Gata6tm2.1Sad mice (Sodhi et al., 
2006) to generate a mouse strain with a select myeloid deficiency of Gata6 (‘Gata6-
KOmye’) (figure 6.5). The peritoneal cells of Gata6-KOmye mice were analysed by flow 
cytometry. This revealed a marked change in the canonical F4/80 phenotype of 
ResMØs (figure 6.6); creating F4/80low ResMØs synonymous with data retrieved from 
the lentiviral-shRNA knockdown (figure 6.2) and lentiviral Cre-mediated knockout of 
Gata6 (figure 6.3). Interestingly, there was a small (≈5 %) population of residual 
F4/80high ResMØs in Gata6-KOmye mice. 
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Figure 6.5. Breeding strategy to generate Gata6-KOmye mice 
A diagram showing the breeding strategy used to yield Gata6-KOmye and WT 
littermates. X symbols indicate breeding and arrows indicate offspring. The dotted 
lines partition separate generations. 
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Figure 6.6. ResMØs of Gata6-KOmye mice have a reduced F4/80 phenotype 
Representative density plots showing F4/80 and CD11b expression on MØ populations 
after excluding doublets and eosinophils as previously described (figures 3.1 and 3.2a). 
Gated populations are annotated and show F4/80low and F4/80high MØs. Note: the 
F4/80low MØ population contains DC and ‘DC-like’ cells (MHCII+ MØs). These plots are 
from naϊve 8 week old female mice, but are representative of all Gata6-WT and Gata6-
KOmye mice used in this study. 
To determine whether the F4/80high ResMØs from Gata6-KOmye mice have ‘normal’ 
levels of Gata6, a polyclonal antibody was used to examine Gata6 protein expression in 
peritoneal cells (figure 6.7a). Nuclear Gata6 content was quantified (see methods 2.11) 
and revealed that F4/80high ResMØs have significantly higher levels of Gata6 than 
F4/80low MØs in Gata6-KOmye mice (figure 6.7b). However, this population likely also 
contained DCs and ‘DC-like’ cells, although ResMØs were still the majority cell type. 
When averaged per mouse, the F4/80high ResMØs from Gata6-KOmye contained a 
comparable level of Gata6 with that of WT mice (figure 6.7c). A similar experiment to 
figure 6.4 was used to reconstitute the Gata6 of Gata6-KOmye mice via intra-peritoneal 
injection of a Gata6-expressing lentivirus. This supported previous data (figure 6.4), in 
that the F4/80 phenotype was ‘rescued’ toward that of WT ResMØs in transduced cells 
(figure 6.8). Dr. Marcela Rosas additionally phenotyped and genotyped the F4/80high 
ResMØs from Gata6-KOmye mice, and showed that there was no Cre activity (i.e. exon 2 
of Gata6 was present). Therefore, the cells were considered effectively ‘WT’ for this 
chapter (see discussion). 
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Figure 6.7. F4/80high resident MØs in Gata6-KOmye express normal Gata6 levels 
A) Representative immunofluorescent images of Gata6 expression (green) in the nuclei 
(blue) of MØs from WT and Gata6-KOmye mice, identified by F4/80 expression (red). 
Examples of F4/80high and F4/80low MØs are indicated in the lower panel by 
arrowheads and arrows respectively. B) Nuclear Gata6 was quantified using Image J 
and expressed as mean pixel intensity after selecting the nuclear DAPI staining. 
Symbols denote individual MØs from a representative Gata6-KOmye mouse. Red lines 
indicate the mean ± SEM of the group. Data were analyzed by Student’s t-test. C. 
Symbols represent individual mice and the F4/80high and F4/80low MØs from the same 
Gata6-KOmye mice are linked by lines. Red lines indicate the mean ± SEM of the groups. 
Data were analyzed by paired t-test. A mean of 188 ± 61 MØs (mean ± SEM) were 
quantified for each mouse. Data is representative of 4 mice (12-16 weeks old) from 
one of two similar experiments. The data analysis using Image J was performed by 
Prof. Phil Taylor. 
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Figure 6.8. Reconstitution of Gata6 restores F4/80 expression in Gata6-KOmye ResMØ 
Density plot showing F4/80 expression 7 days after intra-peritoneal infection of Gata6-
KOmye mice with a Gata6-expressing lentivirus (detected via a self-cleaving truncated 
rat CD2 (trCD2)). This results in the acquisition of an F4/80high phenotype in the 
transduced cells. The control rCD2 virus infected cells (overlaid contour plot) do not 
have altered F4/80 expression. Plots are pre-gated on F4/80+ CD11b+ MHCIIlow/– MØs 
(after removing eosinophils and doublets (figures 3.1 and 3.2a)). Data is from 12-14 
week old male mice and is representative of two experiments with 2-3 mice per group. 
6.2.5 – Knockout of Gata6 has a cell-intrinsic effect on peritoneal ResMØ 
proliferation and polyploidy 
Gata6 has been implicated in control of cell differentiation and proliferation (Beuling et 
al., 2011). Therefore, levels of proliferation were calculated for Gata6-KOmye and WT 
mice using the SG2M strategy discussed in chapter 4 of this thesis (figure 6.9a). The 
quantified basal proliferation of Gata6-KOmye ResMØs (specifically gating the ‘true-KO’ 
F4/80low ResMØs) was significantly higher than ResMØs from both WT and 
heterozygous (‘Het’) mice. The percentage of cells in SG2M was 3.16 ± 0.63 % vs 0.66 ± 
0.12 % (mean ± SEM, n= 5 and 3 respectively) in the Gata6-KOmye vs WT mice, a near 5-
fold increase (figure 6.9b). Interestingly, the level of polyploidy (% >2N DNA content, 
Ki67–) was also dramatically higher in Gata6-KOmye ResMØs, at 13.34 ± 1.41 % (mean ± 
SEM, n= 5), which is over 8-fold greater than the level seen in WT mice (1.65 ± 0.35 %, 
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mean ± SEM, n= 3) (figure 6.9b). This results in an increased number of large multi-
nucleated MØs as shown in figure 6.9c. 
 
 
Figure 6.9. Gata6-KOmye ResMØs exhibit increased levels of proliferation and 
polyploidy 
A) Representative density plots showing SG2M and polyploidy for the F4/80
high ResMØs 
of WT mice and F4/80low ResMØs of Gata6-KOmye mice, as indicated in figure 6.6 
(above). SG2M calculations were based on the gating strategy from figure 4.2b. Cells 
with >2N DNA content, but negative for Ki67 expression were considered to be 
polyploid. B) Graphs showing the quantification of SG2M and polyploidy in ResMØs 
from both groups. Data is represented as mean ± SEM and was analysed by one-way 
ANOVA (P-value as indicated) with Bonferonni post tests (*, P≤ 0.05; **, P≤ 0.01; ***, 
P≤ 0.001). C. Photographs of larger polyploid cells within Gata6-KOmye mice as 
observed on eosin and methylene blue stained cytospin preparations, under oil 
immersion. The scale bar is as indicated and pictures were taken at 100× objective 
magnification. Data (A-C) is derived from one of two independent experiments with 6-
7 week old mice (KOmye, n= 5;’Het’, n= 4; WT, n= 3). 
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The residual F4/80high ResMØs seen in Gata6-KOmye mice (figure 6.6 and 6.7) were used 
as internal controls for subsequent experiments. Proliferation was examined between 
F4/80high and F4/80low ResMØs in Gata6-KOmye mice. This revealed that the F4/80low 
ResMØs had higher levels of proliferation and polyploidy than the F4/80high ResMØs 
within the same environment (figure 6.10). This data was supported by alternative 
experiments using Gata6tm2.1Sad mice. These alternate experiments compared the level 
of proliferation in lentiviral Cre-mediated Gata6 knockout ResMØs to that seen in non-
infected WT ResMØs (as in figure 6.3, comparing the blue ringed populations). This 
revealed that the level of proliferation increased when Gata6 expression was removed 
in adult mice (figure 6.11). Control viruses lacking Cre, e.g. rCD2 or eGFP-expressing 
lentiviruses caused a slight consistent decrease in SG2M, but an increase in polyploidy 
upon infection (examples in supplemental figure S3 and figure 6.20). 
 
 
Figure 6.10. F4/80low ResMØs show increased proliferation and polyploidy in 
comparison to the rare F4/80high ResMØs in the same Gata6-KOmye mice 
Graphs showing quantification of proliferative differences within the same Gata6-
KOmye mice, between the bulk F4/80low ResMØ population and the rare residual 
F4/80high ResMØ, gated as shown in figure 6.9 (above). Data symbols represent 
individual mice (6-7 week old) with readings from the same mice connected by lines 
(n= 5♂ and 4♀). Data were pooled from two similar experiments and analysed by a 
paired two-way ANOVA. Int = interaction between groups, Exp = effect of experiment. 
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Figure 6.11. Selective knockout of Gata6 in ResMØs in adulthood causes an increase 
in proliferation 
Graph showing ResMØs, 7 days after intra-peritoneal delivery of a Cre-expressing 
lentivirus to Gata6tm2.1Sad mice. The proportion of cells in the SG2M phases of cell cycle 
(calculated as in figure 6.9) were compared between F4/80low Cre+ ResMØs and 
F4/80high Cre– ResMØs. The data shows 3 independent experiments with individual 
mice indicated by paired (line connected) data points (n= 3-6/experiment) (8-14 weeks 
old). Data was analysed by a paired two-way ANOVA, P-values are indicated. Int = 
interaction between groups, Exp = effect of experiment. 
6.2.6 – Knockout of Gata6 has a cell-intrinsic effect on pleural ResMØ proliferation, 
polyploidy and phenotype 
Pleural ResMØs are serosal tissue MØs that share a similar phenotype (F4/80high, 
CD11bhigh, majority Tim4+) with peritoneal ResMØs (figure 6.12). Therefore the level of 
Gata6 expression was relatively quantified in pleural ResMØ, using BMMØs as a 
‘negative’ control and ResMØs as a ‘positive’ control. The level of Gata6 expression 
was comparable in pleural and peritoneal cells (figure 6.12a). Interestingly, the Gata6-
KOmye F4/80low peritoneal phenotype (figure 6.6) is reflected in pleural ResMØs (figure 
6.12b). When quantified, proliferation of the F4/80low pleural ResMØs was higher than 
the F4/80high population within the same Gata6-KOmye mice (figure 6.13). Additionally, 
the level of polyploidy seen in Gata6-KOmye mice was substantially increased compared 
to WT, with 9.28 ± 1.33 % vs 1.62 ± 0.20 % (mean ± SEM, n= 8 and 12 respectively) 
polyploidy respectively (figure 6.14a); and a visible increase in the number of 
multinucleate cells viewed under the microscope (figure 6.14b). 
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Figure 6.12. Pleural ResMØs also express Gata6 mRNA and are phenotypically altered 
in Gata6-KOmye mice 
A) A bar graph showing Gata6 expression in mRNA extracted from total peritoneal and 
pleural leukocytes, the majority of which are Tim4+ ResMØs (see B). The data was 
made relative to the endogenously expressed gene Ywhaz and expression of Gata6 in 
BMMØs, and was corrected for numbers of ResMØs in peritoneal and pleural lavages. 
Data shows mean ± SEM from one of two independent experiments in 12-16 week 
129S6 mice (n = 3 per group). B) Density plots showing F4/80 and CD11b expression on 
ResMØs from the pleural cavity of Gata6-KOmye and WT mice. Plots were gated on 
F4/80+ CD11bhigh cells after gating to remove eosinophils and doublets as previously 
described (figures 3.1 and 3.2a). Boxes indicate F4/80high and F4/80low populations. 
Data is representative of 6-8 week old female mice from one of two independent 
experiments (n= 4 per group). 
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Figure 6.13. Pleural F4/80low ResMØs show increased proliferation compared with 
contemporary F4/80high ResMØs in Gata6-KOmye mice 
A graph showing the proliferative differences within the same Gata6-KOmye mice 
between the bulk F4/80low pleural ResMØ population and the minority F4/80high 
pleural ResMØ, gated as shown in figure 6.6 (above). Data symbols represent 
individual 6-8 week old female mice with readings from the same mice connected by 
lines. Data shows two similar experiments and was analysed by a paired two-way 
ANOVA, P-values are indicated. Int = interaction between groups, Exp = effect of 
experiment. 
 
Figure 6.14. Pleural ResMØs show increased polyploidy in Gata6-KOmye mice 
A) Graph showing quantification of polyploidy in F4/80low pleural MØs from the Gata6-
KOmye compared to the F4/80high pleural MØs in WT mice. Data represents mean ± SEM 
of 6-8 week old female mice pooled from two independent experiments (WT, n= 12; 
KOmye, n= 8). Data were analysed by Student’s t-test, and the P-value is indicated. B) 
Photographs of multinucleate cells in the pleural lavage of Gata6-KOmye mice from A. 
Images of cytospun cell preparations were acquired on a Leica PMLB light microscope 
at 100× objective magnification after staining for eosin and methylene blue. The scale 
bar is indicated. 
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6.2.7 – Absence of Gata6 results in a reduced ability of ResMØs to recover after 
inflammation by proliferation 
ResMØs are lost during the early hours of inflammation (2×106 zymosan particles), but 
recover 48 hours after stimulus (see chapter 3). The cellular content of the peritoneal 
cavity was investigated in Gata6-KOmye and WT mice during inflammation (naϊve, 4 and 
48 hours after stimulus) using flow cytometry. Neutrophils were quantified using their 
CD11bhigh F4/80– profile (confirmed with Ly-6G and Ly-6B expression). Mast cells were 
indistinguishable from eosinophils purely by their FSc/ SSc profile. However, although 
both of these cells were F4/80+, they could be separated by the expression of CD11b, 
as mast cells, unlike eosinophils, lack this surface marker (see 3.3.1). MØs were 
quantified by their CD11b+ F4/80+ phenotype after removal of neutrophils, eosinophils 
and mast cells; and further subdivided by their expression of Tim4. Finally, DC-like cells 
(a mixture of MHCII+ MØs and DCs) were quantified using their MHCII+ CD11c+ CD226+ 
profile (defining characteristics established by Dr. Chia-Te Liao in Prof. Phil Taylor’s 
laboratory).  
When quantified, the number of neutrophils and mast cells were not significantly 
different between Gata6-KOmye and WT mice throughout this inflammation (figure 
6.15a). However, the number of eosinophils was significantly higher in naϊve Gata6-
KOmye than WT mice, and throughout inflammation (figure 6.15a). In naϊve mice, this 
quantified as 252,296 ± 107,733 vs 57,574 ± 21,831 (mean ± SEM, n= 8 per group) in 
Gata6-KOmye and WT mice respectively (a ≈5-fold increase). The number of Tim4+ MØs 
was significantly lower in Gata6-KOmye in comparison to WT mice throughout 
inflammation, but notably during the resolution phase (48 hours after zymosan). 
Where there were only 61,485 ± 18,960 (mean ± SEM, n= 5) Tim4+ MØs in Gata6-KOmye 
mice compared to 1,308,000 ± 171,672 in WT mice (n= 11) (figure 6.15a). The numbers 
of Tim4+ MØs in Gata6-KOmye mice 48 hours after inflammation were also significantly 
reduced compared to naϊve Gata6-KOmye mice, suggesting a failure to recover from 
inflammation. It was not possible to calculate the number of Tim4– MØs/ DCs 4 hours 
after inflammation, due to the complexity of flow cytometric staining and the 
limitations of the markers used (Tim4 staining was unaffected). However, the total 
number of Tim4– MØs/ DCs was calculated for naϊve mice and mice 48 hours after 
inflammation. This revealed that Gata6-KOmye mice had significantly lower numbers of 
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total MØs/ DCs than WT mice (figure 6.15b) throughout inflammation. Albeit, when 
DC-like cells were specifically quantified, Gata6-KOmye mice had higher numbers than 
their WT counterparts throughout inflammation (figure 6.15b). This was pronounced in 
naϊve animals, with Gata6-KOmye mice having >3 times the number of DC-like cells than 
WT mice (as measured by means, n= 8). 
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Figure 6.15. Gata6-KOmye Tim4+ MØs are poorly recoverable 48 hours after zymosan 
induced inflammation 
Graphs showing the quantification of cell types present in the peritoneal cavity of 
naϊve mice and mice 4 and 48 hours after an intra-peritoneal injection of zymosan 
(2×106 particles). Data in (B) does not contain cell counts from 4 hours after 
inflammation due to analytical complexity. Data was analysed by two-way ANOVA (P-
values are indicated) with Bonferroni post tests (*, P≤ 0.05; **, P≤ 0.01; ***, P≤ 0.001). 
Int = interaction. Data shown is pooled from two independent experiments in 7-9 week 
old female Gata6-KOmye and WT mice (n= 5-11/group). DCs were quantified by using a 
gating strategy formulated by Dr. Chia Te Liao, which is described at the end of section 
6.2.7.   
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The low number of recoverable Tim4+ MØs seen in Gata6-KOmye mice during 
inflammation was further investigated using delivery of a Cre-expressing lentivirus into 
Gata6tm2.1Sad mice (Sodhi et al., 2006), as in figure 6.3. Peritonitis was initiated by 2x106 
zymosan particles in mice 7 days after an in vivo lentiviral transduction with Cre-
expressing and control viruses (tagged with trCD2). Both transduced (Gata6-KO) and 
non-transduced (WT) cells were analysed in naϊve mice and mice 4 hours after 
zymosan. The recovery of cells transduced with Cre (Gata6-KO) was reduced by 
approximately 50 % in comparison to non-transduced cells and the transduced cells 
from the trCD2 control virus (figure 6.16). 
 
 
Figure 6.16. Selective knockout of Gata6 promotes a loss of ResMØs during 
inflammation 
A) Representative flow cytometric plots showing expression of F4/80 and trCD2 by 
peritoneal cells from Gata6tm2.1Sad/J mice, 7 days after intra-peritoneal administration of 
Cre-trCD2 or control trCD2 lentivirus. These mice were either injected or not (‘naϊve’) 
with 2x106 zymosan particles 4 hours before experimental end-point. Data was derived 
from one of two independent experiments (n= 4/group). B) Graph depicting 
quantification of the relative proportion of virally infected cells in the mice challenged 
with zymosan; this was normalised to the proportion of infected cells in the ‘naϊve’ 
mice that have not received zymosan. The data were analysed by two-way ANOVA (P-
values are indicated). Data represents the mean ± SEM of 7-8 mixed sex mice (8-12 
weeks old) per group, pooled from two independent experiments. 
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In WT mice, ResMØs undergo a burst in proliferation to restore the numbers lost 
during inflammation (chapter 3 of this thesis). The failure of Tim4+ MØs to recover 
after inflammation in Gata6-KOmye mice could therefore be a consequence, at least in 
part, of defective proliferation. Thus markers of proliferation were investigated during 
the inflammatory response to 2×106 zymosan particles. WT ResMØs went through the 
normal proliferative burst 48 hours after zymosan (measured using SG2M, as in figure 
6.9a), while Gata6-KOmye MØs maintained an unaltered low level of proliferation 
(figure 6.17). This (although higher than naϊve WT mice) was only 3.20 ± 0.76 % SG2M 
(mean ± SEM, n= 5) in Gata6-KOmye mice compared to 16.20 ± 1.30 % SG2M in WT mice 
(n= 11). Interestingly, F4/80high cells have significantly higher levels of proliferation 
than F4/80low MØs within the same environment in Gata6-KOmye mice; as measured by 
SG2M, G1 and in vivo EdU incorporation during a late stage of inflammation (figure 
6.18). 
 
 
Figure 6.17. Gata6-KOmye Tim4+ MØs do not undergo a proliferative burst 48 hours 
after initiation of inflammation 
Quantification of SG2M and polyploidy in Tim4
+ MØs from naϊve mice, and mice 4 and 
48 hours after an intra-peritoneal injection of zymosan (2×106 particles) (as in figure 
6.15). Data was analysed by two-way ANOVA (P-values are indicated) with Bonferroni 
post tests (***, P≤ 0.001). Int = interaction. Data shown is pooled from two 
independent experiments in 7-9 week old female Gata6-KOmye and WT mice (n= 5-11 
per group). 
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Figure 6.18. F4/80high but not F4/80low Tim4+ MØs undergo a proliferative burst 48 
hours after initiation of inflammation in Gata6-KOmye mice 
A) Graphs showing differences between SG2M and G1 in Tim4
+ F4/80low MØs and rare 
Tim4+ F4/80high MØs within the same Gata6-KOmye naϊve mice, and mice 4 and 48 hours 
after an intra-peritoneal injection of zymosan (2×106 particles) (as in figure 6.15). Data 
was analysed by two-way ANOVA (P-values are indicated) with Bonferroni post tests 
(*, P≤ 0.05;***, P≤ 0.001). Int = interaction. Data shown is pooled from two 
independent experiments in 7-9 week old female Gata6-KOmye and WT mice (n= 5-11 
per group). B) Bar graph showing EdU incorporation by Tim4+ MØs from the Gata6-
KOmye mice 48 hours after induction of peritonitis with 2x106 zymosan particles, and 16 
hours after subsequent intra-peritoneal administration of a 1mg pulse of EdU. Data 
represents the mean ± SEM of 8 mice pooled from 2 independent experiments and is 
analysed by a paired t-test (**= P≤ 0.01). 
Tim4+ MØs do not recover normal numbers 48 hours after zymosan (2×106 particles) in 
Gata6-KOmye mice. However, when the time course after zymosan is extended to 7 
days, a higher number of Tim4+ MØs can be recovered by lavage in Gata6-KOmye mice 
(figure 6.19a). Although this number (290,203 ± 62,332, mean ± SEM – 7 days after 
zymosan, n= 4) is significantly lower than that seen in WT mice (2,087,000 ± 261,873, 
n= 4), and lower than Gata6-KOmye naϊve mice (440,609 ± 10,706, n= 3); it suggests 
that the cells have recovered slightly when compared to the 4 and 48 hours time 
points from the previous experiment (41,090 ± 10,581 and 61,485 ± 18,960 
respectively, n= 7 and 4) (figure 6.15). When the proliferation was measured by SG2M, 
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it was found to be higher in the F4/80low Tim4+ MØs of Gata6-KOmye mice when 
compared to both the F4/80high MØs of WT mice (figure 6.19b) and F4/80high ResMØs 
within the same Gata6-KOmye mouse (figure 6.19c), 7 days after zymosan. This level 
was also much higher than that seen in naϊve Gata6-KOmye mice (figure 6.17) and 
comparable to that seen in the F4/80high MØs of Gata6-KOmye mice 48 hours after 
zymosan (figure 6.18). 
 
 
Figure 6.19. Tim4+ MØs start to recover 7 days after zymosan inflammation 
A) Graph depicting the number of recoverable Tim4+ MØs in naϊve mice and mice 7 
days after intra-peritoneal administration of 2x106 particles of zymosan. Data was 
analysed by two-way ANOVA with Bonferroni post tests (**, P≤ 0.01;***, P≤ 0.001). 
The P-value was not significant for interaction and zymosan, but was <0.0001 for effect 
of Gata6. Data shows mean ± SEM of one experiment with 10 week old female mice 
(n= 3 naϊve and n= 4 for 7-day zymosan), but is representative of two independent 
experiments with Gata6-KOmye and WT mice. B) Graph showing the difference in SG2M 
in Tim4+ MØs from Gata6-KOmye and WT mice. Data was analysed by t-test, with 
significance indicated (**, P≤ 0.01). The bar shows the median. C. Graph showing the 
difference in SG2M in Tim4
+ F4/80low MØs and rare Tim4+ F4/80high MØs (linked by 
lines) within the same Gata6-KOmye mice. Data was analysed by paired t-test, with 
significance indicated (**, P≤ 0.01). Data shown (B-C) is a pool of two independent 
experiments with 10-12 week female mice. Each dot represents a single mouse. 
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A microarray study by Dr. Marcela Rosas identified Map3k8 (Rosas et al., 2014) as a 
potential regulator of the increased homeostatic proliferation seen in Gata6-KOmye 
mice, since it was significantly >2.5-fold increased in ResMØs in the absence of Gata6. 
To test the role of Map3k8 in ResMØ proliferation, WT (FoxP3-eGFP, see chapter 5, 
5.27) ResMØs were lentivirally transduced with Map3k8-targeting shRNA or non-
silencing shRNA in vivo, and left for 7 days before inflammation was initiated with 2 × 
106 particles of zymosan (to trigger a proliferative response). Addition of Map3k8-
targeting shRNA resulted in decreased proliferation compared to control, 48 hours 
after zymosan (measured by SG2M and Ki67
high mitotic cells) (figure 6.20). 
 
 
Figure 6.20. Map3k8 controls ResMØ proliferation 
A) Graphs showing the proportion of ResMØs with >2N DNA content and Ki67high 
expression (mitotic, see 3.23), which were transduced (eGFP+) or non-transduced 
(eGFP–) (linked by lines) with lentivirus, within the same FoxP3-eGFP mice. B) Graphical 
representation of the transduced (eGFP+) ResMØs in (A), showing the difference in the 
% SG2M vs % Ki67
high (mitotic) cells between Map3k8 and non-silencing (Non. Sil.) 
shRNA. Data was a pool of two independent experiments with 13-21 week old mixed 
sex mice 9 days after intra-peritoneal transduction with lentiviruses, and 2 days after 2 
× 106 particles of zymosan. Data was analysed by two-way ANOVA and interaction (Int) 
significance values are indicated. 
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6.2.8 – Myeloid Gata6 deficiency is associated with delayed clearance of neutrophils 
from the peritoneal cavity during inflammation 
The number of neutrophils seen 4 hours after intra-peritoneal delivery of 2x106 
particles of zymosan is comparable between Gata6-KOmye and WT mice. However, this 
is a mild model of inflammation (see figure 6.15), and a higher dose of zymosan (2x107 
particles) is known to exhibit less MØ dependency on the initiation of inflammation, 
invoking alternative mechanisms (Taylor et al., 2007, McDonald et al., 2012, Rosas et 
al., 2008, Mullaly and Kubes, 2007). Zymosan peritonitis was initiated using this higher 
dose in Gata6-KOmye and WT mice, and the cellular content of the peritoneal cavity 
was analysed 20 and 40 hours later. This highlighted again, the lower number of Tim4+ 
MØ, but also revealed an increased retention of neutrophils in Gata6-KOmye mice 40 
hours after stimulus, in spite of the comparable level of neutrophil recruitment seen at 
20 hours (figure 6.21). Interestingly, there was no significant difference in the numbers 
of eosinophils, but slightly higher Tim4– MØs in Gata6-KOmye than WT mice. 
 
 
Figure 6.21. Absence of Gata6 results in alterations in the resolution from 
inflammation 
Bar graphs showing the quantification of cell types 20 and 40 hours after an intra-
peritoneal injection of a higher dose of zymosan (2x107 zymosan particles). Data was 
analysed by two-way ANOVA (significant P-values are indicated) with Bonferroni post 
tests (**, P≤ 0.01;***, P≤ 0.001). Data represents the mean ± SEM of individual mice 
pooled from 3 independent experiments (n= 11-13 per group/time).  
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6.2.9 – Enforced expression of Gata6 in adoptively transferred BMMØs alters their 
phenotype and peritoneal retention 
Previous experiments in this chapter have highlighted the transcription factor Gata6 as 
a controller of cell phenotype and proliferative renewal. The data from figures 6.15 
and 6.16, suggest that the loss of Gata6 can have a negative influence on the retention 
of ResMØs in the peritoneal cavity. InfMØs recruited during inflammation can last for 
weeks after inflammatory stimulus, but are eventually lost (Bellingan et al., 1996, 
Bellingan et al., 2002, Gautier et al., 2013). Therefore, an experiment was designed in 
order to examine the effect of Gata6 on cell phenotype and retention specifically in 
the peritoneal environment. The bone marrow is the source of InfMØs (figure 4.7), so 
BMMØs were chosen to represent a non-ResMØ population. Cultured BMMØs from 
129S6.CD45.1 congenic mice were transduced in vitro with lentiviral vectors encoding 
a self-cleaving Gata6-truncated rat CD2 (trCD2) fusion protein, or control-trCD2. An 
equal number of transduced cells (between 35-60 % virally infected in independent 
experiments) were transferred intra-peritoneally into naïve 129S6 mice (CD45.2). 
Peritoneal cells were harvested after three days. Approximately 10-fold more Gata6-
transduced BMMØs were present in the peritoneal cavity compared to control-
transduced and non-transduced BMMØs (figure 6.22). Due to the complexity of the 
experiment, only a small number of infected cells were injected (35,000-120,000). 
However, the raw numbers of infected cells retrieved from the peritoneal cavity for 
both experiments were: 2618 ± 146 vs 460 ± 132 (experiment 1, n=3 per group) and 
14630 ± 3670 vs 539 ± 282 (experiment 2, n=3 per group), for Gata6-expressing 
lentivirus vs control respectively (mean ± SEM). However this raw data does not take 
infection frequency into account (see figure 6.22 for relative numbers). These Gata6-
transduced BMMØs also had a significantly higher level of F4/80 expression (figure 
6.12d), approaching that of host ResMØ. 
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Figure 6.22. Enforced Gata6 expression promotes retention of bone marrow-derived 
MØs in the peritoneum with an F4/80high phenotype 
A) Representative density plots showing gating of F4/80+ CD11b+ MØs (left panel) from 
the peritoneal cavity of recipient CD45.2+ mice, 3 days after adoptive transfer of donor 
CD45.1+ BMMØs; which had been previously infected in vitro with Gata6-trCD2 or 
trCD2 (control) lentivirus (see methods 2.6.7). Donor cells (gate in the right panel) 
could be separated from recipient cells by expression of the CD45.1 and CD45.2 
alloantigens. B) Representative density plots showing the F4/80 expression of 
lentivirally modified donor cells (trCD2+) and their unmodified counterparts (trCD2–), 
when transduced with control-trCD2 (left) or Gata6-trCD2 (right). Overlaid contour 
plots show the F4/80high phenotype of the endogenous recipient ResMØs. Percentages 
denote the proportion of transferred cells that were transduced at the time of analysis 
(trCD2+). C. Graphical representation of the data shown in A and B. Data is expressed 
as ‘relative tissue retention’, where 1 denotes the mean number of non-transduced 
(trCD2–) cells retained in control-trCD2-transduced BMMØ receiving mice. D. Graph 
showing quantified F4/80 expression in transduced BMMØs, made relative to recipient 
ResMØs (=1 on the scale). Data (A-D) represents the mean ± SEM of 8-12 week old 
recipient CD45.2 129S6/SvEv mice pooled from two similar experiments (3 male, 3 
female). Donor bone marrow was cultured from 12-16 week old sex-matched mice. 
Data were analyzed by Two-way ANOVA (C) (P-value indicated for interaction (Int)) 
with Bonferroni post tests, and Student’s t-test (D) (**, P≤ 0.01;***, P≤ 0.001). 
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6.3 – Discussion 
The aims of this chapter were to: 1) determine whether Gata6 is selective expressed by 
peritoneal and pleural ResMØs; 2) investigate the effect of Gata6 on peritoneal ResMØ 
proliferation and phenotype; 3) investigate the effect of Gata6 on pleural ResMØ 
proliferation and phenotype; and 4) determine the effect of Gata6 on the 
inflammatory response. 
 
6.3.1 –Selective expression of Gata6 in peritoneal and pleural ResMØ 
Microarray analysis of monocyte and MØ populations during peritoneal inflammation 
was performed by Dr. Marcela Rosas, and revealed Gata6 as a selectively expressed 
transcription factor in peritoneal ResMØs (general introduction, 1.3.1). Pleural ResMØs 
are similar to peritoneal ResMØs. Therefore quantitative PCR analysis was performed 
to analyse the level of Gata6 expression in these tissues. Both the ResMØs from the 
pleural and peritoneal cavities expressed Gata6 (figures 6.1 and 6.12). Though absolute 
quantification was not carried out, ResMØs expressed over a thousand-fold more 
transcript than BMMØs, and over ten times more than InfMØs from the same 
inflammatory environment. These InfMØs were purified alongside ResMØs using flow 
cytometric sorting, and the level of purity seen was 90-95 %. Therefore the higher level 
of Gata6 seen in InfMØs (only a tenth of the level seen in ResMØs, compared with a 
thousandth of the level of ResMØs, in BMMØs) is likely, at least in part, attributed to 
contamination by 5-10 % ResMØs. 
 
6.3.2 –Phenotypic changes in ResMØ after Gata6-depletion 
In vivo delivery of a lentivirus expressing Gata6-targeting shRNA molecules resulted in 
a significant reduction in protein expression of the canonical MØ marker F4/80 (figure 
6.2). The decreased Gata6 expression itself was not quantified because this was a 
preliminary study. However, shRNA knockdown is known to not completely ablate 
mRNA. The shRNA sequences used in this study were obtained from Sigma Aldrich and 
have been previously validated to provide ≥70 % knockdown, an unofficial industry 
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standard. Therefore, a more efficient strategy was formulated to further investigate 
the effect of a total loss of Gata6.  
Mice which contained a floxed Gata6 allele (Gata6tm2.1Sad) were generated by Sodhi 
and colleagues in 2006. The addition of a Cre enzyme can be used in these mice to 
recombine loxP sites and excise the floxed region; therefore inactivating the gene. In 
Gata6tm2.1Sad mice, only exon 2 of Gata6 was floxed, meaning that only exon 2 would 
be deleted. This resulted in a short (177 amino acid) Gata6 protein still being 
translated in these mice (Sodhi et al., 2006). The mutant Gata6 was 268 amino acids 
shorter than short Gata6 isoform, and 416 amino acids shorter than long Gata6 
isoform and this translates to a loss of function (Sodhi et al., 2006). In this study, Gata6 
was deleted in Gata6tm2.1Sad mice using intra-peritoneal delivery of a Cre-expressing 
lentivirus. This resulted in the slow formation (over time) of a new population of 
F4/80low ResMØs (figure 6.3), confirming the result seen with delivery of Gata6 
targeting shRNA (figure 6.2). Cre delivery to WT 129S6/SvEv mice did not alter F4/80 
expression in ResMØs. This shows that the reduction in F4/80 levels is accredited to 
Gata6 deletion and not reported Cre toxicity (Schmidt-Supprian and Rajewsky, 2007) 
or viral infection. The reduction of F4/80 protein levels seen in Cre transduced 
Gata6tm2.1Sad ResMØs could be rescued by co-transduction with Gata6-expressing 
lentiviruses (figures 6.4). Showing again that the reduction in F4/80 is a result of Gata6 
deletion and not Cre mediated toxicity.  
The results from the lentiviral experiments above (figures 6.3-6.4) were also 
investigated using a Gata6-KOmye mouse strain. This strain was generated using 
Lysozyme M (Lyz2) Cre ‘knock-in’ congenic mice (‘Lyz2Cre’, B6.129P2-Lyz2tm1(cre)Ifo) 
(Clausen et al., 1999) crossed with conditional KO Gata6tm2.1Sad mice (Sodhi et al., 
2006), as in figure 6.5. These mice exhibited a gross F4/80low ResMØ phenotype in both 
the pleural (figure 6.12) and peritoneal cavities (figure 6.6), which was comparable to 
the result seen in lentiviral Cre delivery to the peritoneum of Gata6tm2.1Sad mice. This 
phenotype could be reversed toward that seen in WT mice, by using intra-peritoneal 
delivery of a Gata6-expressing lentivirus (figure 6.8). This additionally supports that 
this is a Gata6-mediated phenotype, not attributed to Cre toxicity (Schmidt-Supprian 
and Rajewsky, 2007), and that addition of the short form of Gata6 alone is sufficient 
for phenotype restoration. 
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6.3.3 – Identification of ‘WT’ F4/80high ResMØs in Gata6-KOmye mice 
Interestingly, ≈5 % of the ResMØs in Gata6-KOmye mice were F4/80high in the peritoneal 
cavity, a result not seen with Cre delivery. This could be attributed to the incomplete 
penetrance of Lyz2Cre recombination, which is known to be only ≈95 % in peritoneal 
ResMØs (Clausen et al., 1999). Therefore, the level of Gata6 expression was 
investigated in Gata6-KOmye mice using a polyclonal antibody against full length Gata6. 
This antibody also bound to the small 177 amino acid Gata6 after exon 2 deletion. 
However, significantly reduced levels of Gata6 were seen in F4/80low ResMØs 
compared to F4/80high ResMØs (when quantified – figure 6.7). Dr. Marcela Rosas has 
additionally shown that these F4/80high cells are phenotypically normal (confirmed by a 
panel of markers) and express Gata6 mRNA containing exon 2 (which Cre deletes) 
(Rosas et al., 2014). Therefore, they can be considered effectively ‘WT’ cells, and were 
seen in both the peritoneal (figure 6.6) and pleural (figure 6.12) cavities of Gata6-
KOmye mice. 
 
6.3.4 – Gata6 effects cell proliferation and euploidy in a cell-intrinsic manner 
Gata6 is a known regulator of cell proliferation (Beuling et al., 2011) and promotes G1 
cell cycle arrest (Perlman et al., 1998). Loss of Gata6 caused an increase in homeostatic 
ResMØ proliferation (figure 6.9). Comparison of both: F4/80high and F4/80low ResMØs in 
Gata6-KOmye mice (figure 6.10), and Cre transduced and non-transduced Gata6tm2.1Sad 
mice (figure 6.11), show that this increase in proliferation was a cell-intrinsic effect of 
Gata6, and not secondary to environmental alterations. Similar results were also seen 
in the pleural cavity (figure 6.13). Additionally, Gata6 has been reported to control 
nuclear envelope stability. In transformed cells loss of Gata6 caused an increase in 
polyploidy via failed cytokinesis, due to the loss of emerin in the nuclear envelope 
(Capo-chichi et al., 2009). The loss of Gata6 in ResMØs increased the level of 
polyploidy, resulting in a dramatic increase in the number of multi-nuclear ResMØs in 
the pleural (figure 6.14) and peritoneal (figure 6.9) cavities. This was also an intrinsic 
effect seen with the absence of Gata6 (figure 6.10). However, MØs are known to fuse 
under certain conditions, such as that seen with IL-4 stimulation (Helming and Gordon, 
2007). Therefore the increased level of polyploidy could also be explained by cell 
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fusion, but this was not specifically investigated, as it was considered beyond the 
scope of this thesis. 
 
6.3.5 – Conditional myeloid knockout of Gata6 results in altered homeostatic cell 
numbers 
When the cellular content of the peritoneal cavity was quantified, Gata6-KOmye mice 
exhibited a much lower level of Tim4+ ResMØs compared to WT mice (figure 6.15). This 
is likely to affect the tissue physiology, especially in inflammation where ResMØs are 
known to be important modulators (see chapter 1). This reduction could be linked to 
failed cytokinesis (Capo-chichi et al., 2009), decreased tissue retention (mirroring an 
increased tissue retention of Gata6 transduced BMMØs), cell death, or a change in 
environmental factors, such as the availability of growth factors. However, the number 
of eosinophils and F4/80low MHCIIhigh Res DCs/MØs is increased in Gata6-KOmye mice 
(figure 6.15). The mechanisms for this are currently being investigated by Drs. Marcela 
Rosas and Chia-Te Liao in Prof. Phil Taylor’s laboratory, and are not included in this 
thesis. 
 
6.3.6 – Absence of Gata6 results in a reduced ability of ResMØs to recover after 
inflammation by proliferation 
The response of ResMØs in the peritoneal cavity of Gata6-KOmye mice was investigated 
during acute inflammation (2×106 particles of zymosan). The number of recoverable 
ResMØs (by lavage) is reduced 4 hours after inflammation, but this number returns to 
normal levels by 48 hours in WT mice. ResMØs of Gata6-KOmye mice were substantially 
reduced 4 hours after inflammation, but did not recover greatly by 48 hours after 
stimulus (figure 6.15). However, the number of Tim4+ ResMØs seen 7 days after 
stimulus was approaching ‘normal’ levels in Gata6-KOmye mice (figure 6.19a). Thus, it 
looked as though these cells could recover, but this interpretation is complicated by 
the potential for InfMØs to acquire Tim4 expression during the late resolution phase of 
inflammation, and hence a reduction in clarity over cell identification (see below). 
Consequently, this would require further experimentation using models such as bone 
marrow chimeras. The preferential loss of Gata6-KO ResMØs 4 hours after 
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inflammatory stimulus was confirmed as being intrinsically controlled in the absence of 
Gata6, by using Cre transduction of Gata6tm2.1Sad mice (figure 6.16). The mechanism for 
this preferential loss is not known, but could be attributed to an altered activation 
state in Gata6-KOmye ResMØs (currently being studied by Dr. Marcela Rosas), which 
could lead to altered cell adhesion and/ or cell death. The failure of ResMØs to recover 
48 hours after inflammation could also, at least in part, be a result of the dysregulated 
proliferation seen in Gata6-KOmyemice. Therefore, proliferation was investigated 
during zymosan induced inflammation. 
ResMØs undergo a burst in proliferation to recover their numbers after inflammation 
(Chapter 3 of this thesis). Gata6-KOmye peritoneal ResMØs however do not go through 
this key stage, and therefore cannot recover the numbers lost during inflammation 
(figure 6.17). The absence of Gata6 is intrinsically responsible for the failure of Gata6-
KOmye ResMØs to increase their basal proliferation rate. This was confirmed by 
comparing the proliferation of F4/80low and F4/80high ResMØs within the same 
peritoneal environment of Gata6-KOmye mice. F4/80high ResMØs increased their basal 
proliferation rate 48 hours after zymosan, whilst F4/80low ResMØs maintained their 
higher homeostatic level (figure 6.18). However, when the Tim4+ F4/80low ResMØs of 
Gata6-KOmye mice were examined 7 days after zymosan, their numbers were 
approaching that seen in naϊve Gata6-KOmye mice. These cells themselves exhibited 
increased proliferation when compared to both WT cells (figure 6.19b), and F4/80high 
ResMØs within the same peritoneal environment of Gata6-KOmye mice (figure 6.19c). 
This suggests that the MØs from Gata6-KOmye mice can increase their abnormal basal 
proliferation to recover from inflammation, albeit at a later stage. Although, the origins 
of these MØs comes into question at this late stage, as a significant proportion of 
these Tim4+ MØs express Ly-6B; which is usually a marker for recruited MØs (Rosas et 
al., 2010) that proliferate during inflammation (see chapter 4). So this could represent 
a phenotype conversion, or convergence of InfMØs toward the ResMØ phenotype as 
seen in complex immune scenarios (Rosas et al., 2010). However, this data 
demonstrates that the mechanisms for MØ renewal during inflammation are distinct 
and markedly altered in Gata6-KOmye mice. 
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6.3.7 – Potential mechanism for altered ResMØ proliferation 
M-CSF was found to be required for the proliferation of ResMØs during inflammation 
(chapter 4 of this thesis), and IL-4 is known to drive MØs beyond homeostatic levels of 
proliferation (Jenkins et al., 2013). However, the absence of IL-4 signalling had no 
affect on the burst of proliferation seen in acute inflammation, and addition of M-CSF 
could not emulate the massive increase in proliferation (chapter 4 of this thesis). The 
precise mechanism for the switch to increased homeostatic proliferation in acute 
inflammation, and how this is dyregulated in the absence of Gata6 is not yet known, 
and requires further investigation. However, a single preliminary experiment revealed 
that M-CSF antibody blockade completely abrogated ResMØ proliferation in naϊve 
Gata6-KOmye mice, mirroring the result seen in figure 4.11. Additionally, knockdown of 
Map3k8 with shRNA resulted in decreased ResMØ proliferation during acute 
inflammation (figure 6.20). Map3k8 or tumour progression locus 2 (Tpl2) is a protein 
kinase which promotes increased cell proliferation in a different cellular context 
(Patriotis et al., 1993). Considering that Gata6-KOmye ResMØs have increased levels of 
Map3k8 mRNA (Rosas et al., 2014), this could, in part, explain the increased 
homeostatic proliferation seen in these mice. However, the mechanisms controlling 
ResMØ proliferation during homeostasis and inflammation are likely distinct. 
Consequently, the precise mechanism of Map3k8 control of ResMØ proliferation 
requires further investigation. 
 
6.3.8 – The absence of Gata6 is associated with alterations in inflammatory 
resolution 
The number of neutrophils seen 4 hours after 2x106 particles of zymosan is not 
significantly different between Gata6-KOmye and WT mice (figure 6.15). However, a 
higher dose of zymosan (2x107 particles) is known to exhibit less MØ dependency on 
the initiation of inflammation, by invoking alternative mechanisms (Taylor et al., 2007, 
McDonald et al., 2012, Rosas et al., 2008, Mullaly and Kubes, 2007). When the higher 
dose of zymosan was used in Gata6-KOmye mice, the number of neutrophils seen was 
significantly higher than WT mice 40 hours after zymosan – during the resolution 
phase, with the same numbers being recruited at 20 hours (figure 6.21). This shows 
that the clearance of neutrophils from the peritoneal cavity is impaired in Gata6-KOmye 
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mice. Additionally, slightly more Tim4– MØs (InfMØ) were recruited (figure 6.21). 
These defects are associated with the MØ abnormalities and the lower number of 
Tim4+ ResMØs seen in these mice (figure 6.21). A continued presence of neutrophils 
could be detrimental to the tissue environment and could impair wound healing (Dovi 
et al., 2004). Therefore, normal ResMØ phenotype, which controls normal ResMØ 
numbers both promote the normal resolution of the inflammatory response after 
2x107 particles of zymosan. 
 
6.3.9 – Gata6 imparts a peritoneal-like phenotype and increases the tissue retention 
of BMMØs 
An experiment was formulated to determine whether Gata6 controls the retention of 
MØs in the peritoneal cavity. BMMØs (which are effectively deficient in Gata6 
expression – figure 6.1) were transduced with a Gata6-expressing or control lentivirus 
and adoptively transferred into the peritoneal cavity of congenic mice. The expression 
of Gata6 on these cells increased their retention 10-fold, and gave them an F4/80high 
phenotype comparable to the host’s ResMØs (figure 6.22). This suggests that Gata6 
confers a peritoneal (and by analogy also pleural) specific phenotype to these cells, 
which increases their retention and/ or survival in the cavity. These cells had a very low 
level of proliferation, which was not quantifiable due to experimental constraints (a 
low number of cells were injected and recovered). However, the level was low enough 
(<0.05 % SG2M, almost non-existent) to suggest an increased proliferation was not 
responsible for increased cell numbers in the Gata6 transduced BMMØs. 
 
6.3.10 –Microarray analysis of Gata6-deficient ResMØs 
As part of the Immunological Genome Project, Gautier and colleagues carried out a 
global microarray analysis on diverse ResMØ populations between tissues, which 
included peritoneal ResMØ, microglia and numerous DC populations. This array 
identified Gata6 as a peritoneal MØ specific transcription factor (Gautier et al., 2012b). 
This array was combined with Dr. Marcela Rosas’ previous array on MØs in peritoneal 
inflammation to formulate a gene list for peritoneal specific genes both between and 
within the tissue; which included Gata6 (Rosas et al., 2014). Dr. Marcela Rosas carried 
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out an additional microarray study (validated with protein expression studies) on 
Gata6-KOmye vs WT ResMØs (Rosas et al., 2014). This identified 690 genes which were 
regulated by >2-fold in the absence of Gata6 (294 up and 396 down). This list 
preferentially included genes (215 probe sets) that were considered important for the 
peritoneal ResMØ specific phenotype (microarray study outlined in 1.3.1). These genes 
include membrane proteins (e.g. CD73) and regulators of proliferation (e.g. Map3k8), 
which implicate Gata6 as a master controller of peritoneal ResMØ phenotype. 
However, pleural MØs also express Gata6 (figure 6.12), so this could be expanded to 
include other serosal ResMØ.  
 
6.3.11 –Conclusion 
In conclusion, the main studies in this chapter, which are in a manuscript currently in 
submission (Rosas et al., 2014), show that: 1) Gata6 is selectively expressed by 
peritoneal and pleural ResMØs; 2) both peritoneal and pleural ResMØs require Gata6 
for maintenance of their F4/80high phenotype 3) the absence of Gata6 causes a 
dysregulation of both peritoneal and pleural ResMØ proliferation and polyploidy; 4) 
the absence of ResMØ Gata6 is associated with delayed neutrophil clearance in 
inflammation; 5) Gata6 expression imparts a ResMØ-like phenotype upon BMMØs and 
increases their peritoneal retention and/ or survival; and 6) proliferative recovery of 
ResMØs during inflammation is driven in part by Map3k8. This chapter, along with Dr. 
Rosas’ microarray studies, shows that serosal ResMØ phenotype is intrinsically linked 
to their ability to self renew by proliferation via the master transcription factor Gata6. 
The development of viable Gata6-deficient ResMØs in the Gata6-KOmye mouse 
provides a unique opportunity to further investigate the functional interactions 
between tissue-resident cells and their tissue. This will aid in the identification of novel 
approaches to promote tissue homeostasis, the resolution of inflammation and host 
defence. 
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Chapter 7 – General Discussion
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7.1 – MØ origins and self-renewal 
7.1.1 – Past reflection 
ResMØs were originally classified as part of the reticuloendothelial system, where the 
origin of new cells was considered to be local expansion in the tissue (Aschoff, 1924). 
At the same time, blood monocytes were identified as the source of some phagocytic 
cells (Sabin, 1925), however the remaining ResMØs were still considered to be tissue 
derived. In 1968 this changed; Ralph van Furth and Zanvil Cohn showed that major 
populations of MØs were derived from blood monocytes, and this concept was applied 
to all MØs including ResMØs (van Furth and Cohn, 1968). During later years however, 
this claim was disputed by a number of research groups due to evidence of 
proliferation (Parwaresch and Wacker, 1984, Sawyer et al., 1982, Czernielewski and 
Demarchez, 1987), the apparent longevity of ResMØs (Melnicoff et al., 1988), and the 
fact that MØ populations were present in the yolk sac before primitive haematopoiesis 
(Naito et al., 1996). These studies were not conclusive enough to change the dogma of 
the MPS. However, the work carried out during this time supplied researchers with 
fundamental evidence, which slowly formed a well founded hypothesis. Unfortunately 
for the field, the key questions on ResMØ origins could not be answered for years to 
come. However, the evidence supporting the tissue origin of ResMØs gradually 
accumulated (Takahashi, 2000, Naito et al., 1996), and in 2000 Ovchinnikov and 
colleagues concluded that embryonic phagocytes were of a separate lineage and this 
raised the possibility of their persistence into adulthood (Ovchinnikov, 2008, Lichanska 
and Hume, 2000). This theory was cemented with the breakthrough work on 
Langerhans cells and microglia, which are self-renewing populations (Merad et al., 
2002, Ajami et al., 2007, Mildner et al., 2007, Chorro et al., 2009). These seminal works 
in themselves contradict the basic principles of the MPS, but the authors (Chorro et al., 
2009) suggested that this may be restricted to tissues with limited vasculature. 
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7.1.2 – Current paradigms 
Langerhans cells (Chorro et al., 2009) and microglia (Ajami et al., 2007) self-renew by in 
situ proliferation. Supporting these pioneering studies: the origin of Langerhans cells 
was found to be foetal liver and yolk sac MØs (Hoeffel et al., 2012), whilst microglial 
cells were found to derived primarily from the yolk sac (Ginhoux et al., 2010). The 
development of both Langerhans cells and microglia are under the control of IL-34, an 
alternative ligand for the M-CSF receptor (Greter et al., 2012, Wang et al., 2012b). 
The data presented within this thesis has contributed to the growing knowledge on 
MØ origins and renewal (Davies et al., 2013b, Davies et al., 2011). ResMØs from the 
peritoneal cavity, a vascular environment, proliferate: at low levels to maintain their 
numbers during homeostasis (chapter 3), at higher levels during neonatal growth, and 
undergo a burst in proliferation after acute inflammation to restore their depleted 
population (chapter 3). This was independent from the bone marrow (chapter 3 and 
4), and by analogy the MPS, like that of Langerhans cells and microglia, but in a 
vascularised tissue. These studies (Davies et al., 2011) were supported by a later 
publication, which confirmed the self-renewing capacity of peritoneal ResMØs 
(Hashimoto et al., 2013). Pleural ResMØs also show a low level of homeostatic 
proliferation (chapter 6.2.6 and (Jenkins et al., 2011)), and may share other renewal 
characteristics with peritoneal ResMØs.  
In 2012, Yona et al. showed that these ResMØs were seeded into the peritoneal cavity 
before birth, and do not require blood monocytes for homeostatic renewal (Yona et 
al., 2012). Additionally, Schulz et al. discovered that the transcription factor Myb was 
responsible for the development of haematopoietic stem cells; but that another 
population of primitive MØs that are F4/80high was Myb independent and gave rise to a 
number of ResMØs populations in multiple tissues (Schulz et al., 2012). These articles, 
released at similar times, changed the field by showing that that many ResMØs have 
pre-natal origins and do not rely on blood monocytes for their renewal under steady 
state conditions (Schulz et al., 2012, Yona et al., 2012). A list of these self renewing 
populations is shown in table 7.1; figure 7.1 shows these self-renewing populations 
amongst other MØ populations in multiple tissues. Current paradigms state that MØs 
can be of 3 main origins: haematopoiesis in the adult bone marrow, or derived from 
the yolk sac and/ or foetal liver during development (Davies et al., 2013a). 
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Figure 7.1. MØ heterogeneity within different tissues 
Diagram showing the extensity of MØ heterogeneity between tissues, purple text 
indicates self-renewing populations. These self-renewing populations are expanded on 
in table 7.1. 
  
CNS
Microglia
Perivascular MØ
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Self renewing MØ Notes 
Bone Marrow MØ Self renewing population (Hashimoto et al., 2013). 
CNS Microglia 
Derived from yolk sac and maintained during inflammation 
independently of the bone marrow (Ajami et al., 2007, 
Ginhoux et al., 2010, Ajami et al., 2011). 
Liver Kupffer cells 
Pre-natal origins (Yona et al., 2012). Maintained in the 
adult independently of the bone marrow (Schulz et al., 
2012). 
Alveolar MØ 
Maintained in the adult in homeostasis and inflammation 
independently of the bone marrow (Murphy et al., 2008, 
Hashimoto et al., 2013, Guilliams et al., 2013). 
Peritoneal MØ 
Pre-natal origins (Yona et al., 2012). Maintained in adult in 
homeostasis and inflammation independently of the bone 
marrow (Davies et al., 2011). 
Pleural MØ 
Maintained in adult during homeostasis and can expand 
during Th2 inflammation, independently of the bone 
marrow (Jenkins et al., 2011) 
Langerhans cells 
Derived from yolk sac/ foetal liver and maintained 
independently of the bone marrow (Chorro et al., 2009, 
Hoeffel et al., 2012). 
Spleen red pulp MØ 
Pre-natal origins (Yona et al., 2012, Schulz et al., 2012). 
Maintained in adult independently of the bone marrow 
(Hashimoto et al., 2013). 
Table 7.1. Self-renewing MØ populations 
Table showing self renewing MØ populations in different tissues, some with known 
pre-natal origins (seeded into the tissue before birth). The locations of these 
populations are better represented in figure 7.1. CNS = central nervous system. This 
table was adapted from (Davies et al., 2013b). 
The proliferation of peritoneal ResMØs is dependent upon the growth factor M-CSF 
(chapter 4). InfMØs also require M-CSF for recruitment/ retention and/or proliferation 
in the peritoneal cavity (chapter 4). Both peritoneal and pleural ResMØs can also 
proliferate in Th2 inflammation, which is dependent on the cytokine IL-4 (Jenkins et al., 
2011). However, IL-4 is not required for proliferation of both ResMØs and InfMØs 
during acute inflammation (2 × 106 particles of zymosan) (chapter 4). Although, both 
peritoneal and pleural ResMØs can proliferate beyond homeostatic levels controlled 
by M-CSF, with IL-4 during Th2 inflammation (Jenkins et al., 2013). 
Additionally, InfMØs can also proliferate within an inflammatory lesion (chapter 4). 
This suggests that InfMØs can expand their numbers during inflammation, perhaps 
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limiting the need for additional monocyte recruitment. A reduction in monocyte 
recruitment has been associated with improved wound healing (Kaikita et al., 2004), 
but this is likely more complicated as the monocyte/ MØ milieu is poorly categorised 
during this process (Gurtner et al., 2008).  
All of these studies shed new light onto the origins of MØs and opens new avenues for 
studies on molecular control of the specific phenotypes of resident cells. One such 
study by the Immunological genome project shows a broad separation of MØs and 
DCs, but also tissue-specific gene regulation (Gautier et al., 2012b, Miller et al., 2012). 
The significance of this study is that MØs in different tissues have distinct gene 
profiles. 
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7.2 – MØ tissue specific phenotype and function 
7.2.1 – Gata6 as a transcriptional regulator of ResMØ phenotype and renewal 
Chapter 6 of this thesis investigated the effects of Gata6-depletion upon peritoneal 
and pleural ResMØs. In summary, Gata6 is selectively expressed by peritoneal and 
pleural ResMØs, which require Gata6 for: 1) the maintenance of their F4/80high 
phenotype, 2) regulation of normal proliferation, and 3) maintenance of euploidy. 
Gata6 expression also imparts a ResMØ-like phenotype upon BMMØs and increases 
their peritoneal retention and/ or survival.  
In addition to these studies, Dr. Marcela Rosas carried out a microarray analysis of 
Gata6-KOmye vs WT ResMØs (Rosas et al., 2014), and combined this with her previous 
microarray on the ResMØ specific gene profile (mentioned in the general introduction 
of this thesis 1.3.1). This revealed that the majority of genes considered to be ResMØ 
specific were altered (the vast majority down-regulated) in the absence of Gata6. This 
implies that Gata6 is a master controller of the ResMØ specific phenotype. 
The results from chapter 6 of this thesis, along with Dr. Rosas microarray studies, show 
that serosal ResMØ phenotype is intrinsically linked to their ability to self renew by 
proliferation via the master transcription factor Gata6. The studies on Gata6 in chapter 
6 of this thesis have been incorporated into a manuscript currently in submission 
(Rosas et al., 2014), a summary of which is depicted in figure 7.2. 
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Figure 7.2. Summary of the role of Gata6 in ResMØs 
Diagram showing the effects of Gata6 on MØs, including its removal from ResMØs and 
addition to BMMØs. The >2-fold regulated probe-sets in the Gata6-deficient ResMØs 
(red cell) were from a microarray study between Gata6-KOmye and WT ResMØs (Rosas 
et al., 2014). 
7.2.2 – Other examples of MØ transcriptional regulation 
Generally, when discussing transcriptional control of MØ populations, the chief 
transcription factor considered is SFFV proviral integration oncogene (Spi) 1 (or PU.1). 
PU.1 deficient mice lack monocytes and MØs (including most ResMØ populations) 
(Scott et al., 1994), but also show deficiencies in other haematopoietic cells, such as 
neutrophils (Anderson et al., 1998). The loss of MØs in these mice could be explained 
by the loss of PU.1 enhanced expression of the M-CSF receptor (Zhang et al., 1994). 
The spontaneous osteopetrotic (op/op) mutation has significant defects in many MØ 
populations, which were attributed to a point mutation in the gene for M-CSF (Yoshida 
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et al., 1990). The defects of the op mouse were also evident in the mice deficient in its 
receptor (Dai et al., 2002). These defects include increased bone mass (osteopetrosis), 
which is attributed to loss of osteoclasts that resorb bone, a lack of teeth, due to a 
failure for the tooth buds to erupt (Van Wesenbeeck et al., 2002), and decreased fat 
storage, attributed to defects in adipose tissue MØs (Wiktor-Jedrzejczak et al., 1991). 
Many of the defects in PU.1 deficient mice are shared in M-CSF and M-CSF receptor 
deficient mice. Consequently, PU.1 is important for the formation of most ResMØ 
populations, however it does not discriminate between cells of different origin or 
tissue niche. The functions of which require fine-tuning by tissue-specific transcription 
factors, as demonstrated by these studies of Gata6 in the peritoneal cavity.  
Specific transcriptional control of the development of specific MØ populations has 
been identified in other tissues. Examples of which are listed below. 
Langerhans cells of the epidermis are controlled by the transcriptional regulators: 
inhibitor of DNA binding 2 (Id2) (Hacker et al., 2003) and Runt-related transcription 
factor 3 (Runx3) (Fainaru et al., 2004). Deletion of Id2 resulted in a complete loss of 
Langerhans cells, but also some DC populations; whilst loss of Runx3 impaired only 
Langerhans cell development. In the spleen, only red pulp MØs were ablated in the 
absence of the transcriptional regulator Spi-C (Kohyama et al., 2009); whilst 
metallophilic and marginal zone MØs were specifically lost in liver X receptor α (LXRα) 
deficient mice (A-Gonzalez et al., 2013).  
Genetic deletion of these transcriptional controllers usually results in the 
disappearance of a specific MØ subset, and consequently, a loss of tissue-specific 
function. In the Gata6-KOmye mouse however, the ResMØs are viable, albeit with an 
altered phenotype and function. Therefore unlike previous studies, the Gata6-KOmye 
mouse provides a unique opportunity to further investigate the functional interactions 
between ResMØs and their host tissue; which has been poorly categorised in the 
peritoneal cavity. 
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7.3 – Conclusion 
7.3.1 – Conclusions 
In conclusion, the studies in this thesis contribute to the field of MØ biology in several 
ways; the main findings are listed below, with associated manuscripts, published or in 
submission.  
 Peritoneal cavity (a vascular tissue) ResMØs proliferate in situ to maintain their 
population during homeostasis and neonatal growth (Davies et al., 2011) 
 Peritoneal ResMØs proliferate independently of the bone marrow during 
inflammation, to restore their depleted population (Davies et al., 2011). This is 
M-CSF dependent, but IL-4 is not required (Davies et al., 2013b) 
 A subset of bone marrow monocyte-derived MØs can also proliferate in situ 
during inflammation (Davies et al., 2013b) 
 The transcription factor Gata6 has a cell-intrinsic effect on pleural and 
peritoneal MØ proliferation and phenotype (Rosas et al., 2014) 
 Proliferative recovery of ResMØs during inflammation is driven in part by 
Map3k8 (Rosas et al., 2014) 
 
7.3.2 – Future perspectives and experimentation 
This thesis, along with other work, has answered definitive questions on MØ origins, 
renewal and transcriptional control. The precise mechanisms for ResMØ renewal by 
proliferation are not fully understood. This thesis shows critical roles for the growth 
factor M-CSF, and the secondary regulator Map3k8. However the mechanistic fine-
tuning needed for distinct MØ subsets proliferating at different times in the same 
environment during inflammation is not known. Additionally, the potential for 
phenotype conversion of monocyte-derived MØs to ResMØs is not clear. 
Understanding of these mechanisms may lead to novel paradigms in the approach to 
disease treatment. Especially when considering M-CSF blockade trials in diseases such 
as cancer, in which the milieu of MØ subsets, and their specific functions have not 
been categorised.  
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Additionally, specific to this thesis the individual mechanisms controlled by the 
transcription factor Gata6 need to be investigated. Such mechanistic studies are 
already underway in Prof. Phil Taylor’s laboratory. The advantages of viable Gata6-
deficient ResMØ will help drive this research, as will the method for specific lentiviral 
infection of ResMØs in vivo. Another interesting prospect is the control of extreme MØ 
heterogeneity. Prof. Phil Taylor’s group identified at least 16 separate populations in 
the F4/80high ResMØs using only 4 markers (Tim4, SignR1, CRIg, CD73). These cell 
subsets probably represent the ‘tip of the iceberg,’ and they would be expected to be 
functionally distinct. Tissue niche or epigenetic phenomena are likely to play a role in 
this: chromatin remodelling plays a large part in MØ gene regulation (Bowdridge and 
Gause, 2010), however the mechanisms for this in the control of ResMØ heterogeneity 
and tissue specificity are not currently known. 
Eventually, the tissue-specific controllers of MØ phenotype may be identified in other 
tissues. This could reveal novel functions of specific MØ subsets, which could pave the 
way for tissue-specific treatments aimed at MØs. An example is tumour-associated 
MØs, which have been poorly categorised. It is likely that the new tumour tissue 
contains its own ResMØ population, which may be specialised for the tumour 
environment. As cancer is considered by many as an inflammatory disease, the tumour 
environment also likely hosts monocyte-derived InfMØs. A full categorisation of MØs 
within the tumour environment and their specific functions will perhaps lead to MØ-
specific therapies to improve disease outcome. 
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Supplemental appendix figures 
 
Figure S1. Eosinophil Siglec-F expression 
Density plots showing the light scatter profile of eosinophils and non eosinophils. 
Expression of Siglec-F is shown on eosinophils with a high side scatter profile as 
described in figure 3.2a. Cells were from the pleural cavity of mice from figure 4.11. 
Plots were pre-gated to remove doublets as previously described (figure 3.1). Boxes 
indicate Siglec-F+ and – populations and are used to gate the density plots in the lower 
two panels.  
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Figure S2. Description of mast cells and neutrophils in flow cytometry 
Representative density plots showing the small light scatter profile of CD11b+ Ly-6G+ 
fixed/ permeabilized neutrophils, and the CD11blow/– profile of mast cells, 2 days after 
intra-peritoneal injection of 2×106 zymosan particles. Plots were pre-gated to remove 
doublets as previously described (figure 3.1), the three right panels are gated as shown 
in the far left panel. N = neutrophils, Not N = not neutrophils. Cells shown were from 
mice in figure 3.9. 
 
 Figure S3. Decrease in proliferation upon viral infection 
Scatter plot showing a decrease in proliferation in 
ResMØs, 7 days after intra-peritoneal injection of a trCD2-
expressing non-silencing lentivirus (measured by SG2M as 
shown in figure 4.2). Data shown compares transduced 
and non-transduced cells from mice used in figure 6.2. 
Data was analysed by paired Student’s t-test, and the P-
value is indicated. 
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